0001051627--12-312024Q3錯誤000000AXT INCDEP4Yhttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent0001051627axti公司:設備租賃會員2024-01-012024-09-300001051627axti公司:設備租賃會員2024-01-012024-09-3000010516272016-01-012023-12-3100010516272015-01-012015-12-310001051627axti公司:朝陽新美高純半導體材料有限公司會員axti : Loan From Related Party Member2022-05-012022-05-310001051627us-gaap:普通股成員2024-07-012024-09-300001051627us-gaap:留存收益成員2024-09-300001051627us-gaap:優先股會員2024-09-300001051627母公司成員2024-09-300001051627美國通用會計準則:非控股權益成員2024-09-300001051627us-gaap:CommonStockMember2024-09-300001051627us-gaap:額外實收資本成員2024-09-300001051627美國通用會計準則:累計其他綜合收益成員2024-09-300001051627美國通用會計準則:留存收益項目2024-06-300001051627美國通用會計準則:優先股項目2024-06-300001051627美國通用會計準則:母公司項目2024-06-300001051627美國通用會計準則:非控制權益項目2024-06-300001051627美國通用會計準則:普通股項目2024-06-300001051627美國通用會計準則:額外資本溢價項目2024-06-300001051627美國通用會計準則:其他綜合收益累積項目2024-06-300001051627美元指數:留存收益成員2024-03-310001051627美元指數:優先股成員2024-03-310001051627美元指數:母公司成員2024-03-310001051627美元指數:非控制權益成員2024-03-310001051627美元指數:普通股成員2024-03-310001051627美元指數:股本溢價成員2024-03-310001051627美元指數:其他綜合收益累積額成員2024-03-3100010516272024-03-310001051627美元指數:留存收益成員2023-12-310001051627us-gaap:優先股成員2023-12-310001051627us-gaap:母公司成員2023-12-310001051627us-gaap:非控制權益成員2023-12-310001051627us-gaap:普通股成員2023-12-310001051627us-gaap:額外支付的資本成員2023-12-310001051627us-gaap:累積其他綜合收益成員2023-12-310001051627us-gaap:留存收益成員2023-09-300001051627us-gaap:優先股成員2023-09-300001051627us-gaap:母公司成員2023-09-300001051627us-gaap:非控制權益成員2023-09-300001051627us-gaap:普通股成員2023-09-300001051627us-gaap:額外實收資本成員2023-09-300001051627us-gaap:累積其他綜合收益成員2023-09-300001051627us-gaap:留存收益成員2023-06-300001051627us-gaap:優先股成員2023-06-300001051627us-gaap:母公司成員2023-06-300001051627美元指數:非控股權益成員2023-06-300001051627美元指數:普通股成員2023-06-300001051627美元指數:額外已支付資本成員2023-06-300001051627美元指數:累積其他綜合收益成員2023-06-300001051627美元指數:留存收益成員2023-03-310001051627美元指數:優先股成員2023-03-310001051627美元指數:母公司成員2023-03-310001051627美元指數:非控股權益成員2023-03-310001051627美國通用會計準則:普通股份成員2023-03-310001051627美國通用會計準則:額外實收資本成員2023-03-310001051627美國通用會計準則:累積其他綜合收益成員2023-03-3100010516272023-03-310001051627美國通用會計準則:留存收益成員2022-12-310001051627美國通用會計準則:優先股份成員2022-12-310001051627美國通用會計準則:母公司成員2022-12-310001051627美國通用會計準則:非控制權益成員2022-12-310001051627美國通用會計準則:普通股份成員2022-12-310001051627us-gaap:其他股本溢價成員2022-12-310001051627us-gaap:累計其他綜合收益成員2022-12-310001051627axti:朝陽新美高純半導體材料有限公司成員axti:非控制權短期貸款成員2024-09-300001051627axti:北京博宇半導體艙體工藝技術有限公司成員axti:2024年12月到期的2.7%銀行貸款成員axti:中國工商銀行成員2023-12-310001051627us-gaap:員工股票期權成員2023-01-012023-12-310001051627美國通用會計準則:員工股票期權成員2023-12-310001051627績效股份成員2024-02-012024-02-290001051627美國通用會計準則:績效股份成員2023-03-012023-03-310001051627美國通用會計準則:員工股票期權成員2024-07-012024-09-300001051627srt:首席財務官成員美國通用會計準則:績效股份成員2024-02-202024-02-200001051627srt : 首席執行官成員美國通用會計準則:績效股份成員2024-02-202024-02-200001051627美國通用會計原則:員工股票期權成員2023-07-012023-09-300001051627srt:首席財務官成員美國通用會計原則:績效股份成員2023-03-152023-03-150001051627srt:首席執行官成員美國通用會計原則:績效股份成員2023-03-152023-03-150001051627美國通用會計原則:員工股票期權成員2023-01-012023-09-300001051627axti:情景績效財務指標介於50到200之間的成員srt:首席財務官成員us-gaap:業績股票成員2022-02-152022-02-150001051627axti : 場景表現金融指標介於50到200的成員srt : 首席執行官成員us-gaap:業績股票成員2022-02-152022-02-150001051627axti : 場景表現金融指標大於200的成員srt : 首席執行官成員us-gaap:業績股票成員2022-02-152022-02-150001051627srt : 首席財務官成員us-gaap:PerformanceSharesMember2022-02-152022-02-150001051627srt : 首席執行官成員us-gaap:PerformanceSharesMember2022-02-152022-02-150001051627us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001051627axti : Equity Incentive 2015 Plan Member2015-05-310001051627axti : Equity Incentive 2015 Plan Member2024-05-012024-05-310001051627axti : Equity Incentive 2015 Plan Member2021-05-012021-05-310001051627axti : Equity Incentive 2015 Plan Member2019-05-012019-05-310001051627axti inc:2015年股權激勵計劃成員2015-05-012015-05-310001051627srt : 最大成員美元指數:員工股票期權成員axti inc:2015年股權激勵計劃成員2024-01-012024-09-300001051627us-gaap:受限股票會員2023-12-310001051627美元指數:績效股份成員2023-12-310001051627美元指數:限制性股票成員2024-01-012024-09-300001051627美元指數:限制性股票成員axt inc:股權激勵2015計劃成員axt inc:基於時間的歸屬成員2024-01-012024-09-300001051627美國通用會計準則:限制性股票成員axt inc:股權激勵2015計劃成員axt inc:績效歸屬成員2024-01-012024-09-300001051627axt inc:顧問成員美國通用會計準則:限制性股票成員axt inc:股權激勵2015計劃成員2024-01-012024-09-300001051627us-gaap:績效股份成員US-GAAP:股份補償獎勵第一檔次成員2024-01-012024-09-300001051627us-gaap:員工期權成員axti:2015年權益激勵計劃成員2024-01-012024-09-300001051627報告地理成員組件srt:北美成員2024-07-012024-09-300001051627srt:可報告地理成分成員srt:歐洲會員2024-07-012024-09-300001051627srt:可報告的地理組件成員country:TW2024-07-012024-09-300001051627srt:可報告的地理組件成員國家:日本2024-07-012024-09-300001051627srt:可報告的地理組件成員country: 中國2024-07-012024-09-300001051627srt:可報告的地理組件成員axti:不包括日本和臺灣的亞太地區成員2024-07-012024-09-300001051627srt: 可報告地理成員組件2024-07-012024-09-300001051627axti: 襯底成員2024-07-012024-09-300001051627axti: 原材料和其他成員2024-07-012024-09-300001051627srt: 可報告地理成員組件srt: 北美成員2024-01-012024-09-300001051627srt: 可報告地理成員組件srt: 歐洲成員2024-01-012024-09-300001051627srt: 可報告地理成員組件國家: 臺灣2024-01-012024-09-300001051627srt : 可報告地理成分會員國家: 日本2024-01-012024-09-300001051627srt : 可報告地理成分會員國家: 中國2024-01-012024-09-300001051627srt : 可報告地理成分會員axti : 亞太地區不包括日本和臺灣會員2024-01-012024-09-300001051627srt : 可報告地理成分會員2024-01-012024-09-300001051627axt inc:基板成員2024-01-012024-09-300001051627axt inc:原材料和其他成員2024-01-012024-09-300001051627srt:可報告地理組件成員srt:北美洲成員2023-07-012023-09-300001051627srt:可報告地理組件成員srt:歐洲成員2023-07-012023-09-300001051627srt:可報告地理組件成員country:TW2023-07-012023-09-300001051627報告地理組件成員國家:JP2023-07-012023-09-300001051627報告地理組件成員國家:CN2023-07-012023-09-300001051627報告地理組件成員axt inc: 亞太地區,不含日本和臺灣 成員2023-07-012023-09-300001051627報告地理組件成員2023-07-012023-09-300001051627axt inc: 襯底 成員2023-07-012023-09-300001051627axt inc:原材料和其他成員2023-07-012023-09-300001051627srt:可報告地理組件成員srt:北美成員2023-01-012023-09-300001051627srt:可報告地理組件成員srt:歐洲成員2023-01-012023-09-300001051627srt:可報告地理組件成員國家:臺灣2023-01-012023-09-300001051627srt:可報告地理組件成員國家:日本2023-01-012023-09-300001051627SRT:可申報的地理成分成員國家:中國2023-01-012023-09-300001051627SRT:可申報的地理成分成員axti inc:不包括日本和臺灣的亞太地區成員2023-01-012023-09-300001051627SRT:可申報的地理成分成員2023-01-012023-09-300001051627axti inc:基板成員2023-01-012023-09-300001051627axti inc:原材料和其他成員2023-01-012023-09-300001051627us-gaap:後續事件成員2024-11-300001051627axt inc:朝陽凱美石英有限公司成員axt inc:朝陽新美高純半導體材料有限公司成員2022-09-012022-09-300001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:關聯方借款成員axt inc:北京通美晶體科技成員2021-12-012021-12-310001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:關聯方借款成員axti : Minority Investor Member2021-10-012021-10-310001051627axti:ChaoyangXinmeiHighPuritySemiconductorMaterialsCo.LtdMemberaxti : Loan From Related Party Memberaxti : Minority Investor Member2021-09-012021-09-300001051627srt : North America Member2024-09-300001051627country:CN2024-09-300001051627srt : North America Member2023-12-310001051627country:CN2023-12-310001051627在建工程2024-09-300001051627axt inc:其他關聯子公司在建工程會員2024-09-300001051627axt inc:製造設備採購在建工程會員2024-09-300001051627axt inc:丁新和數歐地點在建工程會員2024-09-300001051627us-gaap:ConstructionInProgressMember2023-12-310001051627axt inc:其他關聯子公司在建工程會員2023-12-310001051627axt inc:製造設備採購在建工程會員2023-12-310001051627axt inc:丁新和數歐地點在建工程會員2023-12-3100010516272024-06-3000010516272023-06-300001051627axt inc:朝陽凱美石英有限公司成員axt inc:朝陽新美高純半導體材料有限公司成員2023-01-012023-01-310001051627axt inc:朝陽通美高純半導體材料有限公司成員2024-01-012024-01-310001051627axt inc:小義興安鎵有限公司成員2024-05-012024-05-310001051627axt inc:小義興安鎵有限公司成員2023-11-012023-11-300001051627axt inc:北京吉亞半導體材料有限公司投資成員2023-11-012023-11-300001051627axt inc:小義興安鎵有限公司成員2023-04-012023-04-300001051627axt inc:北京吉亞半導體材料有限公司投資成員2023-04-012023-04-300001051627axt inc:北京集雅半導體材料有限公司投資成員2022-08-012022-08-310001051627axt inc:小屹新甘鎵有限公司成員2022-07-012022-07-310001051627axt inc:北京博宇半導體器工技術有限公司投資成員2022-06-012022-06-300001051627axt inc:北京同美晶科技成員axt inc:朝陽新美高純半導體材料有限公司成員2021-05-012021-05-310001051627axt inc:北京同美晶科技成員axt inc:朝陽新美高純半導體材料有限公司成員2021-02-012021-02-280001051627axt inc:朝陽開美石英有限公司成員2024-07-012024-07-310001051627axti: 朝陽凱美石英有限公司成員2024-06-012024-06-300001051627axti: 朝陽凱美石英有限公司成員2023-01-012023-12-310001051627axti: 朝陽新煤高純半導體材料有限公司成員axti: 關聯方借款成員axti: 少數投資者成員2022-05-012022-05-310001051627axti: 朝陽凱美石英有限公司成員axti: 朝陽新煤高純半導體材料有限公司成員美國通用會計準則:預付費用和其他流動資產會員2024-09-300001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:關聯方融資成員axt inc:北京通美晶體技術成員2022-01-310001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:關聯方融資成員axt inc:少數投資者成員2021-12-310001051627axt inc:峨眉山佳美高純金屬有限公司投資成員US-GAAP:其他非流動資產成員2024-09-300001051627axt inc:峨眉山佳美高純金屬有限公司投資成員2023-12-310001051627美國通用會計準則:累計其他綜合收益成員2024-07-012024-09-300001051627美國通用會計準則:累積其他綜合收益成員2024-04-012024-06-300001051627美國通用會計準則:累積其他綜合收益成員2024-01-012024-03-310001051627美國通用會計準則:累積其他綜合收益成員2023-07-012023-09-300001051627美國通用會計準則:累積其他綜合收益成員2023-04-012023-06-300001051627美國通用會計準則:累積其他綜合收益成員2023-01-012023-03-310001051627axt inc:朝陽鑫美高純半導體材料有限公司成員axt inc:來自關聯方成員的貸款axt inc:少數投資者成員2022-04-012022-04-300001051627axt inc:朝陽新美高純度半導體材料有限公司成員axt inc:來自關聯方成員的貸款axt inc:北京通美Xtal科技成員2022-04-012022-04-300001051627axt inc:朝陽新美高純度半導體材料有限公司成員axt inc:來自關聯方成員的貸款2022-04-012022-04-300001051627axt inc:朝陽新美成員2022-04-012022-04-300001051627axt inc:朝陽碩美高純半導體材料有限公司成員2023-08-012023-08-310001051627axt inc:朝陽碩美高純半導體材料有限公司成員2023-05-012023-05-310001051627axt inc:朝陽碩美高純半導體材料有限公司成員2023-01-012023-01-310001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:關聯方借款成員axt inc:北京同美晶體科技成員2022-05-012022-05-310001051627axt inc:朝陽新美高純半導體材料有限公司成員axt inc:北京同美晶體科技成員axt inc:來自關聯方成員的貸款2022-05-012022-05-310001051627axt inc:朝陽鑫美高純半導體材料有限公司成員axt inc:來自關聯方成員的貸款axt inc:北京通美晶技術成員2022-01-012022-01-310001051627axt inc:南京金美鎵有限公司投資成員axt inc:南京金美鎵有限公司投資成員2024-09-300001051627axt inc:朝陽鑫美高純半導體材料有限公司成員axt inc:朝陽鑫美高純半導體材料有限公司成員2024-09-300001051627axt inc:朝陽碩美高純半導體材料有限公司會員axt inc:朝陽碩美高純半導體材料有限公司會員2024-09-300001051627axt inc:朝陽金美鎵有限公司會員axt inc:朝陽金美鎵有限公司會員2024-09-300001051627axt inc:北京博宇半導體器皿工藝科技有限公司投資會員axt inc:北京博宇半導體器皿工藝科技有限公司投資會員2024-09-300001051627axt inc:北京瞳美晶技術會員2021-06-300001051627axt inc:北京瞳美晶技術會員2024-09-300001051627axti:NanjingJinMeiGalliumCo.LtdInvestmentMember2020-12-310001051627axti:BeijingBoyuSemiconductorVesselCraftworkTechnologyCo.LtdInvestmentMember2020-12-310001051627axti:ChaoYangTongmeiHighPuritySemiconductorMaterialsCo.LtdMemberus-gaap:其他非流動負債會員2024-09-300001051627axti:ChaoyangXinmeiHighPuritySemiconductorMaterialsco.LtdMemberus-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001051627axti:ChaoyangXinmeiHighPuritySemiconductorMaterialsco.LtdMember2024-09-300001051627axti:ChaoYangTongmeiHighPuritySemiconductorMaterialsCo.LtdMember2024-09-300001051627axt inc:朝陽通美高純半導體材料有限公司成員axt inc:短期貸款非控制權益成員2024-09-3000010516272024-01-300001051627axt inc:設施租賃成員2023-09-300001051627axt inc:設施租賃成員2020-05-310001051627axt inc:北京通美晶體技術成員2020-12-310001051627us-gaap:OtherAssetsMember2024-09-300001051627us-gaap:其他資產成員2023-12-310001051627axt inc:孝義興安鎵有限公司成員2023-12-310001051627axt inc:朝陽凱美石英有限公司成員2023-12-310001051627axt inc:北京吉亞半導體材料有限公司投資成員2023-12-310001051627axt inc:朝陽凱美石英有限公司成員2023-08-310001051627axt inc:朝陽凱美石英有限公司成員2023-07-310001051627axt inc:朝陽凱美石英有限公司成員2023-01-310001051627axt inc:峨眉山佳美高純金屬有限公司投資成員2023-01-012023-09-300001051627axt inc:南京金美鎵有限公司投資成員axt inc:北京吉亞半導體材料有限公司投資成員2024-09-300001051627安徽校裔興安鎵有限公司會員2024-09-300001051627峨眉山嘉美高純金屬有限公司投資會員2024-09-300001051627朝陽凱美石英有限公司會員2024-09-300001051627東海縣東方高純電子材料有限公司投資會員2023-11-300001051627峨眉山嘉美高純金屬有限公司投資會員2023-05-310001051627朝陽碩美高純半導體材料有限公司會員2023-05-310001051627朝陽新美高純半導體材料有限公司會員2022-07-310001051627除北京吉亞半導體材料有限公司之外的投資會員2024-07-012024-09-300001051627axt inc:北京嘉醫半導體材料有限公司成員,不包括投資2024-01-012024-09-300001051627axt inc:北京嘉醫半導體材料有限公司成員,不包括投資2023-07-012023-09-300001051627axt inc:北京嘉醫半導體材料有限公司投資成員2023-04-012023-06-300001051627axt inc:北京嘉醫半導體材料有限公司成員,不包括投資2023-01-012023-09-300001051627us-gaap:員工股票期權成員2024-09-300001051627us-gaap:受限股票會員2024-09-300001051627績效股份成員2024-09-300001051627根據銷售處理的非終止運營會員axt inc : AxtTongmeiInc 會員2021-06-300001051627美國通用會計準則:存單成員2023-12-310001051627axt inc : 利率爲2.4至3.9%的銀行貸款會員us-gaap:後續事件成員2024-11-012024-11-300001051627axt inc : 利率爲2.4至3.9%的銀行貸款會員us-gaap : 後續事項會員2024-10-012024-10-310001051627Srt: 最低會員axt inc : 利率爲2.4至3.9%的銀行貸款會員us-gaap:後續事項成員2024-11-300001051627srt : 最大成員axt inc:利率爲2.4至3.9%的銀行貸款成員us-gaap:後續事項成員2024-11-300001051627srt : 最小成員axt inc:利率爲2.4至3.9%的銀行貸款成員us-gaap:後續事項成員2024-10-310001051627srt : 最大成員axt inc:2.4至3.9%的銀行貸款會員us-gaap:隨後發生的事件會員2024-10-310001051627axt inc:2.4至3.9%的銀行貸款會員無抵押債務成員us-gaap:隨後發生的事件會員2024-11-300001051627axt inc:2.4至3.9%的銀行貸款會員us-gaap:擔保債務成員us-gaap:隨後發生的事件會員2024-11-300001051627axt inc:利率爲2.4%至3.9%的銀行貸款會員美元指數:隨後發生的事件會員2024-11-300001051627axt inc:利率爲2.4%至3.9%的銀行貸款會員美元指數:無擔保債務會員美元指數:隨後發生的事件會員2024-10-310001051627axt inc:利率爲2.4%至3.9%的銀行貸款會員美元指數:有擔保債務會員美元指數:隨後發生的事件會員2024-10-310001051627axt inc:銀行貸款利率爲2.4至3.9%的成員us-gaap:後續事件成員2024-10-310001051627axt inc : 北京同美晶體科技成員axt inc:2024年9月到期的銀行貸款利率爲4.3%的成員axt inc : 工商銀行成員2024-09-300001051627axt inc : 北京同美晶體科技成員axt inc:2024年11月到期的銀行貸款利率爲4.3%的成員axt inc : 寧波銀行成員2024-09-300001051627axt inc:北京同煤晶能技術成員axt inc:2025年3月到期的4.3%銀行貸款會員axt inc:寧波銀行會員2024-09-300001051627axt inc:北京同煤晶能技術成員axt inc:2024年7月到期的4.3%銀行貸款會員axt inc:興業銀行會員2024-09-300001051627axt inc:北京同煤晶能技術成員axt inc:2025年1月到期的4.3%銀行貸款會員axti: 寧波銀行會員2024-09-300001051627axti: 北京同煤Xtal科技會員axti: 2024年12月到期,利率4.3%的銀行貸款會員axti: 寧波銀行會員2024-09-300001051627axti: 北京同煤Xtal科技會員axti: 2024年9月到期,利率4.2%的銀行貸款會員axti: 寧波銀行會員2024-09-300001051627axti: 北京同煤Xtal科技會員axt inc:銀行貸款,截至2025年9月,利率3.9%,會員axt inc:工商銀行會員2024-09-300001051627axt inc:北京同美晶科技會員axt inc:銀行貸款,截至2024年10月,利率3.8%,會員axt inc:南京銀行會員2024-09-300001051627axt inc:北京同美晶科技會員axt inc:銀行貸款,截至2024年11月,利率3.5%,兩名會員axt inc:中國銀行會員2024-09-300001051627axt inc:北京同晶科技成員axt inc:2024年11月到期的銀行貸款,利率爲3.5%,一名成員axt inc:中國銀行成員2024-09-300001051627axt inc:北京同晶科技成員axt inc:2025年1月到期的銀行貸款,利率爲3.5%,一名成員axt inc:招商銀行成員2024-09-300001051627axt inc:北京同晶科技成員axt inc:2025年2月到期的銀行貸款,利率爲3.5%,一名成員axt inc:中國招商銀行會員2024-09-300001051627axt inc:北京通美晶體科技會員axt inc:2025年4月到期的銀行貸款,利率爲3.5% 會員axt inc:中國招商銀行會員2024-09-300001051627axt inc:北京通美晶體科技會員axt inc:2025年9月到期的銀行貸款,利率爲3.3% 會員axt inc:中國工商銀行會員2024-09-300001051627axt inc:北京通美晶體科技會員axt inc: 2024年9月到期的3.3%銀行貸款成員axt inc:中國工商銀行成員2024-09-300001051627axt inc:北京同美晶體科技成員axt inc: 2025年5月到期的3.0%銀行貸款兩名成員axt inc:交通銀行成員2024-09-300001051627axt inc:北京同美晶體科技成員axt inc: 2025年5月到期的3.0%銀行貸款一名成員axt inc:交通銀行成員2024-09-300001051627axt inc:北京同煤晶體科技成員axt inc:2025年6月到期的3.0%銀行貸款會員axt inc:中國中信銀行成員2024-09-300001051627axt inc:北京同煤晶體科技成員axt inc:2025年6月到期的3.0%銀行貸款會員axt inc:北京銀行成員2024-09-300001051627axt inc:北京同煤晶體科技成員axt inc:2025年1月到期的3.0%銀行貸款會員axti:中國銀行會員2024-09-300001051627axti:北京同煤晶體技術會員axti:2025年2月到期的銀行貸款,利率爲3.0%,會員axti:北京銀行會員2024-09-300001051627axti:北京同煤晶體技術會員axti:2024年12月到期的銀行貸款,利率爲3.0%,會員axti:北京銀行會員2024-09-300001051627axti:北京同煤晶體技術會員axt inc:2024年12月到期,3.0%銀行貸款會員axt inc:北京銀行會員2024-09-300001051627axt inc:北京通美晶體技術會員axt inc:2025年9月到期,2.9%銀行貸款會員axt inc:中信銀行會員2024-09-300001051627axt inc:北京通美晶體技術會員axt inc:2025年7月到期,2.9%銀行貸款會員axt inc:中信銀行會員2024-09-300001051627axt inc:北京同美晶體科技成員axt inc:2024年9月到期的2.7%銀行貸款成員axt inc:中國銀行成員2024-09-300001051627axt inc:北京同美晶體科技成員axt inc:2025年9月到期的2.4%銀行貸款成員axt inc:中國銀行成員2024-09-300001051627axt inc:北京博宇半導體船舶工藝技術有限公司成員axt inc:2024年9月到期的3.6%銀行貸款成員axt inc:工銀會員2024-09-300001051627axt inc:北京博宇半導體船工藝術科技有限公司會員axt inc: 2025年1月到期的銀行貸款,利率爲3.5%,會員axt inc:南京銀行會員2024-09-300001051627axt inc:北京博宇半導體船工藝術科技有限公司會員axt inc: 2024年10月到期的銀行貸款,利率爲3.2%,會員axt inc:寧波銀行會員2024-09-300001051627axt inc:北京博宇半導體船工藝術科技有限公司會員axti:2024年11月到期的銀行貸款,利率爲3.0%,會員axti:寧波銀行會員2024-09-300001051627axti:北京博宇半導體船舶工藝科技有限公司會員axti:2025年5月到期的銀行貸款,利率爲3.0%,單一會員axti:交通銀行會員2024-09-300001051627axti:北京博宇半導體船舶工藝科技有限公司會員axti:2025年9月到期的銀行貸款,利率爲2.8%,會員axti:中國工商銀行會員2024-09-300001051627axt inc:北京博宇半導體船舶工藝技術公司成員axt inc:銀行貸款,到期日2024年12月,利率2.7%,成員axt inc:中國工商銀行成員2024-09-300001051627axt inc:北京博宇半導體船舶工藝技術公司成員axt inc:銀行貸款,到期日2025年9月,利率2.3%,成員axt inc:中國銀行成員2024-09-300001051627axt inc:北京同美晶體技術成員axt inc:銀行貸款,到期日2024年9月,利率4.3%,成員axt inc:工銀會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc:2024年11月到期的4.3%銀行貸款會員axt inc:寧波銀行會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc:2024年6月到期的4.3%銀行貸款會員axt inc:工銀會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc: 2024年7月到期的銀行貸款,利率爲4.3%,會員axt inc:工銀會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc: 2024年12月到期的銀行貸款,利率爲4.3%,會員axt inc:寧波銀行會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc: 2024年9月到期的銀行貸款,利率爲4.2%,會員axt inc:寧波銀行會員2023-12-310001051627axt inc:北京同志晶元科技成員axt inc:於2024年1月1日到期的4.2%銀行貸款成員axt inc:北京銀行成員2023-12-310001051627axt inc:北京同志晶元科技成員axt inc:於2024年10月到期的3.8%銀行貸款成員axt inc:南京銀行成員2023-12-310001051627axt inc:北京同志晶元科技成員axt inc:於2024年5月到期的3.8%銀行貸款成員axt inc:交通銀行會員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:3.8%利率銀行貸款,到期日2024年5月會員axt inc:交通銀行會員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:3.7%利率銀行貸款,到期日2024年1月會員axt inc:招商銀行會員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:2024年11月到期的3.5%銀行貸款,兩名成員axt inc : 中國銀行成員2023-12-310001051627axt inc : 北京同美晶體科技成員axt inc:2024年11月到期的3.5%銀行貸款,一名成員axt inc : 中國銀行成員2023-12-310001051627axt inc : 北京同美晶體科技成員axt inc:2024年1月到期的3.5%銀行貸款,兩名成員axt inc : 中國銀行成員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:2024年1月到期的銀行貸款,利率3.5%,一位會員axt inc:中國銀行會員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:2024年9月到期的銀行貸款,利率3.3%,一位會員axt inc:中國工商銀行會員2023-12-310001051627axt inc:北京同煤晶體科技會員axt inc:2024年1月到期的銀行貸款,利率3.3%,兩位會員axt inc:交通銀行會員2023-12-310001051627axt inc:北京同煤晶體技術會員axt inc:3.2%利率2024年5月到期銀行貸款會員axt inc:北京銀行會員2023-12-310001051627axt inc:北京同煤晶體技術會員axt inc:3.2%利率2024年2月到期銀行貸款會員axt inc:北京銀行會員2023-12-310001051627axt inc:北京同煤晶體技術會員axt inc:2024年12月到期的3.0%銀行貸款會員axt inc:北京銀行會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc:2024年3月到期的2.8%銀行貸款一個會員axt inc:中國銀行會員2023-12-310001051627axt inc:北京同美晶體科技會員axt inc:2024年9月到期的2.7%銀行貸款會員axt inc:中國銀行會員2023-12-310001051627axt inc:北京博宇半導體船舶工藝科技有限公司成員axt inc:銀行貸款,截至2024年9月支付日利率爲3.6%的成員axt inc:工銀會員2023-12-310001051627axt inc:北京博宇半導體船舶工藝科技有限公司成員axt inc:銀行貸款,截至2024年5月支付日利率爲3.3%的成員axt inc:寧波銀行會員2023-12-310001051627axt inc:北京博宇半導體船舶工藝科技有限公司成員axt inc:銀行貸款,截至2024年5月支付日利率爲3.0%的成員axt inc:交通銀行會員2023-12-310001051627axt inc:北京博宇半導體船舶工藝科技有限公司會員axt inc:2025年9月到期銀行貸款,利率爲2.8%axt inc:中國工商銀行會員2023-12-310001051627axt inc:北京博宇半導體船舶工藝科技有限公司會員axt inc:2024年1月到期銀行貸款,利率爲2.4%axt inc:中國銀行會員2023-12-310001051627axt inc:朝陽鑫美高純度半導體材料有限公司會員2023-12-310001051627axt inc:朝陽碩美高純半導體材料有限公司會員axt inc:朝陽金美鎵有限公司會員axt inc:朝陽碩美高純半導體材料有限公司會員2023-08-310001051627axt inc:少數投資者會員2023-08-310001051627axt inc:朝陽碩美高純半導體材料有限公司會員axt inc:朝陽金美鎵有限公司會員axt inc:朝陽碩美高純半導體材料有限公司會員2023-05-310001051627axt inc:少數投資者會員2023-05-310001051627axt inc:朝陽金美鎵有限公司會員axt inc:朝陽碩美高純半導體材料有限公司會員2023-01-310001051627axt inc:少數投資者會員2023-01-310001051627axt inc:朝陽新美高純半導體材料有限公司會員axt inc:北京通美Xtal技術會員2022-01-310001051627axt inc:朝陽新美高純半導體材料有限公司會員axt inc:北京通美Xtal技術會員2021-12-310001051627axt inc:朝陽新美高純半導體材料有限公司會員axt inc : 與關聯方成員的貸款axt inc : 少數投資方成員2021-10-310001051627axt inc : 朝陽新梅高純半導體材料有限公司成員axt inc : 與關聯方成員的貸款axt inc : 少數投資方成員2021-09-300001051627axt inc : 北京通美晶體科技成員2021-01-012021-01-310001051627axt inc : 主要客戶之一成員us-gaap:應收賬款成員us-gaap:客戶集中風險成員2024-01-012024-09-300001051627axt inc: 重要客戶一會員美國通用會計準則:應收賬款會員美國通用會計準則:客戶集中風險會員2023-01-012023-12-3100010516272023-09-3000010516272022-12-310001051627us-gaap:公允價值輸入等級2成員us-gaap:公允價值計量反覆成員美國通用會計準則:存單成員2023-12-310001051627美國通用會計準則:重估後的可重複計量會員us-gaap:存款憑證成員2023-12-310001051627us-gaap:存款憑證成員2023-12-310001051627us-gaap:公允價值輸入二級成員us-gaap:重複發生的公允價值測量成員2023-12-310001051627us-gaap:重複發生的公允價值測量成員2023-12-310001051627axt inc: 租賃設施成員2024-09-300001051627us-gaap:受限股票會員2024-07-012024-09-300001051627us-gaap:員工股票期權成員2024-07-012024-09-300001051627us-gaap:RestrictedStockMember2024-01-012024-09-300001051627us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001051627us-gaap:RestrictedStockMember2023-07-012023-09-300001051627us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001051627us-gaap:RestrictedStockMember2023-01-012023-09-300001051627us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001051627美國通用會計準則:銷售、總務及管理費用成員2024-07-012024-09-300001051627us-gaap:研發費用成員2024-07-012024-09-300001051627us-gaap:CostOfSalesMember2024-07-012024-09-300001051627美元指數:銷售、一般和管理費用會員2024-01-012024-09-300001051627美元指數:研究與開發費用會員2024-01-012024-09-300001051627美元指數:銷售成本會員2024-01-012024-09-300001051627美元指數:銷售、一般和管理費用會員2023-07-012023-09-300001051627美元指數:研究與開發費用會員2023-07-012023-09-300001051627美元指數:銷售成本會員2023-07-012023-09-300001051627美元指數:銷售、一般和管理費用會員2023-01-012023-09-300001051627us-gaap:研發費用成員2023-01-012023-09-300001051627us-gaap:CostOfSalesMember2023-01-012023-09-300001051627美股:機械與設備成員2024-09-300001051627us-gaap:租賃改善成員2024-09-300001051627us-gaap:建築成員2024-09-300001051627美元指數:機械和設備成員2023-12-310001051627美元指數:租賃改善成員2023-12-310001051627美元指數:建築成員2023-12-3100010516272014-10-2700010516272024-11-010001051627axt inc:朝陽硅美高純半導體材料有限公司成員2022-04-300001051627axt inc:朝陽凱美石英有限公司成員2022-04-300001051627axt inc:朝陽鑫美高純半導體材料有限公司成員2021-05-310001051627axt inc:朝陽鑫美高純半導體材料有限公司成員2021-02-280001051627axt inc:北京博宇半導體器皿工藝科技公司成員axt inc:卡佐成員2024-09-300001051627axt inc:卡佐成員2024-09-300001051627axt inc:定興成員2024-09-300001051627axt inc: 交叉許可協議成員2024-01-012024-09-300001051627績效股份成員2023-03-150001051627axt inc: 情景表現最低財務指標成員srt:首席財務官成員美元指數: 績效股份成員2024-02-202024-02-200001051627axt inc: 情景表現最低財務指標成員srt : 首席執行官成員美元指數: 績效股份成員2024-02-202024-02-200001051627axt inc:情景表現最低財務指標成員srt:首席財務官成員us-gaap:績效股份成員2023-03-152023-03-150001051627axt inc:情景表現最低財務指標成員srt:首席執行官成員us-gaap:績效股份成員2023-03-152023-03-150001051627axt inc:北京同美晶科技成員2020-10-012020-12-310001051627us-gaap:績效股份成員2024-01-012024-09-300001051627Srt: 最低會員axt inc:場景績效財務指標小於50名成員us-gaap:PerformanceSharesMember2022-02-152022-02-150001051627srt:最少成員axt inc:場景績效財務指標介於50至200名成員之間us-gaap:PerformanceSharesMember2022-02-152022-02-150001051627srt:最少成員axt inc:場景績效財務指標大於200名成員us-gaap:績效股份會員2022-02-152022-02-150001051627srt : 最大成員axti: 場景績效財務指標在50至200之間的會員us-gaap:績效股份會員2022-02-152022-02-150001051627axti: 北京同美晶體技術會員2020-01-012020-12-310001051627axti: 北京同美晶體技術會員2024-01-012024-09-300001051627axti: 北京同美晶體技術會員2021-01-252021-01-250001051627axti: 南京金美鎵材料有限公司會員axt inc: 南京金美鎵有限公司投資成員2020-01-012020-12-310001051627axt inc : 南京金美鎵有限公司成員axt inc : 北京同美晶體科技成員2020-01-012020-12-310001051627axt inc : 北京博宇半導體器皿工藝科技有限公司成員axt inc : 北京同美晶體科技成員2020-01-012020-12-310001051627axt inc : 北京博宇半導體器皿工藝科技有限公司成員axt inc: 北京博宇半導體器皿工藝科技有限公司投資成員2020-01-012020-12-310001051627axt inc: 峨眉山佳美高純金屬有限公司投資成員2023-05-012023-05-310001051627美國通用會計準則:績效股份成員2024-02-200001051627美國通用會計準則:績效股份成員2023-02-140001051627axt inc:前五大主要客戶成員美國通用會計準則:銷售會員us-gaap:客戶集中風險成員2024-07-012024-09-300001051627美國通用會計準則:銷售成員美國通用會計準則:客戶集中風險成員2024-07-012024-09-300001051627axt inc:前五大主要客戶成員美元指數:銷售會員美元指數:客戶集中風險會員2024-01-012024-09-300001051627美元指數:銷售會員美元指數:客戶集中風險會員2024-01-012024-09-300001051627us-gaap:應收賬款成員2024-01-012024-09-300001051627axt inc : 前五大客戶會員美元指數:銷售會員美元指數:客戶集中風險會員2023-07-012023-09-300001051627美元指數:銷售會員美元指數:客戶集中風險會員2023-07-012023-09-300001051627美元指數:應收賬款會員2023-01-012023-12-310001051627axt inc:前五大主要客戶會員美元指數:銷售會員美元指數:客戶集中風險會員2023-01-012023-09-300001051627美元指數:銷售會員美元指數:客戶集中風險會員2023-01-012023-09-300001051627us-gaap:留存收益成員2024-07-012024-09-300001051627美國通用會計準則:非控股權益成員2024-07-012024-09-300001051627us-gaap:留存收益成員2024-04-012024-06-300001051627us-gaap:非控制權益成員2024-04-012024-06-300001051627us-gaap:留存收益成員2024-01-012024-03-310001051627us-gaap:非控制權益成員2024-01-012024-03-310001051627us-gaap:留存收益成員2023-07-012023-09-300001051627us-gaap:非控制權益成員2023-07-012023-09-300001051627美國通用會計準則:留存收益成員2023-04-012023-06-300001051627美國通用會計準則:非控股權益成員2023-04-012023-06-300001051627美國通用會計準則:留存收益成員2023-01-012023-03-310001051627美國通用會計準則:非控股權益成員2023-01-012023-03-310001051627axti inc:北京同美晶體技術成員axti inc:朝陽新美高純半導體材料有限公司成員2022-07-012022-07-310001051627axti inc:朝陽新美高純半導體材料有限公司成員2022-07-012022-07-310001051627axti inc:朝陽新美高純半導體材料有限公司成員axt inc : 朝陽碩美高純半導體材料有限公司成員2022-08-012022-08-310001051627axt inc : 朝陽碩美高純半導體材料有限公司成員2022-08-012022-08-310001051627axt inc : 朝陽新美高純半導體材料有限公司成員axt inc : 朝陽碩美高純半導體材料有限公司成員2022-07-012022-07-310001051627axt inc : 朝陽凱美石英有限公司成員2022-07-012022-07-310001051627axt inc : 朝陽新美高純半導體材料有限公司成員2021-05-012021-05-310001051627axt inc : 朝陽新美高純半導體材料有限公司成員2021-02-012021-02-280001051627srt:子公司成員2024-09-300001051627axti:NanjingJinMeiGalliumCo.LtdInvestmentMember2024-09-300001051627axti:ChaoyangXinmeiHighPuritySemiconductorMaterialsCo.LtdMember2024-09-300001051627axti : Chao Yang Shuo Mei High Purity Semiconductor Materials Co Ltd Member2024-09-300001051627axti:ChaoyangJinmeiGalliumCo.LtdMember2024-09-300001051627axti:BeijingBoyuSemiconductorVesselCraftworkTechnologyCo.LtdInvestmentMember2024-09-300001051627srt : Subsidiaries Member2023-12-310001051627axti:NanjingJinMeiGalliumCo.LtdInvestmentMember2023-12-310001051627axti:ChaoyangXinmeiHighPuritySemiconductorMaterialsCo.LtdMember2023-12-310001051627axt inc:朝陽碩美高純半導體材料有限公司成員2023-12-310001051627axt inc:朝陽金美鎵有限公司成員2023-12-310001051627axt inc:北京博宇半導體器皿工藝科技有限公司投資成員2023-12-310001051627axt inc:北京同美晶體科技成員2021-01-250001051627axt inc:北京同美晶體科技成員2021-06-012021-06-300001051627srt:最高成員2024-01-012024-09-300001051627axt inc:東海縣東方高純電子材料有限公司投資成員2023-11-012023-11-300001051627axt inc:東海縣東方高純電子材料有限公司投資成員2023-10-012023-12-310001051627axt inc:五個少數投資成員2024-07-012024-09-300001051627axt inc:五個少數投資成員2024-01-012024-09-300001051627axt inc:五個少數投資成員2023-07-012023-09-300001051627axt inc:五個少數投資成員2023-01-012023-09-300001051627axt inc:北京佳獲半導體材料股份有限公司投資成員2024-09-3000010516272023-01-012023-09-300001051627axt inc:峨眉山佳美高純金屬股份有限公司投資成員2024-01-012024-09-300001051627axt inc:北京通玫晶技術成員axt inc:工銀會員2024-01-012024-09-300001051627axt inc:北京博宇半導體船舶工藝科技有限公司會員axt inc:興業銀行會員2023-01-012023-12-3100010516272024-09-3000010516272023-12-3100010516272024-01-012024-09-3000010516272023-01-012023-12-310001051627美元指數:PerformanceShares會員2023-02-142023-02-140001051627母公司成員2024-07-012024-09-300001051627us-gaap:額外實收資本成員2024-07-012024-09-3000010516272024-07-012024-09-300001051627美元指數:母公司會員2024-04-012024-06-300001051627美元指數:額外實收資本會員2024-04-012024-06-3000010516272024-04-012024-06-300001051627美元指數:母公司會員2024-01-012024-03-310001051627美元指數:其他資本溢價成員2024-01-012024-03-3100010516272024-01-012024-03-310001051627美元指數:母公司成員2023-07-012023-09-300001051627美元指數:其他資本溢價成員2023-07-012023-09-3000010516272023-07-012023-09-300001051627美元指數:母公司成員2023-04-012023-06-300001051627美元指數:其他資本溢價成員2023-04-012023-06-3000010516272023-04-012023-06-300001051627美元指數:母公司成員2023-01-012023-03-310001051627美元指數:其他資本溢價成員2023-01-012023-03-3100010516272023-01-012023-03-310001051627axt inc: 朝陽凱美石英有限公司成員2023-09-30iso4217:美元指數xbrli:純形axti:companyaxti:customerxbrli股份平方英尺iso4217:USDxbrli:sharesaxti:segment

0

美國
證券交易委員會

華盛頓特區20549

表格10-Q

(標記一)

根據1934年證券交易法第13或15(d)條進行的季度報告

截至季度結束 2024年9月30日

或者

根據1934年證券交易法第13或15(d)條進行的過渡報告

在從 到的過渡期間

委員會文件號 000-24085

AXt,INC.

(根據其章程規定的註冊人準確名稱)

特拉華。

94-3031310

(國家或其他管轄區的
註冊或組織)

(IRS僱主
唯一識別號碼)

4281 Technology Drive, Fremont, 加利福尼亞州 94538

,(主要行政辦公地址) (郵政編碼)

(510) 438-4700

(註冊人電話號碼,包括區號)

在法案第12(b)條的規定下注冊的證券:

每個類別的名稱:

    

交易代碼

    

註冊在每個交易所的名稱:

普通股,每股0.001美元面值

AXTI

股市 納斯達克 股票市場有限責任公司

請以複選標記形式指示:報告主體(1)在過去12個月內已按照1934年證券交易所法案第13或第15(d)條的規定提交了所有要求提交的報告(或要求提交此類報告的較短時期),並且(2)在過去90天內一直受到此類提交要求的約束。 

請通過複選標記指出註冊申報人是否在過去12個月內(或註冊申報人需要提交此類文件的更短期間)根據《Regulation S-T》規則405(本章第232.405條)要求提交每個交互式數據文件。 

請勾選表示註冊申報人是大型責任審核加速器、加速器、非加速器、較小的報告公司還是新興增長公司。請參閱《交易所法》第120億.2條對「大型責任審核加速器」、「加速器」、「較小的報告公司」和「新興增長公司」的定義。

大型加速歸檔人

加速文件提交人 

非加速報告人

小型報表公司

新興成長公司

如果是新興成長公司,請在複選框中標明註冊者是否選擇不使用按照《交易所法》第13(a)條規定提供的任何新的或修訂後的財務會計準則的延期過渡期。

請通過複選框標明註冊者是否爲外殼公司(定義見《交易所法》120億條規定)。是 不是

截至2024年11月1日, 44,750,581 註冊公司普通股中有0.001美元面值的股份流通。

AXt,INC.

第10-Q表格

目錄

頁面

第一部分 財務信息

項目1:基本報表(未經審計)

截至2024年9月30日和2023年12月31日的精簡合併資產負債表

3

2024年9月30日和2023年的三個月和九個月的營運基本報表

4

2024年9月30日和2023年截至九個月的控件綜合損益簡明綜合報表

5

2024年9月30日止九個月的精簡合併現金流量表和2023年

6

簡明綜合基本報表附註

7

項目2. 管理層對財務狀況和業績的討論與分析

35

項目3.有關市場風險的定量和定性披露

56

項目4.控制和程序

58

第二部分。其他信息

項目1.法律訴訟

59

項目1A.風險因素

59

項目2. 未註冊的股權銷售和款項使用

86

項目3. 高級證券違約

86

項目4.礦山安全披露

86

項目5.其他信息

86

項目6.附件

87

簽名

88

2

目錄

第一部分 財務信息

項目1:基本報表(未經審計)

AXt,INC.

簡明綜合資產負債表S

(未經審計,單位爲千,除每股數據外)

    

九月30日

    

運營租賃負債:

 

2024

2023

資產

流動資產:

現金

$

24,898

$

37,752

限制性現金

13,893

12,362

短期投資

 

 

2,140

應收賬款,減去$的信貸損失263 和$579 截至2024年9月30日和12月31日的股票

 

27,970

 

19,256

存貨

 

86,109

 

86,503

預付費用和其他流動資產

 

14,991

 

12,643

總流動資產

 

167,861

 

170,656

物業、廠房和設備,淨值

 

166,459

 

166,348

經營租賃權使用資產

2,451

2,799

其他

 

18,809

 

18,898

總資產

$

355,580

$

358,701

負債、可贖回非控制權益和股東權益

流動負債:

應付賬款

$

12,780

$

9,617

應計負債

 

11,941

 

19,019

短期貸款

54,052

52,921

流動負債合計

 

78,773

 

81,557

非流動工程租賃負債

1,993

2,351

其他長期負債

 

8,595

 

5,647

負債合計

 

89,361

 

89,555

承諾和擔保(詳見第12注)

可贖回的非控股權益(附註18)

41,237

41,663

股東權益:

優先股,系列A,每股面值 $215688680,截至2023年12月31日和2024年3月31日,已發行並流通股數分別爲 $227838680。0.001 面值; 2,000 股份已授權; 883 於2024年9月30日和2023年12月31日已發行並流通的股份(偏愛清算價值爲$8,008 和$7,875 截至2024年9月30日和2023年12月31日

 

3,532

 

3,532

普通股,每股面值爲 $0.0001;0.001 面值; 70,000 股份已授權; 44,677 並且 44,239 截至2024年9月30日和2023年12月31日,發行並流通的股份數量

 

45

 

44

額外實收資本

 

240,770

 

238,452

累積赤字

 

(38,576)

 

(32,040)

累計其他綜合損失

 

(5,038)

 

(5,999)

AXt公司股東權益總額

 

200,733

 

203,989

非控制權益

 

24,249

 

23,494

股東權益總額

 

224,982

 

227,483

負債、可贖回的非控制性權益和股東權益總計

$

355,580

$

358,701

請參閱附註事項的簡明合併財務報表。

3

目錄

ub

AXt,INC.

簡明合併利潤表

(未經審計,單位爲千,除每股數據外)

    

結束於3個月的期間

    

結束於9個月的期間

九月30日

9月30日

2024

    

2023

2024

    

2023

營業收入

$

23,645

$

17,366

$

74,256

$

55,366

營運成本

 

17,963

 

15,500

 

54,828

 

46,675

毛利潤

 

5,682

 

1,866

 

19,428

 

8,691

營業費用:

銷售、一般和管理費用

 

5,650

 

5,667

 

17,656

 

17,439

研發費用

 

3,438

 

2,926

 

10,410

 

9,261

總營業費用

 

9,088

 

8,593

 

28,066

 

26,700

營運虧損

 

(3,406)

 

(6,727)

 

(8,638)

 

(18,009)

利息支出,淨額

 

(391)

 

(381)

 

(1,022)

 

(1,143)

未合併聯營企業的權益

 

1,007

 

369

 

2,495

 

2,344

其他收入,淨額

 

529

 

223

 

2,052

 

1,282

稅前虧損

 

(2,261)

 

(6,516)

 

(5,113)

 

(15,526)

所得稅徵(免)額

 

626

 

(101)

 

1,021

 

(92)

淨虧損

 

(2,887)

 

(6,415)

 

(6,134)

 

(15,434)

減少:歸屬於非控股利益和可贖回非控股利益的淨(收益)損失

 

(50)

 

592

 

(402)

 

1,174

歸屬於AXt,Inc.的淨損失

$

(2,937)

$

(5,823)

$

(6,536)

$

(14,260)

AXt,Inc.歸屬於普通股的淨虧損每股:

基本

$

(0.07)

$

(0.14)

$

(0.15)

$

(0.34)

攤薄

$

(0.07)

$

(0.14)

$

(0.15)

$

(0.34)

普通股股份加權平均數:

基本

 

43,157

 

42,638

 

43,079

 

42,574

攤薄

 

43,157

 

42,638

 

43,079

 

42,574

請參閱附註事項的簡明合併財務報表。

4

目錄

AXt, INC.

基本報表綜合損益表

(未經審計,以千爲單位)

結束於3個月的期間

結束於9個月的期間

9月30日

9月30日

    

2024

    

2023

    

2024

    

2023

 

淨虧損

$

(2,887)

$

(6,415)

$

(6,134)

$

(15,434)

其他綜合收益(損失), 淨額(稅後):

外幣翻譯盈虧變動(稅後淨額)

 

3,932

 

(580)

 

1,175

 

(6,938)

可供出售債務投資未實現收益變動,稅後淨額

 

5

 

65

 

20

 

253

其他綜合收益(損失),淨所得稅後

 

3,937

 

(515)

 

1,195

 

(6,685)

歸屬於AXt,Inc.的綜合收益(損失)

 

1,050

 

(6,930)

 

(4,939)

 

(22,119)

減:歸屬於非控制股東及可贖回非控制股東的綜合(損益)

 

(798)

 

701

 

(636)

 

2,396

歸屬於AXt,Inc.的綜合收益(損失)

$

252

$

(6,229)

$

(5,575)

$

(19,723)

請參閱附註事項的簡明合併財務報表。

5

目錄

AXt,INC.

現金流量表簡明綜合報表

(未經審計,以千爲單位)

結束於9個月的期間

9月30日

    

2024

    

2023

經營活動現金流量:

淨虧損

$

(6,134)

$

(15,434)

用於調節淨虧損至經營活動現金流量淨額的調整項目:

折舊和攤銷

 

6,736

 

6,424

可交易證券溢價攤銷

 

 

18

股票補償

 

2,344

 

2,718

設備處置損失

 

 

18

將權益法投資的回報作爲股息支付

2,063

3,666

未合併聯營企業的權益

 

(2,495)

 

(2,344)

遞延所得稅資產

(22)

122

經營性資產和負債變動:

應收賬款

 

(8,526)

 

9,594

存貨

 

1,134

 

(1,013)

預付費用和其他流動資產

 

(5,823)

 

1,909

其他

 

1,173

 

219

應付賬款

 

3,043

 

(3,375)

應計負債

 

(1,387)

 

(1,742)

其他長期負債

 

(5,488)

 

1,194

經營活動產生的淨現金流量

 

(13,382)

 

1,974

投資活動現金流量:

購買固定資產

 

(5,604)

 

(11,178)

可供出售債務證券的銷售收益和到期收益

 

2,160

 

7,423

Proceeds from sales of equity securities - 15% Jia Mei

 

 

827

Investments in non-marketable equity investments

(560)

(1,918)

投資活動產生的淨現金流出

 

(4,004)

 

(4,846)

籌集資金的現金流量:

行使普通股期權所得款項

 

28

 

10

短期銀行借款款項

 

41,582

 

42,197

短期銀行貸款償還

(42,295)

(40,673)

來自非控制股東子公司股份增資的款項

708

長期貸款的收益

5,831

長期貸款的付款

(643)

籌資活動產生的現金淨額

 

4,503

 

2,242

匯率變動對現金和限制性現金的影響

 

1,560

 

(1,418)

現金和受限現金的淨減少

 

(11,323)

 

(2,048)

年初的現金和限制性現金

 

50,114

 

41,348

期末現金和限制性現金

$

38,791

$

39,300

非現金流量信息的補充披露:

應收票據用於購買固定資產

$

3,608

$

從非控制股權持有人處投資子公司股份

$

$

308

與在建工程相關的應付款項,包括在應計負債中

$

149

$

3,315

請參閱附註事項的簡明合併財務報表。

6

目錄

AXt,INC.

簡明合併財務報表附註

(未經審計)

註釋1. 報告的基礎

AXt,Inc.(以下簡稱爲「AXt」,「公司」,「我們」和「我們」均指AXt,Inc.及其所有的子公司)的附屬公司簡明合併財務報表未經審計,並按照美國通用會計準則(「U.S. GAAP」)制定的美國的中期財務信息和《10-Q表格》的指示以及《S-X法規》第10條的要求編制。因此,本中期季度財務報告未包含美國通用會計準則要求的所有披露以供完整合並財務報表。在我們管理層的意見中,未經審計的簡明合併財務報表反映了所有調整,僅包括被認爲必要的常規調整,以公正地呈現公司所有期間的財務狀況、經營業績和現金流量。

我們的管理層就資產和負債的報告以及揭示潛在資產和負債方面作出了衆多估計和假設,以符合美國通用會計準則。由於COVID-19大流行,全球經濟和金融市場出現了不確定性和混亂。這些估計和假設可能隨着新事件的發生和獲得的額外信息而發生變化。實際結果可能與這些估計存在實質性差異。

2024年9月30日結束的三個月和九個月的運營結果並不一定能反映未來或整個財年所預期的結果。建議閱讀這些簡明合併財務報表時結合我們年度報告中包括於2023年12月31日提交給證券交易委員會(「SEC」)的《10-K表格》以及我們於2024年3月15日提交給SEC的季度報告中附註在2024年3月31日、2024年6月30日提交給SEC的季度報告,分別於2024年5月10日和2024年8月9日提交給SEC。

精簡綜合財務報表包括AXt及其子公司北京同美晶科技有限公司(「同美」)、AXt-Tongmei 公司(「AXt-Tongmei」)、保定同美晶科技有限公司(「保定同美」)、朝陽同美晶科技有限公司(「朝陽同美」)、朝陽力美半導體科技有限公司(「朝陽力美」)、朝陽信美高純度半導體材料有限公司(「朝陽信美」)、南京金美鎵有限公司(「金美」)、朝陽金美鎵有限公司(「朝陽金美」)、朝陽碩美高純度半導體材料有限公司(「朝陽碩美」)、馬鞍山金美鎵有限公司(「馬鞍山金美」)及北京博譽半導體器皿工藝技術有限公司(「博譽」)。所有重要的公司間帳戶和交易已經被消除。我們對那些雖沒有控制權但有能力對經營和財務政策產生重大影響(一般20-50%的持股權益)的企業投資採用權益法進行會計處理。截至2024年9月30日和2023年12月31日,我們有 家公司採用權益法覈算。2023年5月,我們通過向第三方出售部分嘉美股份,將對峨眉山嘉美高純金屬有限公司(「嘉美」)的持股比例從 25百分比至 10%的份額降至$827,000左右。由於我們持股比例降低以及無法對嘉美的經營產生重大影響,截至2023年5月,我們不再將嘉美作爲綜合財務報表中的權益投資進行披露。我們對嘉美投資在售出時重新計量其公允價值。今後對公允價值的任何變化均通過淨收益確認(「公允價值法」)。對於我們合併的控股子公司,我們反映我們不擁有的部分,或者作爲我們綜合財務報表和綜合損益表中的非控股權益,或者作爲我們綜合財務報表和綜合損益表中的可贖回的非控股權益。

根據有利的市場條件,我們打算在朝陽麗美的位置建設設施,以爲我們提供額外的生產能力。 截至2024年9月30日的三個和九個月,與朝陽麗美相關的費用對我們的簡明綜合財務報表幾乎沒有影響。

7

目錄

2021年2月,銅煤公司與特定投資者簽署了一份合資協議,爲一家名爲朝陽新美的新創業公司提供基金支持。該協議要求總投資額約爲$3.0 百萬元,其中銅煤公司將爲朝陽新美提供約$1.8 million for a 58.5 的股權。2021年2月,銅煤公司和投資者完成了約爲$1.5 百萬元的初次投資。銅煤公司在這次投資中的部分約爲$0.9 百萬元。2021年5月,銅煤公司和投資者完成了約爲$1.5 的剩餘資金注資。銅煤公司在最終投資中的部分約爲$0.9 百萬美元,總投資額約爲$1.8 百萬美元的投資 58.5 持有朝陽新梅0.9 百萬和$1.0 分別獲得一家少數投資方的$百萬美元1.4 分別獲得了來自同美的$百萬美元和$百萬美元的基金1.4 分別收到了來自同美的$百萬美元和$百萬美元的投資4.5 在朝陽新梅獲得這筆額外投資後,中國當地政府在2022年1月認證其爲股權投資。2022年4月,同美與少數投資方簽訂了一份資本增加協議(「資本增加協議」),進一步在朝陽新梅投資約$百萬美元。同美在此次投資中的份額約爲$2.6 百萬美元,其中$1.1 在2022年4月投資了1000萬美元和$0.8 在2022年5月投資了1000萬美元。 少數投資者所佔投資約爲$1.9 百萬,其中400萬美元投資於2022年4月,500萬美元投資於2022年5月。 結果,非控股權益增加百萬美元,可贖回的非控股權益增加百萬美元。 2022年7月,同美和少數投資者又投資了$0.7 百萬美元和$0.6 百萬美元分別投資於2022年4月和2022年5月。 結果,非控股權益增加百萬美元,可贖回的非控股權益增加百萬美元。 2022年7月,童美和少數投資者進一步投資了$1.4 百萬美元,可贖回的非控股權益增加百萬美元。 2022年7月,同美和少數投資者再次投資了$0.1 美創業公司和少數投資者進一步投資了$0.8 百萬美元和美元0.6 Chaoyang Xinmei分別投資了百萬美元。這完成了增資協議下的投資義務。因此,非控股權益增加了610,000 ,贖回性非控股權益增加了美元57,000。通過這些股權投資後,桐梅的所有權保持在 58.5%。

2022年4月,朝陽金美與某些投資者簽署了一項合資協議,爲一個新公司創業公司朝陽碩美提供資金,成爲我們的合併子公司(「朝陽碩美合資協議」)。朝陽碩美合資協議要求總投資約爲美元4.4 百萬美元,其中朝陽金美將出資約美元3.3 投資了一千萬美元用於購買 75 擁有朝陽金梅百分之1.0 美元的初步投資334,000 美元。因此,非控制權益增加了406,000 美元,可贖回的非控制權益增加了73,000百萬美元的資金。0.5 百萬美元的投資,並從其中一位少數投資者那裏獲得了0.2 百萬美元的資金。因此,非控制權益增加了0.2 百萬美元,並贖回的非控制權益增加了$36,000。2023年5月,朝陽碩美收到了$1.0 百萬美元的融資,其中包括來自朝陽金美的$0.3 百萬美元的融資,其中包括來自一位少數投資者的$。因此,非控制權益增加了$0.4 百萬美元,並贖回的非控制權益增加了$75,000。2023年8月,朝陽碩美收到了$0.6 百萬美元的融資,其中包括來自朝陽金美的$0.2 百萬美元的融資,其中包括來自一位少數投資者的$。因此,非控制權益增加了$0.2 百萬美元和可贖回的非控股權益增加了$44,000朝陽金美已完成其在朝陽碩美合資協議下的投資義務。朝陽金美對朝陽碩美的所有權仍保持在 75%的股份投資後這些股權投資。

2022年4月,通美與某些投資者簽署了一項合資協議,爲一家名爲朝陽凱美石英有限公司(「朝陽凱美」)的新公司提供資金(「朝陽凱美合資協議」),總投資約爲$7.6 百萬美元,其中通美將爲了獲得3.0 %的朝陽凱美所有權,資助約$ 40 百萬美元。2022年7月,通美和投資者完成了約$的首次融資。2.2 百萬美元。通美在投資中的部分大約爲$0.9 百萬美元。2023年1月,通美向朝陽開美投資了$0.9 百萬美元。2023年7月和8月,通美分別向朝陽開美投資了約$0.6 百萬美元。2023年9月,通美與同一群投資者再次達成合資協議。根據這項新協議,需要額外投資約$5.6 百萬美元,通美承諾資助約$2.3 百萬美元。2023年12月,通美首次額外投資了約$0.6 百萬美元,隨後在2024年6月和7月分別進行了約$0.3 百萬美元的額外投資。通美對朝陽開美的持股比例保持在 40% 在這些股權投資之後。

萬安山金煤的所有活動在2022年上半年停止,隨後於2022年5月解散。萬安山金煤的解散對簡明合併財務報表的影響不大。

8

目錄

During the quarter ended December 31, 2020, Tongmei entered into two sets of definitive transaction documents, each consisting of a capital increase agreement along with certain supplemental agreements in substantially the same form (collectively, the 「Capital Investment Agreements」), with several private equity investors in China.

In preparation for Tongmei’s application for a listing of shares in an initial public offering (the 「IPO」) on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd (the 「STAR Market」), in late December 2020, we reorganized our entity structures in China. JinMei and BoYu and their subsidiaries were assigned to Tongmei and effectively merged with Tongmei although they retained their own respective legal entity status and are wholly owned subsidiaries of Tongmei. The 33% minority interest stakeholders of BoYu converted their ownership to a 7.59% minority interest in Tongmei. The 8.5% minority interest stakeholders, employees of JinMei, converted their ownership to a 0.38銅煤中的少數股權。此外,許多員工、關鍵經理和貢獻者購買了 0.4銅煤中的少數股權。此外,保定銅煤和朝陽銅煤被指定爲銅煤的全資子公司。2020年,私募股權基金(「投資者」)已向銅煤轉移了約48.1 百萬美元的新資金。2021年1月,又注資約1.5 百萬美元的新資金。根據中國法規,這些投資必須得到相關政府機構的正式批准,在獲得批准之前不被視爲具有稀釋效應。政府於2021年1月25日全額批准約49 百萬美元的投資,屆時投資者持有銅煤可贖回的非控制權益 7.28。截至2024年9月30日,銅煤的非控制權益和可贖回的非控制權益總額約爲 14.5。我們仍然是銅煤的控股股東,並持有銅煤董事會的大部分董事職位。2021年6月,我們以1的價格將AXt-Tongmei出售給了 85.5持有我們的%股權,並且交易是在共同利益持有人之間進行的,交易按淨賬面價值計入,並導致非控股權益增加$1.2 百萬至非控股權益和$1.2 百萬至可贖回的非控股權益。

注2. 投資和公平價值計量

我們的投資包括原始到期日超過三個月的工具。 截至2024年9月30日和2023年12月31日,我們的現金和債務投資分類如下(以千爲單位):

2024年9月30日

2023年12月31日

 

    

    

總額

    

Gross

    

    

    

總和

    

總和

    

 

按攤銷計算的

未實現

未實現的

公平

攤銷的

未實現

未實現

公允

 

    

成本

    

Gain

    

(虧損)

    

    

成本

    

收益

    

(虧損)

    

價值

 

分類爲:

現金和受限制的現金

$

38,791

$

$

$

38,791

$

50,114

$

$

$

50,114

投資(可供出售):

存單 1

 

 

 

 

2,160

 

(20)

 

2,140

現金總額,受限制的現金和投資

$

38,791

$

$

$

38,791

$

52,274

$

$

(20)

$

52,254

投資的合約到期

一年內到期 2

$

$

$

2,160

$

2,140

$

$

$

2,160

$

2,140

1.存款證書的原始到期日超過三個月。
2.在我們的簡明綜合資產負債表中分類爲「短期投資」。

我們將債務投資管理爲一攬子高度市場化證券的單一投資組合,此投資組合旨在應對我們目前的現金需求。存款證書和公司債券通常持有至到期日。

從歷史來看,我們以可供出售債務證券組成的投資組合的總未實現損失相對較小,主要是由於正常市場波動,而不是由於增加的信用風險或其他估值問題。

9

目錄

關注。 截至2024年9月30日,我們持有的可供出售債務證券存在微不足道的未實現損失,而且從歷史數據看,此類未實現損失通常是暫時性的,我們認爲按照合同條款收回本金和利息的可能性很大。我們至少每季度或在信用風險或其他潛在估值問題發生變化時審查我們的債務投資組合,以確定是否需要爲信用損失或減值設置準備金。確定損失是否爲暫時性的考慮因素包括市場價值下降幅度、市場價值低於成本(或調整後成本)的時間長短、信用質量以及我們持有證券並打算持有足夠時間以便預期市場價值的任何恢復。

以下表格總結了截至2024年9月30日持有的可供出售債務證券的公允價值和未實現損失,按投資類別和個別證券持續處於未實現損失位置的時間長度分類(以千爲單位):

虧損中

虧損中

總計

 

< 12 個月

> 12 個月

虧損位置

 

總和

總和

總和

 

公允

未實現

公允

未實現

公允

未實現

 

截至2024年9月30日

    

價值

    

(虧損)

    

價值

    

(虧損)

    

價值

    

(虧損)

 

投資:

定期存單

$

$

$

$

$

$

全部處於虧損位置

$

$

$

$

$

$

以下表格總結了截至2023年12月31日的可供出售債務證券的公允價值和毛未實現損失,按投資類別和證券處於連續未實現損失位置的時間長度進行彙總(以千爲單位):

處於虧損狀態

處於虧損狀態

總計

 

< 12個月

> 12 個月

虧損位置

 

    

    

    

總和

    

    

    

總和

    

    

    

總和

 

公允

未實現

公允

未實現

公允

未實現

 

截至2023年12月31日

價值

(虧損)

價值

(虧損)

價值

(虧損)

 

投資:

定期存單

$

$

$

2,140

$

(20)

$

2,140

$

(20)

處於虧損位置的總計

$

$

$

2,140

$

(20)

$

2,140

$

(20)

受限制現金

我們持有受限現金,與因常規業務操作暫時受限的現金餘額有關。這些餘額已被排除在公司的現金餘額之外。截至2024年9月30日,受限現金中包含了$13.9 百萬美元被包括在我們的簡明綜合資產負債表中的受限現金中。

對私人持有的原材料公司的投資

我們已經在中國對其他一傢俬人公司進行了戰略性投資,以獲取對原材料的競爭成本,這對我們的基板業務至關重要(見注7)。 非合併公司的投資餘額按權益法覈算,在精簡合併資產負債表中計入「其他資產」,截至2024年9月30日和2023年12月31日,分別總計$13.5 百萬美元和美元12.5 百萬美元。截至2024年9月30日,按權益法覈算的公司有 家。 我們的一項股權投資,Beijing JiYa Semiconductor Material Co., Ltd.(「JiYa」),確定其中一項股權投資已完全減值,並將資產餘額減記爲 。 這導致了一筆$754,000 在我們2023年第二季度的財務報告中計提減值損失。除上述提及外,截至2024年和2023年9月30日的三個月和九個月期間,其他投資未發生減值損失。 沒有 在2024年和2023年9月30日結束的三個月和九個月期間,我們對這些投資的剩餘部分未發生減值損失。

2023年5月,我們減少了對佳美的持股。 25百分比至 10%的份額降至$827,000由於我們持股比例減少以及我們無法對佳美的經營施加重大影響,我們採用了公允價值計量法進行會計處理。

10

目錄

report on the investment in Jia Mei. Our investments under the fair value method are reviewed for other-than-temporary declines in value on a quarterly basis. We monitor our investments for impairment and record reductions in carrying value when events or changes in circumstances indicate that the carrying value may not be recoverable. As of September 30, 2024, our investments in this unconsolidated company had a carrying value of $551,000 and were included in 「Other assets」 in the condensed consolidated balance sheets. As a result of the share sale, we recognized a gain of $575,000. Additionally, in accordance with Accounting Standards Codification (「ASC」) 321-10-35-2, we adjusted the investment in Jia Mei to its fair value at the time of the sale, which resulted in a gain of $383,000. The gain resulting from the sale and the subsequent remeasurement was incorporated as a component of 「Equity in income of unconsolidated joint ventures」 in the condensed consolidated statements of operations in the second quarter of 2023.

公允價值衡量

我們主要投資於存款單據、公司債券和票據、政府證券以及貨幣市場帳戶。我們會定期或在信用風險或其他潛在估值擔憂發生變化時審查我們的債務投資組合。截至2024年9月30日和2023年12月31日,在其他綜合收益中包括的淨未實現損失總額,扣除稅款後爲微不足道。我們認爲按照合同條款收回本金和利息的可能性很高,這些證券的未實現損失是由於正常市場波動引起的,而不是由於信用風險增加或其他估值擔憂。ASC 820建立了三個可能用於衡量公平值的輸入級別。一級工具估值是從資產或相同資產的活躍交易市場的實時報價中獲取的。二級工具估值是從可供獲取的觀察到的價格來源中爲類似工具獲取的。三級工具估值是從幾乎沒有市場數據的不可觀察輸入中獲取的,這要求我們制定自己的假設。我們定期衡量某些按公平值計量的金融資產和負債,主要包括我們的短期和長期債務投資。 公允價值計量和披露建立了三個可能用於衡量公平值的輸入級別。一級工具估值是從資產或相同資產的活躍交易市場的實時報價中獲取的。二級工具估值是從可供獲取的觀察到的價格來源爲類似工具獲取的。三級工具估值是從幾乎沒有市場數據的不可觀察輸入中獲取的,這要求我們制定自己的假設。我們定期衡量某些按公平值計量的金融資產和負債,主要包括我們的短期和長期債務投資。

基於活躍市場報價的一級市場價格來進行估值的工具類型包括我們的貨幣市場基金,通常被分類爲公平值層次結構中的一級。我們將可供出售的債務證券(包括存款單據和公司債券)分類爲具有二級輸入的工具。用於衡量具有二級輸入的這些金融工具的公允值的估算技術來源於銀行報表、報價市價、經紀人或交易商報表或報價,或具有合理價格透明度的另類定價來源。

我們進行短期外幣對沖,旨在抵消美元與日幣匯率波動導致的現金風險。我們根據美國通用會計準則(U.S. GAAP)利用實時匯率,在每月末和季末衡量這些外幣對沖的公允價值。在季末,未結算的外幣對沖會在「應計負債」中抵銷,並被分類爲三級資產和負債。截至2024年9月30日,在整個季度,從對沖安排至每月末結算的公允價值變動對簡明合併財務報表的影響微乎其微。

2024年9月30日前三個月和前九個月裏,估值技術或相關輸入沒有發生變化。 沒有 2024年9月30日前三個月和前九個月間,各種公允價值測量水平之間發生了轉移。

以下表格總結了截至2024年9月30日根據ASC 820重複計量的金融資產和負債(以千爲單位):

11

目錄

    

    

在活躍市場中

    

重要的

 

活躍的市場

對於相同的重要其他方

不可觀察的

 

截至目前餘額

相同資產

可觀察輸入

輸入

 

    

2024年9月30日

    

(一級)

    

(2級)

    

非市場可觀察到的輸入(三級)

 

資產:

投資:

定期存單

$

$

$

$

總計

$

$

$

$

以下表格總結了截至2023年12月31日按照ASC 820測量的我們的金融資產和負債的公允價值(以千爲單位):

    

    

報價中

    

重要的

 

活躍的市場

重要的另一半

不可觀察

 

截至日期的餘額

相同的資產

可觀察的輸入

輸入

 

    

2023年12月31日

    

(一級)

    

(2級)

    

(3級)

 

資產:

投資:

存款證書

$

2,140

$

$

2,140

$

總計

$

2,140

$

$

2,140

$

非經常性計量基礎上的公允價值測量項目

表格中未包括一些資產,這些資產需進行非經常性公允價值測量。這些資產包括對私人持有公司的投資,按權益法或公允價值法進行覈算(見注7)。我們在2024年和2023年截至9月30日的三個月和九個月內,未記錄這些投資的除其他臨時性減值損失。

注3. 存貨

存貨的元件如下所示(以千爲單位):

9月30日

運營租賃負債:

    

2024

    

2023

 

存貨:

原材料

$

30,535

$

32,910

在製品

 

52,676

 

50,008

成品

 

2,898

 

3,585

$

86,109

$

86,503

截至2024年9月30日和2023年12月31日,存貨的賬面價值已減去存貨準備金$元23.2 分別獲得了來自同美的$百萬美元和$百萬美元的基金21.9 百萬,分別用於過剩和陳舊庫存$元68,000 和$78,000,分別用於成本或淨變現價值準備金。

12

目錄

注意 4. 不動產、廠房和設備,淨值

我們的不動產、廠房和設備的組成如下總結(以千爲單位):

9月30日

運營租賃負債:

2024

2023

物業,廠房和設備:

機器和設備,按成本

$

68,288

$

65,918

減:累計折舊和攤銷

(44,429)

(42,112)

建築,成本

142,371

125,786

減:累計折舊和攤銷

(26,463)

(23,339)

租賃改良,按成本

 

7,828

 

7,596

減:累計折舊和攤銷

(6,446)

(5,984)

在建工程

 

25,310

 

38,483

$

166,459

$

166,348

截至2024年9月30日,施工中的餘額爲$25.3 百萬,其中400萬美元投資於2022年4月,500萬美元投資於2022年5月。 結果,非控股權益增加百萬美元,可贖回的非控股權益增加百萬美元。 2022年7月,同美和少數投資者又投資了$18.5 百萬與我們在新的丁星和和佐地點的建築有關,$2.3 百萬用於尚未投入使用的製造設備採購,$4.5 百萬用於我們其他合併子公司的施工中的餘額。截至2023年12月31日,施工中的餘額爲$38.5 百萬,其中$31.2 百萬用於我們在新的丁星和和佐地點的建築,$3.1 百萬用於尚未投入使用的製造設備採購,$4.2 百萬是用於我們其他合併子公司的在建施工。

注5. 應計負債

應計負債的元件總結如下(單位:千):

9月30日,

12月31日,

    

2024

    

2023

 

優先股送轉應付

$

2,901

$

2,901

與在建工程相關的應付款項

1,481

7,249

應計薪酬及相關費用

1,135

3,707

應計專業服務費

947

868

應計所得稅$39,614

654

其他應交稅費

564

493

經營租賃負債流動部分

488

458

應計產品保修

392

703

來自客戶預付款

367

305

其他人事相關費用

336

286

銷售退貨的應計

45

39

其他應計負債

2,631

2,010

$

11,941

$

19,019

13

目錄

備註6. 關聯方交易

在2021年9月和2021年10月,我們的合併子公司朝陽新梅分別收到一位少數投資者提供的資金$0.9 分別獲得了來自同美的$百萬美元和$百萬美元的基金1.0 百萬美元。截至2021年12月31日,在我們的簡明合併資產負債表中,有$1.9 百萬美元計入非控股權利的短期貸款。2021年12月和2022年1月,同一子公司從銅煤獲得了$1.4 百萬美元和$1.4 分別增加了數百萬美元。2022年1月,中國地方政府認證這筆額外資金作爲超羊新梅的股權投資。結果,非控股權益增加了 $2.2 百萬美元,可贖回的非控股權益增加百萬美元。 2022年7月,同美和少數投資者再次投資了$0.2 百萬美元。非控制股利短期借款減少至美元0。2022年4月,禮順與少數投資者簽署了增資協議,進一步向超陽新梅投資約合美元4.5 百萬。2022年4月和2022年5月,超陽新梅分別從禮順獲得了美元和美元的資金,作爲股權投資。2022年4月和2022年5月,少數投資者分別投資了美元和美元1.1 百萬和0.8 百萬美元,分別作爲股權投資。2022年4月和2022年5月,少數投資者投資了0.7 百萬美元和0.6 百萬元及五百萬元,分別。因此,非控股權益增加了$1.4 百萬元和可贖回非控股權益增加了$0.1 美創業公司和少數投資者進一步投資了$0.8 百萬元和$百萬元0.6 Chaoyang Xinmei分別投資了百萬美元。這完成了增資協議下的投資義務。因此,非控股權益增加了610,000 ,贖回性非控股權益增加了美元57,000。通過這些股權投資後,桐梅的所有權保持在 58.5%的股份投資後這些股權投資。

2022年9月,我們的合併子公司朝陽麗美完成了將土地及其附屬建築物出售給我們的股權投資實體。,朝陽開美,總代價爲 $1.5 百萬。2023年1月,朝陽開美向朝陽麗美支付了 $1.5 百萬。截至2024年9月30日,有 $0 百萬計入了我們簡明合併資產負債表中的「預付費用和其他流動資產」。

我們的關聯交易政策旨在禁止所有衝突。 在關聯方與我們之間的交易中,除非經董事會批准,否則不得涉及利益。本政策適用於我們所有員工、董事以及我們的合併子公司。我們的高管在中國大陸合資企業的董事會上擔任董事席位。有關詳細信息,請參見第7注。

第7注。對私人持有的原材料公司的投資

爲了以競爭成本獲得對我們基板業務至關重要的原材料,我們在中國的私營公司進行了戰略投資。這些公司是我們整體供應鏈戰略的一部分。

截至2024年9月30日,投資情況總結如下(以千爲單位):

截至投資餘額

9月30日

運營租賃負債:

會計

所有權

*

公司

    

2024

    

2023

    

攤銷方法

    

百分比

南京金美鎵業有限公司。

$

592

$

592

 

合併

 

** 85.5

%

朝陽金美鎵業有限公司。

1,820

1,820

合併

** 85.5

%

北京博宇半導體船舶工藝科技有限公司

 

1,346

 

1,346

 

合併

 

** 85.5

%

朝陽碩美高純度半導體材料有限公司

3,122

3,122

合併

**** 75.0

%

朝陽新美高純度半導體材料有限公司。

7,331

7,331

合併

 

*** 58.5

%

$

14,211

$

14,211

北京吉亞半導體材料有限公司。

$

4,681

3,806

股權

39

%

曉益興安鎵有限公司。

4,969

5,516

股權

** 25

%

朝陽凱美石英有限公司。

3,883

3,154

Equity

***** 40

%

$

13,533

$

12,476

峨眉山甲美高純度金屬有限公司。

 

551

 

551

 

公允價值

 

****** 10

%

$

551

$

551

* 這些百分比反映了在中國重新組織完成後目前生效的所有權,以及2021年1月私人股權投資者進行新資金注資完成後的所有權。 所有板塊反映了中國重組完成時的所有權,以及2021年1月私募股權投資者完成新資金注資時的所有權。

14

目錄

**在2020年底,爲了魯能董事會在科創板上市股份的申請,我們重新組織了在中國的實體結構。JinMei和BoYu及其子公司,之前隸屬於AXt,Inc.,被分配給了魯能並與魯能有效合併,儘管它們保留了各自的法律實體地位,是魯能的全資子公司。 33% minority interest stakeholders of BoYu converted their ownership to a 7.59% minority interest in Tongmei. The 8.5% minority interest stakeholders, employees of JinMei, converted their ownership to a 0.38% 的股份是在Tongmei中的少數股東利益。此外,許多僱員、關鍵經理和貢獻者購買了% 的少數股權。 0.4%。基金投資者在2020年轉移了大約$48.1 百萬美元的新資金。2021年1月,又注資約1.5 新資本金額於2021年初獲得基金。根據中國法規,這些投資必須經有關政府機構正式批准,並在獲得批准前不被視爲稀釋。政府於2021年1月25日批准了約$49 百萬投資整體上,那時投資者在通酶持有可贖回的非控制性權益,佔通酶 7.28。截至2024年9月30日,銅煤的非控制權益和可贖回的非控制權益總額約爲 14.5%。AXt仍然是通酶的控股股東,並持有通酶董事會大部分董事職位。

***在2021年2月,通酶與某些投資者簽署了一項合資協議,用於基金朝陽信盟。

**** In April 2022, ChaoYang JinMei signed a joint venture agreement with certain investor to fund a new company, ChaoYang ShuoMei.

***** In April 2022, Tongmei signed a joint venture agreement with certain investors to fund a new company, ChaoYang KaiMei.

****** In May 2023, we sold 15% of our equity investments in Jia Mei to a third party. We now own 10% of Jia Mei and account for it under the fair value method.

2023年5月,我們減少了對佳美的持股。 25百分比至 10%的份額降至$827,000考慮到我們所持股權的減少,我們不再對其運營和財務政策具有重大影響,因此我們採用公允價值覈算方法對對嘉美的投資進行報告。由於股份出售,我們確認了一筆盈利$。575,000此外,根據ASC321-10-35-2,我們將對嘉美的投資調整爲出售時的公允價值。出售和後續重新計量導致的收益被納入「未納入聯合經營企業收益」這一項目之中 在2023年第二季度的合併利潤表中,股份出售和後續重新計量產生的收益包括以下內容: 2023年第二季度的合併利潤表中包括股份出售和後續重新計量所產生的收益,具體包括以下內容:

金額

    

(以千計)

所得到的公允價值對等物

$

779

外國所得稅預扣

48

攜帶價值爲 15峨眉山佳美高純金屬有限公司的%

(252)

出售金屬期貨獲得的收益 15在峨眉山嘉美高純金屬有限公司的%

$

575

金額

(以千計)

對峨眉山嘉美高純金屬有限公司持有投資的公允價值。

$

551

持有非控股投資的賬面價值(10%)

(168)

由於重新計量而獲得保留的非控制投資收益(10%)

$

383

對嘉美投資進行其他非暫時性減值檢查,每季度進行一次。截至2024年9月30日的三個月和九個月內,我們沒有爲嘉美投資記錄任何其他非暫時性減值損失。

15

目錄

2023 年 11 月,我們的 46東海縣東方高純電子材料有限公司(「東方」)的股權百分比已出售給第三方,對價約爲美元0.6 百萬,包括原材料、設備和車輛。結果,我們對東方股權的持股權益從 46% 到 0%。出售造成的虧損作爲 「未合併合資企業的收益權益」 的一部分納入了2023年第四季度的合併經營報表。銷售損失包括以下內容:

金額

    

(以千計)

收到的對價的公允價值

$

585

賬面價值爲 46東海縣東方高純電子材料有限公司的百分比

(1,710)

出售物品時確認的損失 46東海縣東方高純電子材料有限公司的百分比

$

(1,125)

儘管我們在每傢俬營原材料公司的董事會中都有代表,但這些公司的日常運營都由當地管理層而不是我們管理。有關各自的短期戰略和運營、正常業務資本支出和成品銷售的決策由當地管理層在我們定期的指導和意見下做出。

對於未合併的AXT少數投資實體,投資餘額包含在我們的簡明合併資產負債表中的 「其他資產」 中,總額爲美元13.5 百萬和美元12.5 截至 2024 年 9 月 30 日和 2023 年 12 月 31 日,分別爲百萬人。截至2024年9月30日,我們在朝陽凱美、吉亞、孝義興安鎵有限公司(「小義興安」)和佳美的所有權爲 40%, 39%, 25%,以及 10分別爲%。這些少數股權投資實體不被視爲可變權益實體,因爲:

所有少數投資實體都有自己的可持續業務;

我們的投票權與我們的所有權利益成正比;

我們僅在公司產生的損失和/或剩餘回報中確認我們各自的份額;以及

我們對這些公司沒有控股權,不維持對這些公司的運營或管理控制權,不控制董事會,也不需要向這些公司提供額外的投資或財務支持。

2022年6月,我們收到了一美元1.3 來自BoYu的百萬股息。2022年7月,我們收到了一美元1.5 來自我們的股權投資實體之一小義興安的百萬股息。2022年8月,我們收到了一美元125,000 來自我們的股權投資實體之一JiYa的股息。2023 年 4 月和 2023 年 11 月,小易興安派發了美元的股息1.8 百萬,JiYa派發的股息爲美元2.0 百萬和美元0.5 分別爲百萬。2024 年 5 月,小易興安分發了 $2.1 向我們分發百萬股息。我們目前無意向投資者分配公司結構下的收益。所有這些分配都支付給了中國公司和少數股東。

16

目錄

AXT的少數投資實體未進行合併,並按權益法計量。截至2024年9月30日和2023年的三個月和九個月,權益投資實體的經營摘要信息如下(單位:千美元):

截至三個月

截至九個月

9月30日,

9月30日

    

2024

    

2023

    

2024

    

2023

 

淨收入

$

10,473

$

8,834

$

27,915

$

24,486

毛利潤

$

4,876

$

2,620

$

12,966

$

8,174

營業收入

$

4,135

$

1,962

$

11,541

$

7,134

淨利潤

$

3,443

$

1,449

$

8,624

$

6,307

我們從這些未合併且按股權法計量的少數投資實體中獲得的收入份額分別爲$1.0 百萬美元和$0.4 百萬,截至2024年和2023年9月30日結束的三個月。我們從這些未合併且按股權法計量的少數投資實體中獲得的收入份額分別爲$2.5 百萬和$1.4 2024年和2023年截至9月30日的九個月分別爲XX百萬美元。在簡明合併利潤表中,「未納入合併聯營企業收入中的股權」包括從嘉美銷售中獲得的收益,金額爲$958,000 ,導致淨收入爲$2.3 百萬美元。

17

目錄

注8.股東權益

股東權益的簡化合並報表

(以千計)

2024年9月30日結束的三個月和九個月的股東權益變動如下:

 

 

 

 

 

 

 

 

 

累積

其他

AXt, Inc.

 

 

 

總計

 

優先的

 

Common

 

額外的

 

累積

 

全面的

股東的

 

非控制權益

 

股東的

  

股票

  

股票

  

實收資本

  

赤字

  

收益(損失)

  

Equity

  

利益

  

Equity

 

截至2023年12月31日的餘額

 

$

3,532

 

$

44

 

$

238,452

 

$

(32,040)

 

$

(5,999)

$

203,989

 

$

23,494

 

$

227,483

普通股期權行使

20

20

20

同梅股份股權激勵的非控股權益部分

(24)

(24)

13

(11)

股票補償

614

614

614

童美股票期權薪酬

195

195

195

淨虧損

(2,083)

(2,083)

106

(1,977)

其他綜合損失

(1,627)

(1,627)

(187)

(1,814)

2024年3月31日的餘額

$

3,532

$

44

$

239,257

$

(34,123)

$

(7,626)

$

201,084

$

23,426

$

224,510

普通股期權行使

5

5

5

統盟股票酬勞的非控制權益部分

(15)

(15)

7

(8)

股票補償

621

621

621

同美股票期權酬勞

94

94

94

淨虧損

(1,516)

(1,516)

316

(1,200)

其他綜合損失

(601)

(601)

(69)

(670)

截至2024年6月30日的餘額

 

$

3,532

$

44

$

239,962

$

(35,639)

$

(8,227)

$

199,672

$

23,680

$

223,352

普通股期權已行使

1

2

3

3

通美股份的非控股權利益部分股權補償

(14)

(14)

7

(7)

股票補償

723

723

723

同美股權報酬

97

97

97

淨虧損

(2,937)

(2,937)

190

(2,747)

其他綜合收益

3,189

3,189

372

3,561

2024年9月30日的餘額

 

$

3,532

$

45

$

240,770

$

(38,576)

$

(5,038)

$

200,733

$

24,249

$

224,982

淨利潤(損失)和其他全面收入(損失)應歸可贖回的非控股權益所有者(淨損失140,000和$376,0002024年9月30日結束的三個月分別爲($)210,000和$118,0002024年9月30日結束的九個月分別爲($),不存在於上表中。

18

目錄

2023年9月30日結束的三個月和九個月的股東權益變動如下:

 

 

 

 

 

 

 

 

 

累積

其他

AXt, Inc.

 

 

 

總計

 

優先的

 

Common

 

額外的

 

累積

 

全面的

股東的

 

非控制權益

 

股東的

  

股票

  

股票

  

實收資本

  

赤字

  

收益(損失)

  

Equity

  

利益

  

Equity

截至2022年12月31日的餘額

 

$

3,532

 

$

44

 

$

235,308

 

$

(14,159)

 

$

(3,118)

$

221,607

 

$

23,293

 

$

244,900

常見股票期權行使

8

8

8

對附屬公司的投資,包括非控股權益

(36)

(36)

239

203

投資於具有可贖回非控制權益的子公司

(36)

(36)

(36)

Noncontrolling interest portion of Tongmei stock-based compensation

33

33

(16)

17

股票補償

717

717

717

同美股票期權薪酬

198

198

198

淨虧損

(3,348)

(3,348)

(169)

(3,517)

其他綜合收益

858

858

70

928

2023年3月31日餘額

$

3,532

$

44

$

236,192

$

(17,507)

$

(2,260)

$

220,001

$

23,417

$

243,418

行使普通股期權

2

2

2

投資於附屬公司,有非控股利益

(74)

(74)

380

306

對可贖回非控制權益的子公司投資

(75)

(75)

(75)

同煤公司股權激勵中的非控制權益部分

31

31

(14)

17

股票補償

720

720

720

同煤股票期權激勵

192

192

192

淨利潤(損失)

(5,089)

(5,089)

38

(5,051)

其他全面收益(虧損)

(5,915)

(5,915)

(623)

(6,538)

截至2023年6月30日的餘額

 

$

3,532

$

44

$

236,988

$

(22,596)

$

(8,175)

$

209,793

$

23,198

$

232,991

普通股期權行權

投資擁有非控股權益的子公司

(43)

(43)

242

199

對可贖回的非控股權投資

(44)

(44)

(44)

統美股份股份報酬中的非控股權益部分

(139)

(139)

68

(71)

股票補償

703

703

703

同煤股票期權激勵

188

188

188

淨虧損

(5,823)

(5,823)

(236)

(6,059)

其他全面收益(虧損)

(406)

(406)

(54)

(460)

截至2023年9月30日的餘額

 

$

3,532

$

44

$

237,653

$

(28,419)

$

(8,581)

$

204,229

$

23,218

$

227,447

淨虧損和其他全面收入歸可贖回非控股權益人爲$356,000 和$55,000截至2023年9月30日的三個月分別爲$807,000 和$615,000截至2023年9月30日的九個月分別爲$,未列入上表。

19

目錄

截至2023年7月31日,續借貸款協議下未償還的借款額爲沒有 重新分類調整從累積其他全面收益(損失)中 截至2024年和2023年9月30日的三個和九個月.

股票回購計劃

2014年10月27日,我們的董事會批准了一個股票回購計劃,根據該計劃,我們可以回購高達 $5.0 我們可以不時地在開放市場上回購這些股票,並且這些回購是使用我們現有的現金餘額和營業收入產生的現金資金支持的。 在2015年,我們以約908,000美元的平均價格回購了大約2.52美元每股,總購買價格約爲2.3百萬美元,在股票回購計劃下。 沒有 在2016年至今回購了股份 2023在2024年9月30日結束的三個月和九個月內,我們沒有回購任何股份 沒有在2024年9月30日,根據已批准的回購計劃,尚有大約$2.7 萬美元可用於未來的回購。目前,我們不計劃回購其它股份。

注9. 股權激勵

我們根據ASC 718規定來計算股權補償。 Stock Compensation-補償 股權補償成本是在每個授予日期根據獎勵的公允價值來衡量,並在員工必要服務期內確認爲費用。我們所有的股權補償均作爲權益工具進行覈算。

2015年5月,我們的股東批准了我們的2015年股權激勵計劃(「2015計劃」)。2015計劃取代了2007計劃。2007計劃的股份儲備成爲2015計劃的儲備,連同2015計劃下批准發行的額外股份。 399,562 在2019年5月,我們的股東批准了2015計劃下的發行的額外股份。 3,000,000 在2021年5月,我們的股東批准 1,600,000 進行了額外股份的發行。 3,600,000 根據2015年計劃,董事會於2024年5月批准了對發行額外股份的修正案,增加了用於發行的股份數量。 3,600,000 可以在2015年計劃下進行的獎勵包括股票期權、股票增值權、限制性股票、限制性股票單位、績效股票、績效單位、延期薪酬獎勵和其他基於股票的獎勵。未經股東批准,不得對2015年計劃下授予的股票期權和股票增值權重新定價。股票期權和股票增值權不得低於公允市場價授予。一般而言,股票期權或股票增值權的完全歸屬期不得少於授予日起的期限,且不得超過授予後 公司使用資產和負債的會計方法來計算所得稅。根據這種方法,根據資產和負債的金融報表及稅基之間的暫時區別,使用實施稅率來決定遞延稅資產和遞延稅負債,該稅率適用於預期差異將反轉的年份。稅法的任何修改對遞延稅資產和負債的影響將於生效日期在財務報告期內確認在彙總的綜合收益報表上。 從授予日起超過的期限內不得行使。 10年 限制性股票、限制性股票單位和績效獎勵一般不得超過 三年 期內變得歸屬(或者 十二個月 基於績效指標的權益獎勵通常具有分期解禁的特性。然而,授予顧問的期權和授予獨立董事會成員的限制性股票獎勵通常在分期解禁 一年 2015計劃確實允許員工享有類似的分期解禁。

以下表格總結了與我們的股權獎勵相關的薪酬成本(以千爲單位,每股數據除外):

截至三個月

截至九個月

9月30日

9月30日

    

2024

    

2023

    

2024

    

2023

 

營運成本

$

73

$

102

$

246

$

310

銷售、一般和管理費用

 

623

 

639

 

1,702

 

1,926

研發費用

 

124

 

150

 

396

 

482

淨損失的淨影響

$

820

$

891

$

2,344

$

2,718

截至2024年9月30日,未攤銷的與向員工授予的未行權股票期權相關的補償成本是 $0我們 截至2024年9月30日,由於所涉金額微不足道,未對任何基於股票的補償進行資本化。 由於所涉金額微不足道,截至2024年9月30日和2023年12月31日,未將任何基於股票的補償計入存貨。

20

目錄

我們使用與ASC 718規定一致的Black-Scholes期權定價模型估算股票期權的公允價值。 no 2024年和2023年截至9月30日的三個月和九個月中,授予了期權。

以下表格總結了2024年9月30日截至九個月內的股票期權交易(以千爲單位,每股數據除外):

Weighted-

    

    

    

價格

    

 

Weighted-

剩餘

 

數量的

平均

加權

總計

 

Options

行權

壽命

截至2023年7月29日的餘額

 

期權未行使/未投資的限制性股票,截至2023年10月1日

    

未償還金額

    

價格

    

(以年爲單位)

    

價值

 

2024年1月1日的餘額

1,198

$

5.10

 

4.09

$

14

Granted

 

 

已行使

 

(12)

2.24

已取消和已過期

 

2024年9月30日的餘額

 

1,186

$

5.13

 

3.38

$

13

2024年9月30日解鎖的期權以及預計會解鎖的未解鎖期權,扣除被放棄的部分

 

1,186

$

5.13

 

3.38

$

13

截至2024年9月30日可行使的期權

 

1,186

$

5.13

 

3.38

$

13

上表中的總體內在價值表示總稅前內在價值,基於我們收盤價爲$2.42 於2024年9月30日,如果所有期權持有人在該日期行使其期權,持有人將獲得的總內在價值。

限制性股票獎勵

2024年9月30日結束的爲期九個月的限制性股票獎勵相關活動摘要如下(以千爲單位,每股數據除外):

    

    

平均

 

授予日期

 

股份獎勵

    

分享

    

分享價值

 

截至2024年1月1日未歸屬

1,220

$

3.75

授予

 

204

$

3.08

34,105

 

(166)

$

5.04

被取消

(4)

$

3.29

截至2024年9月30日尚未歸屬

 

1,254

$

3.47

截至2024年9月30日,未攤銷的與未歸屬限制性股票獎勵相關的補償成本約爲$3.0 百萬,將按加權平均期限直線攤銷。 1.1 年。

風險,績效股份

在2023年3月和2024年2月,公司發行了分類爲股權獎勵的風險,績效股份。根據所需服務期間,根據實現指定財務績效指標的概率,按照直線法每季度確認費用,預期變化被認可爲調整於變動發生的期間。對於未獲得歸屬權的風險,績效股份,因爲服務或績效條件未得到滿足,並且之前已確認的補償成本將被撤銷,不會確認補償成本。風險,績效股份有資格根據公司的2015年股權激勵計劃(「計劃」)獲得股息相當價值,由董事會確定。公司將在出現棄權時確認棄權。

公司的風險,績效股份被分類爲股權,包含必須滿足的績效和服務條件,員工才能獲得股份。2022年2月發行的風險,績效股份的財務績效指標是基於2021年年底實際結果與公司2022年年底實際結果的比較。2022年3月發行的風險,績效股份的財務績效指標是基於2021年年底實際結果與公司2022年年底實際結果的比較。

21

目錄

2023年基於公司2023年的年終實際業績。2024年2月發行的風險高績效股票的財務業績指標基於公司2024年的年終實際業績。所有績效股份,如果獲得,仍需按年度歸屬 四年 時期,除了 股票將在一週年之際歸屬,因爲業績衡量標準分別基於2023年和2024年的年終業績。

風險高績效股票的公允價值是根據公司最近一個財季的業績公開發行後的第一天公司普通股的收盤價確定的,此前經薪酬委員會和董事會批准,該批准被視爲授予日期。2024年2月和2023年3月被歸類爲股票獎勵的風險高績效股票的每股公允價值爲 $2.28 和 $3.71,分別地。

2022年2月15日,薪酬委員會建議向莫里斯·楊博士提供補助金,董事會批准了該補助金 114,320 本計劃下存在風險的績效股份。2022年2月15日,薪酬委員會批准了對加里·菲舍爾的補助金 32,100 本計劃下存在風險的績效股份。如果績效財務指標小於 50已實現的百分比這些股份將被沒收。如果績效財務指標介於 50% 和 200已達到%,則相應的按比例分配 114,320 發行給楊博士的股票將有資格歸屬,相應的按比例分配 32,100 向菲舍爾先生髮行的股票將有資格歸屬。任何沒有資格歸屬的股份都將被沒收。如果目標財務指標超過 200%,則有資格歸屬的風險績效股票的最大數量爲 114,320 送給楊博士和 32,100 送給菲舍爾先生2023年2月14日,薪酬委員會開會並認證,2022財年實現的年收入同比增長率(以百分比表示)爲 2.7%。因此, 的風險績效股票有資格歸屬。

2023 年 3 月 15 日,薪酬委員會建議向莫里斯·楊博士提供補助金,董事會批准了該補助金 223,590 本計劃下存在風險的績效股份。2023 年 3 月 15 日,薪酬委員會批准了向加里·菲舍爾提供的補助金 77,600 本計劃下存在風險的績效股份。如果達到了2023財年的最低財務指標,則根據績效公式,相應的部分 223,590 發行給楊博士的股票將有資格歸屬,相應部分的股份 77,600 向菲舍爾先生髮行的股票將有資格歸屬。如果超過目標財務指標並實現了2023財年的額外財務指標,則根據該績效公式,將獲得超過目標股票數量的額外股份,獲得的最大額外股票數量上限爲 100目標的百分比。如果未達到2023財年的最低財務指標,則這些獎勵將被沒收。2024年2月20日,薪酬委員會開會並認證未達到2023財年的最低收入指標。因此, 的風險績效股票有資格歸屬。

2024 年 2 月 20 日,薪酬委員會建議向莫里斯·楊博士提供補助金,董事會批准了該補助金 223,590 本計劃下存在風險的績效股份。2024 年 2 月 20 日,薪酬委員會批准了向加里·菲舍爾提供的補助金 77,600 本計劃下存在風險的績效股份。如果實現了2024財年的最低財務指標,則根據績效公式,相應的部分財務指標 223,590 發行給楊博士的股票將有資格歸屬,相應部分的股份 77,600 向菲舍爾先生髮行的股票將有資格歸屬。如果超過目標財務指標,則將根據該績效公式獲得超過目標股數的額外股份,獲得的最大額外股票數量上限爲 100目標的百分比。如果未達到2024財年的最低財務指標,則這些獎勵將被沒收。

22

目錄

2024年9月30日,我們未投資的高風險績效股份狀況摘要如下(以千爲單位,每股數據除外):

    

    

平均

授予日期

股份獎勵

    

分享

    

分享價值

截至2024年1月1日未歸屬

38

$

15.37

授予(1)

 

226

$

2.28

34,105

 

$

被取消

$

截至2024年9月30日尚未歸屬

 

264

$

4.16

(1)呈現的股份數量是基於實現 150% 目標財務績效指標,如在風險、績效股協議中定義。

截至2024年9月30日,未確認的股權報酬支出爲$0.3 百萬未承認的與未歸屬人員、績效股相關的補償費用,預計將在加權平均期內確認。 1.3 年。

注10 每股淨虧損

基本每股淨利潤(虧損)是根據期內流通在外的普通股加權平均數量計算的,減去尚待回購和未實現的股票獎勵的普通股數。每股攤薄淨利潤(虧損)是根據期間內流通的普通股加權平均數量和潛在攤薄普通股數量計算的。未行使的股票期權和受限制股票獎勵的攤薄效應通過庫存法體現在攤薄每股收益中。潛在攤薄普通股包括可通過行使股票期權和解禁受限制股票獎勵而發行的普通股。在淨損失年度中,潛在攤薄普通股被排除在計算普通股加權平均數的計算之外,因爲其效應對計算產生增稀效應。

基本和攤薄每股淨虧損的分子和分母調節如下(以千爲單位,每股數據除外):

截至三個月

截至九個月

9月30日

九月三十日

    

2024

    

2023

    

2024

    

2023

 

分子:

歸屬於AXt,Inc.的淨損失

$

(2,937)

$

(5,823)

$

(6,536)

$

(14,260)

Less:優先股股利

 

(44)

 

(44)

 

(132)

 

(132)

可歸屬於普通股股東的淨虧損

$

(2,981)

$

(5,867)

$

(6,668)

$

(14,392)

分母:

基本每股淨虧損的分母-加權平均普通股份

 

43,157

 

42,638

 

43,079

 

42,574

攤薄效應:

普通股期權

 

 

 

 

限制性股票獎勵

 

 

 

 

每普通股攤薄後淨虧損的分母

 

43,157

 

42,638

 

43,079

 

42,574

AXt,Inc.歸屬於普通股的淨損失每股:

基本

$

(0.07)

$

(0.14)

$

(0.15)

$

(0.34)

攤薄

$

(0.07)

$

(0.14)

$

(0.15)

$

(0.34)

期權被排除在每股稀釋淨虧損之外,因爲其影響是不利於稀釋的

 

1,186

 

1,200

 

1,186

 

1,200

受限股票不包括在攤薄每股虧損中,因爲影響是抗稀釋的

 

1,518

 

1,006

 

1,518

 

1,006

股市 883,000$,總股數0.001 2024年9月30日和2023年12月31日,價值爲$的帶有面值的A系列優先股已發行並流通3,532,000,不是可投票也不可轉換的優先股

23

目錄

配合 5.0% 累積年度股息率,在董事會宣佈時支付,以及每股 $4 每股優先股權,優先於普通股,必須在向普通股股東分配任何收益之前支付。這些優先股是在1999年5月28日完成我們對Lyte Optronics, Inc.的收購時發行給Lyte Optronics, Inc.股東的。

注11.地域板塊信息和外國業務

分段信息

我們經營消費和調味品兩個業務板塊。消費板塊在全球範圍內生產、銷售和分銷香料、草藥、調味料混合物、調味品等美味佳餚。我們的消費板塊銷售規模包括零售渠道(如雜貨店、大型量販店、倉儲俱樂部、折扣店和藥店)和電子商務,使用「McCormick」品牌以及「French's」、 「Frank's RedHot」、「OLD BAY」、「Lawry's」、「Zatarain's」、「Simply Asia」、「Thai Kitchen」、「Ducros」、「Vahine」、「Cholula」、「Schwartz」、「Club House」、「Kamis」、「DaQiao」、「La Drogheria」、「Stubb's」和「Gourmet Garden」等世界各地品牌。我們的調味品解決方案板塊面向食品製造商和餐飲行業銷售,通過分銷商直接或間接銷售,我們在中國的業務除外,中國的餐飲銷售由我們的消費板塊管理並報告。之一 設計、開發、製造和分銷高性能複合和單元半導體襯底,並銷售與這些襯底密切相關的原材料。根據ASC 280,分部報告,我們的首席經營決策者已確定爲首席執行官,他審查經營結果以做出關於資源分配和評估公司表現的決策。由於我們在進行操作 之一 部門,所有財務部門和產品線信息均可在簡明綜合財務報表中找到。

產品信息

以下表格顯示不同產品類型的營業收入金額(以千爲單位):

截至三個月

截至九個月

9月30日

9月30日

    

2024

    

2023

    

2024

    

2023

 

 

產品類型:

底物

$

15,007

$

10,385

$

51,655

$

34,901

原材料和其他

 

8,638

 

6,981

 

22,601

 

20,465

總計

$

23,645

$

17,366

$

74,256

$

55,366

地理信息

以下表格顯示了針對運往對應地理區域客戶的產品報告的營業收入金額(以千爲單位):

截至三個月

截至九個月

9月30日

9月30日

    

2024

    

2023

    

2024

    

2023

 

 

地域板塊:

中國

$

13,807

$

10,307

$

42,271

$

28,698

臺灣。

2,140

2,491

10,142

6,369

日本

 

1,623

 

558

 

3,409

 

3,489

亞太地區(不包括中國、臺灣和日本)

797

894

2,307

2,722

歐洲(主要是德國)

2,720

2,407

11,134

8,992

北美洲(主要是美國)

 

2,558

 

709

4,993

5,096

總計

$

23,645

$

17,366

$

74,256

$

55,366

24

目錄

長期資產主要包括房地產、廠房及設備和經營租賃權使用資產,並歸屬於其所在地的地理位置。按地域板塊劃分的長期資產淨值(減值後)如下(單位:千元):

截至

九月三十日

運營租賃負債:

    

2024

    

2023

 

各地域板塊的長期資產,減去折舊:

北美洲

$

1,423

$

1,631

中國

 

167,487

 

167,516

$

168,910

$

169,147

重要客戶

沒有 顧客在截至2024年9月30日和2023年的三個月的營業收入中佔了10%。我們的前十 五個營運部門:獵鷹創意集團、PDP、Sierra Parima、目的地運營和Falcon's Beyond Brands,所有這些板塊均爲可報告板塊。公司的首席營運決策者是執行主席和首席執行官,他們評估財務信息以做出營運決策、評估財務表現和分配資源。營運板塊基於產品線組織,對於我們的基於位置的娛樂板塊,根據地理位置組織。營運板塊的結果包括直接歸屬於板塊的成本,包括項目成本、工資和與工資有關的開支以及與業務板塊運營直接相關的間接費用。未分配的企業費用,包括高管、會計、財務、市場營銷、人力資源、法律和信息技術支持服務、審計、稅收企業法律開支的工資和相關福利,作爲未分配的企業開銷呈現,成爲報告板塊的總收入(虧損)和公司未經審計的彙總財務報表結果之間的調節項。 客戶,雖然不相同 五個營運部門:獵鷹創意集團、PDP、Sierra Parima、目的地運營和Falcon's Beyond Brands,所有這些板塊均爲可報告板塊。公司的首席營運決策者是執行主席和首席執行官,他們評估財務信息以做出營運決策、評估財務表現和分配資源。營運板塊基於產品線組織,對於我們的基於位置的娛樂板塊,根據地理位置組織。營運板塊的結果包括直接歸屬於板塊的成本,包括項目成本、工資和與工資有關的開支以及與業務板塊運營直接相關的間接費用。未分配的企業費用,包括高管、會計、財務、市場營銷、人力資源、法律和信息技術支持服務、審計、稅收企業法律開支的工資和相關福利,作爲未分配的企業開銷呈現,成爲報告板塊的總收入(虧損)和公司未經審計的彙總財務報表結果之間的調節項。 每個時期的客戶,代表 29%和 312024年9月30日和2023年分別代表我們營業收入的%。

沒有 客戶代表我們2024年9月30日和2023年結束的九個月內營業收入的10%。我們的頭部 五個營運部門:獵鷹創意集團、PDP、Sierra Parima、目的地運營和Falcon's Beyond Brands,所有這些板塊均爲可報告板塊。公司的首席營運決策者是執行主席和首席執行官,他們評估財務信息以做出營運決策、評估財務表現和分配資源。營運板塊基於產品線組織,對於我們的基於位置的娛樂板塊,根據地理位置組織。營運板塊的結果包括直接歸屬於板塊的成本,包括項目成本、工資和與工資有關的開支以及與業務板塊運營直接相關的間接費用。未分配的企業費用,包括高管、會計、財務、市場營銷、人力資源、法律和信息技術支持服務、審計、稅收企業法律開支的工資和相關福利,作爲未分配的企業開銷呈現,成爲報告板塊的總收入(虧損)和公司未經審計的彙總財務報表結果之間的調節項。 儘管客戶不盡相同, 五個營運部門:獵鷹創意集團、PDP、Sierra Parima、目的地運營和Falcon's Beyond Brands,所有這些板塊均爲可報告板塊。公司的首席營運決策者是執行主席和首席執行官,他們評估財務信息以做出營運決策、評估財務表現和分配資源。營運板塊基於產品線組織,對於我們的基於位置的娛樂板塊,根據地理位置組織。營運板塊的結果包括直接歸屬於板塊的成本,包括項目成本、工資和與工資有關的開支以及與業務板塊運營直接相關的間接費用。未分配的企業費用,包括高管、會計、財務、市場營銷、人力資源、法律和信息技術支持服務、審計、稅收企業法律開支的工資和相關福利,作爲未分配的企業開銷呈現,成爲報告板塊的總收入(虧損)和公司未經審計的彙總財務報表結果之間的調節項。 各個時期的客戶,分別代表 30%和 252024年和2023年截至9月30日的九個月的營業收入的%。

我們對客戶的財務狀況進行持續信用評估,並在認爲必要時限制授信金額,但通常不要求提供抵押物。 Ginkgo 客戶佔超開多 10截至2024年9月30日,我們應收賬款餘額佔比,no 客戶佔超開多 10截至2023年12月31日,我們應收賬款餘額佔比。

附註12. 承諾和事項

保護協議

我們已經與董事和高管簽訂了賠償協議,要求我們賠償董事和高管由於其作爲董事或高管的身份或服務而可能產生的責任(除了因故意不當行爲導致的責任),爲他們提前支付因任何可能獲得賠償的訴訟而產生的費用,並在合理條件下獲得董事和高管保險,我們目前已經具備該保險。

產品保修

我們爲產品提供特定時間範圍的保修服務,一般來說, 十二個月防止材料缺陷。當相關營業收入確認時,我們在銷售成本中提供預計未來保修義務的費用。應計的保修費用代表我們在銷售時期能合理預計的,預計要爲在保修期內失效的產品部件維修或更換所需的全部費用。應計的預估保修費用金額主要基於產品故障的歷史經驗以及當前維修成本信息。每季度,我們會審查已計提的餘額並更新歷史保修費用趨勢。

25

目錄

以下表格反映了截至2024年和2023年9月30日三個月和九個月內包含在壓縮綜合資產負債表中「應計負債」中的保修準備金的變動情況(以千爲單位):

截至三個月

截至九個月

 

九月三十日

九月30日,

 

    

2024

    

2023

    

2024

    

2023

 

開始計提產品保修

$

421

$

852

$

703

$

669

已發出的保脩金的應計

 

94

 

104

 

282

 

762

與預先存在的保修相關的調整,包括到期和估計變更

 

9

 

21

 

(251)

 

(18)

保修維修成本

 

(132)

 

(101)

 

(342)

 

(537)

Ending accrued product warranty

$

392

$

876

$

392

$

876

合同義務

在2020年,我們與一家競爭對手簽訂了一項交叉許可和盟約協議("交叉許可協議"),該協議於2020年1月1日開始,到2029年12月31日到期。交叉許可協議是一項固定成本的交叉許可協議,而不是基於營業收入或單位的變量成本交叉許可協議。根據交叉許可協議,我們有義務每年進行支付 10年 期內行權。

土地購買與投資協議

2017年,保定通美在中國定興建立了硅片加工生產線。除了與一傢俬人房地產開發公司簽訂的土地權和建築購買協議以收購我們的新制造業-半導體設施外,保定通美還與定興當地政府簽訂了合作協議。定興當地政府除了承諾全力支持和合作,還將根據保定通美達到一定里程碑而發放一定的信用額度或折扣。保定通美則同意隨着時間僱傭當地工人,按時支付稅款,並最終展示價值、資產、資金總額約爲1000萬美元的投資。該投資將包括用於購買土地和建築的現金,存在於本地銀行以我們名義存放的現金,新舊設備的總價值(包括將來可能用於硒化銦和鍺基片生產的設備),客戶清單或我們基片最終用戶的視爲價值,例如,三維傳感VCSEL(垂直腔面發射激光器)的最終用戶,當地公民就業的視爲價值,我們專有工藝技術的視爲價值,其他知識產權,其他無形資產以及其他價值附加項目。沒有必須在特定時間完成的時間表或截止日期,而是一項保定通美與定興當地政府達成的善意契約。此外,如果任何一方違反協議,協議中並未規定具體處罰。然而,協議規定雙方各自有權要求對方賠償損失。在特定條件下,定興當地政府可按評估價購買土地和建築。我們認爲這類合作協議在中國是正常的、慣例的和普遍的,未來的估值是靈活的。朝陽通美在中國卡佐市也與當地政府簽訂了類似的協議,儘管規模較小。朝陽通美在卡佐市的目標總投資約爲90 百萬美元15 價值不超過百萬美元的資產和資本。此外,博宇與和和市也達成了類似協議。博宇在和和市的目標投資總額約爲$8 價值不超過百萬美元的資產和資本。

具有違約罰款的購買義務

在正常業務過程中,我們向各種供應商發出購買訂單。在某些情況下,如果我們取消購買訂單,我們可能會支付罰款。 截至2024年9月30日,公司沒有任何未履行的購買訂單會導致罰款。

26

目錄

法律訴訟

我們可能不時涉及司法或行政訴訟,涉及業務常規事務。我們預計這些事項中的任何一個,無論是個別的還是總體的,都不會對我們的業務、財務狀況、現金流或運營結果產生重大不利影響。

2024年5月6日,在美國紐約東區地方法院代表購買或獲取我們公開交易證券的個人或實體提起了股東集體訴訟訴訟。被告包括我們、首席執行官Morris S. Young和首席財務官Gary L. Fischer。法院將案件轉至位於我們總部所在地加利福尼亞北區地方法院。已指定首席原告,並提交了修正訴狀。修正訴狀聲稱一個假定的訴訟期間爲2021年3月24日至2024年4月3日(「訴訟期」)。修正訴狀聲稱被告違反了1934年修正案《證券交易法》第10(b)條和20(a)條,以及被告制定並頒佈的規則1005,要求未指定的經濟賠償、利息和律師費。2014年11月8日截止提交駁回動議。

2024年8月22日,在加利福尼亞北區地方法院,一位股東對首席執行官Morris S. Young、首席財務官Gary L. Fischer、現任董事David C. Chang、Jesse Chen和Christine Russell,以及前董事Leonard J. LeBlanc提起了一起衍生訴訟,公司被指定爲名義被告。訴狀聲稱被告基於假定的股東集體訴訟原告方訴狀中所陳述的指控,違反了對公司的受託責任。駁回動議截止日期爲2024年11月15日。

目前無法合理評估這些訴訟的最終結果,也無法合理估計這些訴訟可能的損失或損失範圍。管理層認爲這些索賠毫無根據,並打算積極進行辯護。

注意13。其他收益(費用),淨額

2024年9月30日和2023年,其他收益(費用),淨額,包括分別來自政府機構的技術創新和就業創造獎的$0.5 百萬和$0.1 百萬,其他收益(費用),淨額,分別爲截至2024年9月30日和2023年的九個月,包括一筆$1.9 百萬和$1.9 分別獲得了分別來自政府機構的數百萬美元作爲技術創新和就業創造獎。

此外,我們分別在2024年和2023年截至9月30日的三個月期間,分別獲得了外幣交易所得$800 和$146,000 分別在2024年和2023年截至9月30日的九個月期間,我們分別獲得了外幣交易所得$101,000 $的收益和$的損失分別在2024年6月30日結束的三個月和六個月內產生,在2023年6月30日結束的三個月和六個月內產生的虧損爲$的外匯合規之外的其他費用。57,000 ,分別爲2024年和2023年截至9月30日的九個月期間。

附註14. 所得稅

我們按照ASC主題740的規定進行所得稅覈算,所得稅(「ASC 740」)要求使用實施稅率來確認遞延稅資產和負債,以反映已記錄資產和負債的賬面與稅基之間的暫時差異。ASC 740還要求若遞延稅資產可能不會實現的部分超過實現的概率,遞延稅資產須減記減值準備。

我們根據全球收入的地理構成和每個地域的稅法規定(尤其是中國)提供所得稅準備。計算稅務責任涉及對估計複雜稅法應用中不確定性影響的重要判斷,尤其是在中國等外國國家。

我們將與不確定稅務立場相關的利息和罰款識別在所得稅費用中。2024 年 9 月 30 日結束的三個月和九個月的所得稅費用包括 no 利息和罰款。截至2024年9月30日,我們已經計提了與不確定稅務立場相關的利息和罰款。我們報送所得稅 no

27

Table of Contents

returns in the U.S. federal, various states and foreign jurisdictions. Currently, there is no tax audit in any of the jurisdictions and we do not expect there will be any significant change to this. 

Provision for income taxes for the three and nine months ended September 30, 2024 was mostly related to our wholly owned China subsidiaries and our partially owned subsidiaries in China. Income taxes and certain state taxes, have been provided for our U.S. operations as most of the income in the U.S. had been fully offset by utilization of federal and state net operating loss carryforwards.

Under the 2017 Tax Cuts and Jobs Act, research and experimental (“R&E”), expenditures incurred or paid for tax years beginning after December 31, 2021 will no longer be immediately deductible for tax purposes. Instead, businesses are now required to capitalize and amortize R&E expenditures over a period of five years for research conducted within the U.S. or 15 years for research conducted in a foreign jurisdiction. We capitalize the R&E expense incurred by our China subsidiaries and amortize it over 15 years.

California Senate Bill 167 was signed into law by the acting governor on June 27, 2024. The bill makes several tax changes designed to alleviate the 2024-2025 budget. For tax years beginning on or after January 1, 2024, and before January 1, 2027, net operating losses (NOLs) are suspended for both corporate and personal income taxes. The suspension will not apply to any taxpayer with net business income or modified adjusted income of less than $1 million. Another provision in Senate Bill 167 limits the use of credits for tax years beginning on or after January 1, 2024, and before January 1, 2027. During this period, a business (including all taxpayers that are members of a combined report) may claim a total of only $5 million in credits under both the Corporation and Personal Income Tax laws (including the carryover of any business credit). Since the Company’s profit level is below $1 million, Bill 167 has no impact on the Company.

Note 15. Revenue

Revenue Recognition

We manufacture and sell high-performance compound semiconductor substrates including indium phosphide, gallium arsenide and germanium wafers, and our consolidated subsidiaries sell certain raw materials, including high purity gallium (7N Ga), pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). After we ship our products, there are no remaining obligations or customer acceptance requirements that would preclude revenue recognition. Our products are typically sold pursuant to purchase orders placed by our customers, and our terms and conditions of sale do not require customer acceptance. We account for a contract with a customer when there is a legally enforceable contract, which could be the customer’s purchase order, the rights of the parties are identified, the contract has commercial terms, and collectibility of the contract consideration is probable. The majority of our contracts have a single performance obligation to transfer products and are short term in nature, usually less than six months. Our revenue is measured based on the consideration specified in the contract with each customer in exchange for transferring products that are generally based upon a negotiated formula, list or fixed price. Revenue is recognized when control of the promised goods is transferred to our customer, which is either upon shipment from our dock, receipt at the customer’s dock, or removal from consignment inventory at the customer’s location, in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods.

We have elected to account for shipping and handling as activities to fulfill the promise to transfer the goods. Shipping and handling fees billed to customers in a sales transaction are recorded as an offset to shipping and handling expenses. Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and, therefore, are excluded from revenue.

We do not provide training, installation or commissioning services. We provide for future returns based on historical data, prior experience, current economic trends and changes in customer demand at the time revenue is recognized. We do not recognize any asset associated with the incremental cost of obtaining revenue generating customer contracts. As such, sales commissions are expensed as incurred, given that the expected period of benefit is less than one year.

28

Table of Contents

Contract Balances

Contract assets are recorded when we have a conditional right to consideration for our completed performance under the contracts. Accounts receivables are recorded when the right to this consideration becomes unconditional. We believe the fair value of our accounts receivable approximates its carrying value due to its short maturities and nominal credit risk. We do not have any material contract assets as of September 30, 2024. In some contracts we require payment in advance of shipment, per a billing schedule reflected in our customer contracts, and the payment is recorded as a contract liability. The following table reflects the contract liabilities balance, which is included in “Accrued liabilities” on the condensed consolidated balance sheets, as of September 30, 2024 and December 31, 2023 (in thousands):

September 30, 

December 31,

2024

2023

Contract liabilities

$

367

$

305

During the three and nine months ended September 30, 2024, the Company recognized $9,000 and $163,000, respectively, of revenue that was included in the contract balances as of December 31, 2023. During the three and nine months ended September 30, 2023, the Company recognized $1,000 and $278,000, respectively, of revenue that was included in the contract balances as of December 31, 2022.

Disaggregated Revenue

In general, revenue disaggregated by product types and geography (see Note 11) is aligned according to the nature and economic characteristics of our business and provides meaningful disaggregation of our results of operations. Since we operate in one segment, all financial segment and product line information can be found in the condensed consolidated financial statements.

Note 16. Loans and Line of Credit

Our bank loans and credit facilities typically have a term of 12 months or less and are included in “Short-term loans” in our condensed consolidated balance sheets. The following table represents short-term bank loans as of September 30, 2024 and December 31, 2023 (in thousands, except interest rate data):

29

Table of Contents

Loan

Interest

December 31, 

September 30, 

Subsidiary

Bank

Detail

Rate

Start Date

Due Date

2023

2024

Tongmei

Bank of China (1)

$

1,848

3.5

%  

January-23

January-24

$

1,795

$

-

2,184

2.8

%  

March-23

March-24

2,118

-

376

2.7

%  

September-23

September-24

386

-

876

3.5

%  

November-23

November-24

876

884

1,003

3.5

%  

November-23

November-24

1,003

1,012

Bank of China (2)

2,911

3.5

%  

January-23

January-24

2,825

-

2,770

3.0

%  

January-24

January-25

-

2,851

Bank of China (5)

1,426

2.4

%  

September-24

September-25

-

1,426

Bank of Communications (1)

1,455

3.3

%  

January-23

January-24

1,414

-

1,380

3.8

%  

May-23

May-24

1,414

-

1,373

3.8

%  

July-23

May-24

1,414

-

1,376

3.0

%  

May-24

May-25

-

1,426

2,480

3.0

%  

June-24

May-25

-

2,566

China Merchants Bank (1)

4,367

3.7

%  

January-23

January-24

4,235

-

1,386

3.5

%  

January-24

January-25

-

1,426

692

3.5

%  

February-24

February-25

-

713

692

3.5

%  

April-24

April-25

-

713

Bank of Beijing (3)

2,290

4.2

%  

January-23

January-24

2,220

-

3,541

3.2

%  

June-23

May-24

3,626

-

1,380

3.2

%  

June-23

February-24

1,414

-

1,414

3.0

%  

December-23

December-24

1,414

1,426

3,600

3.0

%  

March-24

February-25

-

3,706

1,386

3.0

%  

March-24

December-24

-

1,426

3,580

3.0

%  

June-24

June-25

-

3,706

Industrial Bank (1)

2,757

4.3

%  

June-23

June-24

2,825

-

2,744

4.3

%  

July-23

July-24

2,825

-

2,744

4.3

%  

September-23

September-24

2,825

-

2,851

3.9

%  

September-24

September-25

-

2,851

NingBo Bank (1)

2,744

4.2

%  

August-23

September-24

2,820

-

1,271

4.3

%  

November-23

November-24

1,271

1,284

2,825

4.3

%  

December-23

December-24

2,825

2,851

1,647

4.3

%  

January-24

January-25

-

1,700

1,258

4.3

%  

May-24

March-25

-

1,303

Industrial and Commercial Bank of China (1)

2,744

3.3

%  

September-23

September-24

2,825

-

2,851

3.3

%  

September-24

September-25

-

2,851

NanJing Bank (1)

2,752

3.8

%  

October-23

October-24

2,752

2,779

China Citic Bank (1)

2,752

3.0

%  

June-24

June-25

-

2,851

2,851

2.9

%  

July-24

July-25

-

2,851

1,426

2.9

%  

September-24

September-25

-

1,426

BoYu

Industrial and Commercial Bank of China (4)

1,414

2.7

%  

December-23

December-24

1,414

-

Industrial and Commercial Bank of China (1)

1,426

2.8

%  

September-24

September-25

-

1,426

Bank of China (1)

1,204

2.4

%  

January-23

January-24

849

-

1,145

2.3

%  

September-24

September-25

-

1,145

NingBo Bank (1)

1,414

3.3

%  

November-23

May-24

1,414

-

1,376

3.0

%  

May-24

November-24

-

1,426

1,145

3.2

%  

July-24

October-24

-

1,140

Industrial Bank (1)

688

3.6

%  

September-23

September-24

708

-

Bank of Communications (1)

1,414

3.0

%  

November-23

May-24

1,414

-

275

3.0

%  

May-24

May-25

-

285

NanJing Bank (1)

1,386

3.5

%  

January-24

January-25

-

1,426

Loan Balance

$

52,921

$

52,876

Collateral for the above bank loans and line of credit

(1)Not collateralized.
(2)ChaoYang LiMei time deposit.
(3)AXT time deposit.
(4)BoYu’s land use rights and its building located at its facility in Tianjin, China. In addition, the December 2023 loan attracts a guarantee fee amounting to 0.7% of the loan amount.
(5)Baoding Tongmei’s land use rights and its building located at its facility in Dingxing, China. In addition, the loan attracts a guarantee fee amounting to 1.0% of the loan amount.

Long-term Loans

On January 30, 2024, the Company secured a new line of credit amounting to $9.7 million, structured as a five-year bank loan. The credit facility bears interest at a rate of 6.5% per annum on the amount drawn from the line of credit.

30

Table of Contents

The credit facility is collateralized by the real estate properties owned by ChaoYang Tongmei. In January 2024, the Company borrowed $5.8 million against the credit facility. The intended use of the credit facility is for construction projects. As of September 30, 2024, $5.4 million is included in “Other long-term liabilities” and $428,000 is included in “Short-term loans” in our consolidated balance sheets.

In December 2023, one of our consolidated subsidiaries, ChaoYang XinMei secured a loan of approximately $2.1 million from an unrelated financing company. According to the agreement, ChaoYang XinMei temporarily transferred ownership of its production line and related equipment to the financing company, while retaining the right to use the property for production. At the end of the 30-month contractual period, ChaoYang XinMei holds the option to repurchase the production line and related equipment for $14.00. As of September 30, 2024, $965,000 associated with this financing arrangement is included in “Other long-term liabilities” and $748,000 is included in “Short-term loans” in our consolidated balance sheets.

As of September 30, 2024, the maturities of our long-term loan liabilities in five years (excluding short-term loans) are as follows (in thousands):

Maturity of long-term loans

    

2025

$

321

2026

1,354

2027

998

2028

1,283

2029

2,442

In summary, short-term loans of $54.1 million included under “Short-term loans” in our condensed consolidated balance sheet at September 30, 2024, consisted of $52.9 million of short-term bank loans and $1.2 million of the current portion of long-term debt. Long-term loans of $6.4 million included under “Other long-term liabilities” in our condensed consolidated balance sheet at September 30, 2024 consisted of $5.4 million in a five-year bank loan and $1.0 million in a loan secured by ChaoYang XinMei.

Note 17. Leases

We lease certain equipment, office space, warehouse and facilities under long-term operating leases expiring at various dates through July 2029. The majority of our lease obligations relate to our lease agreement for our facility in Fremont, California with approximately 19,467 square feet, which was scheduled to expire in 2020. Under the terms of the facility lease agreement, in May 2020, we were granted an extension to the term of the lease for an additional three years. Furthermore, in September 2023, we entered into another agreement to extend the lease for an additional five years, commencing December 2023. There are no variable lease payments, residual value guarantees or any restrictions or covenants imposed by the facility lease. The remaining lease obligations relate to a nitrogen system to be used during the manufacturing process for our facility in Dingxing, China. The equipment lease became effective in August 2019 and will expire in July 2029. There are no variable lease payments, residual value guarantees or any restrictions or covenants imposed by the equipment lease. All other operating leases have a term of 12 months or less.

Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any one of these criteria. All of our leases are classified as operating leases and substantially all of our operating leases are comprised of equipment and office space leases. None of our leases are classified as finance leases.

For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease.

31

Table of Contents

The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, our secured incremental borrowing rate for the same term as the underlying lease.

Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early.

Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term.

We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material.

As of September 30, 2024, the maturities of our operating lease liabilities (excluding short-term leases) are as follows (in thousands):

Maturity of Lease Liabilities

    

2024

$

149

2025

607

2026

621

2027

635

2028

617

Thereafter

156

Total minimum lease payments

2,785

Less: Interest

(304)

Present value of lease obligations

2,481

Less: Current portion, included in accrued liabilities

(488)

Long-term portion of lease obligations

$

1,993

The weighted-average remaining lease term and the weighted-average discount rate for our operating leases as of each date is as follows:

September 30, 

December 31, 

2024

2023

Weighted-average remaining lease term (years)

4.47

5.22

Weighted-average discount rate

5.13

%

5.14

%

Supplemental cash flow information related to leases where we are the lessee is as follows (in thousands):

Nine Months Ended

September 30, 

2024

2023

Cash paid for amounts included in the measurement of lease liabilities:

Operating cash flows from operating leases

$

441

$

432

The components of lease expense are as follows (in thousands) within our condensed consolidated statements of operations:

32

Table of Contents

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2024

2023

2024

2023

Operating lease

$

153

$

136

$

459

$

393

Short-term lease expense

46

36

129

107

Total

$

199

$

172

$

588

$

500

Note 18. Redeemable Noncontrolling Interests

As discussed in Note 1, during the quarter ended December 31, 2020, Tongmei entered into the Capital Investment Agreements with Investors that invested approximately $48.1 million in the form of redeemable noncontrolling interests representing 7.06% of the outstanding shares of Tongmei. An additional investment of approximately $1.5 million of new capital was funded in early January 2021. Under China regulations these investments must be formally approved by the appropriate government agency and are not deemed to be dilutive until such approval is granted. The government approved the entire approximately $49 million investment on January 25, 2021, at which time the Investors owned a redeemable noncontrolling interest in Tongmei of 7.28%. The initial carrying amount of the redeemable noncontrolling interest was recorded at fair value on the date of issuance of Tongmei’s common stock, net of issuance costs and presented in temporary equity on the condensed consolidated balance sheets. This classification is due to the existence of certain contingencies that could result in potential redemption at the fixed purchase price as described below. We currently do not believe that this is probable thus no amortization of the issuance costs has been recorded.

Pursuant to the Capital Investment Agreements with the Investors, each Investor has the right to require AXT to redeem any or all Tongmei shares held by such Investor at the original purchase price paid by such Investor, without interest, in the event the IPO fails to pass the audit of the Shanghai Stock Exchange, is not approved by the Chinese Securities Regulatory Commission (“CSRC”) or Tongmei cancels the IPO application. The aggregate redemption amount is approximately $49 million, subject to the foreign exchange rate variable at time of redemption.

Tongmei submitted its IPO application to the Shanghai Stock Exchange in December 2021 and it was formally accepted for review on January 10, 2022. The Shanghai Stock Exchange approved the IPO application on July 12, 2022. On August 1, 2022, the CSRC accepted for review Tongmei’s IPO application. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Subject to review and approval by the CSRC and other authorities, Tongmei hopes to accomplish this goal in the coming months. The listing of Tongmei on the STAR Market will not change the status of AXT as a U.S. public company.

The components of the change in redeemable noncontrolling interests for the nine months ended September 30, 2024 are presented in the following table (in thousands):

Balance as of January 1, 2024

$

41,663

Equity issuance costs incurred

(843)

Stock-based compensation attributable to redeemable noncontrolling interests

29

Net loss attributable to redeemable noncontrolling interests

(210)

Effect of foreign currency translation on redeemable noncontrolling interests

480

Effect of foreign currency translation attributable to redeemable noncontrolling interests

118

Balance as of September 30, 2024

$

41,237

33

Table of Contents

Note 19. Recent Accounting Pronouncements

In November 2023, the Financial Accounting Standards Board (“FASB”) released ASU 2023-07— Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, aiming to enhance the transparency and relevance of segment information provided in financial statements. The amendments in this update require that a public entity disclose significant segment expenses, and profit or loss and assets, among other disclosures, for each reportable segment, on an annual and interim basis. The update is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Adoption of the new standard will not have a material effect on our condensed consolidated financial statements.

In December 2023, FASB issued ASU 2023-09— Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and the ensuing risks and opportunities. Furthermore, the update improves to assess income tax information that affects cash flow forecasts and capital allocation decisions. The update is effective for public business entities for annual periods beginning after December 15, 2024, on a prospective basis. Adoption of the new standard will have an immaterial effect on our condensed consolidated financial statements.

In March 2024, FASB released ASU 2024-01— Compensation—Stock Compensation (Topic 718). The update adds an illustrative example aimed at clarifying the scope application of a profit interest award in accordance with Topic 718. The update is effective for annual periods beginning after December 15, 2024, and interim periods within those annual periods. Adoption of the new standard will have an immaterial effect on our condensed consolidated financial statements.

Note 20. Subsequent Event

In October and November 2024, the Company secured a total of $5.7 million in new one-year bank loans with interest rates ranging from 2.4% to 3.9%. Of the $5.7 million, $3.6 million is unsecured, while the remaining $2.1 million is collateralized by Baoding Tongmei’s real estate. In October and November 2024, the Company repaid $6.1 million of existing loans. The loan repayments also led to a reduction in restricted cash by $1.4 million.

34

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q of AXT, Inc., a Delaware corporation (“AXT”, “the Company”, “we,” “us,” and “our” refer to AXT, Inc. and its consolidated subsidiaries) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Statements relating to our expectations regarding results of operations, market and customer demand for our products, customer qualifications of our products, our ability to expand our markets or increase sales, emerging applications using chips or devices fabricated on our substrates, including the use of InP wafer substrates in artificial intelligence (“AI”) applications, the development and adoption of new products, applications, enhancements or technologies, the life cycles of our products and applications, product yields and gross margins, expense levels, the impact of the adoption of certain accounting pronouncements, our investments in capital projects, ramping production at our new sites, potential severance costs with respect to any reduction in our work force, our ability to have new customers qualify substrates from our new manufacturing locations in China, our ability to utilize or increase our manufacturing capacity, and our belief that we have adequate cash and investments to meet our needs over the next 12 months are forward-looking statements. Additionally, statements regarding completing steps in connection with the proposed listing of shares of our wafer manufacturing company, Beijing Tongmei Xtal Technology Co., Ltd. (“Tongmei”), on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd (the “STAR Market”), being accepted to list shares of Tongmei on the STAR Market, the timing and completion of such listing of shares of Tongmei on the STAR Market are forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “goals,” “should,” “continues,” “would,” “could” and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Quarterly Report on Form 10-Q. Additionally, statements concerning future matters such as our strategy and plans, industry trends and the impact of trends, tariffs and trade wars, geopolitical tensions, export restrictions in China, the potential or expected impact of the COVID-19 pandemic on our business, results of operations and financial condition, mandatory factory shutdowns in China, changes in policies and regulations in China and economic cycles on our business are forward-looking statements.

Our forward-looking statements are based upon assumptions that are subject to uncertainties and factors relating to the Company’s operations and business environment, which could cause actual results to differ materially from those expressed or implied in the forward-looking statements contained in this Quarterly Report on Form 10-Q. These uncertainties and factors include, but are not limited to: the withdrawal, cancellations or requests for redemptions by private equity funds in China of their investments in Tongmei, the administrative challenges in satisfying the requirements of various government agencies in China in connection with the investments in Tongmei and the listing of shares of Tongmei on the STAR Market, continued open access to companies to list shares on the STAR Market, investor enthusiasm for new listings of shares on the STAR Market and geopolitical tensions between China and the United States. Additional uncertainties and factors include, but are not limited to: the timing and receipt of significant orders; the cancellation of orders and return of product; emerging applications using chips or devices fabricated on our substrates; end-user acceptance of products containing chips or devices fabricated on our substrates; our ability to bring new products to market; product announcements by our competitors; the ability to control costs and improve efficiency; the ability to utilize our manufacturing capacity; product yields and their impact on gross margins; the relocation of manufacturing lines and ramping of production; possible factory shutdowns as a result of air pollution in China; COVID-19 or other outbreaks of a contagious disease; the availability of current COVID-19 vaccines; tariffs and other trade war issues; export restrictions in China; the financial performance of our partially owned supply chain companies; policies and regulations in China; and other factors as set forth in this Quarterly Report on Form 10-Q, including those set forth under the section entitled “Risk Factors” in Part II, Item 1A below. All forward-looking statements are based upon management’s views as of the date of this Quarterly Report on Form 10-Q and are subject to risks and uncertainties that could cause actual results to differ materially from historical results or those anticipated in such forward-looking statements. Such risks and uncertainties include those set forth under the section entitled “Risk Factors” in Part II, Item 1A below, as well as those discussed elsewhere in this Quarterly Report on Form 10-Q and identify important factors that could disrupt or injure our business or cause actual results to differ materially from those predicted in any such forward-looking statements.

These forward-looking statements are not guarantees of future performance.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  Readers are urged to carefully review and consider the various disclosures made in this Quarterly Report on Form 10-Q, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.  We undertake no obligation to revise or update any forward-looking statements in order to reflect any development, event or circumstance that may arise after the date of this Quarterly Report on Form 10-Q. This discussion should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our

35

Table of Contents

Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Annual Report”) and the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

AXT is a worldwide materials science company that develops and produces high-performance compound and single element semiconductor substrates, also known as wafers. Two of our consolidated subsidiaries produce and sell certain raw materials some of which are used in our substrate manufacturing process and some of which are sold to other companies.

Our substrate wafers are used when a typical silicon substrate wafer cannot meet the performance requirements of a semiconductor or optoelectronic device. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. However, certain chips may become too hot or perform their function too slowly if silicon is used as the base material. In addition, optoelectronic applications, such as LED lighting and chip-based lasers, do not use silicon substrates because they require a wave form frequency that cannot be achieved using silicon. Alternative or specialty materials are used to replace silicon as the preferred base in these situations. Our wafers provide such alternative or specialty materials. We do not design or manufacture the chips. We add value by researching, developing and producing the specialty material wafers. We have two product lines: specialty material substrates and raw materials integral to these substrates. Our compound substrates combine indium with phosphorous (indium phosphide: InP) or gallium with arsenic (gallium arsenide: GaAs). Our single element substrates are made from germanium (Ge).

InP is a high-performance semiconductor wafer substrate used in broadband and fiber optic applications, 5G infrastructure and data center connectivity. Data centers use InP devices for high-speed optical data transmission. We believe the growth of AI applications will increase the need for high-speed data transfer, which may lead to an increase in InP substrate demand from such data centers. Currently, InP substrates are being used in certain consumer products, including proximity sensors in mobile devices, biometric wearables and other health monitoring applications. In recent years, InP demand has increased. Semi-insulating GaAs substrates are used to create various high-speed microwave components, including power amplifier chips used in cell phones, satellite communications and broadcast television applications. Semi-conducting GaAs substrates are used to create opto-electronic products, such as light emitting diodes (LEDs) that are used in a wide range of applications, including automotive lighting, horticulture, signage, display, sensors and machine vision. Semi-conducting GaAs substrates are also used in making industrial lasers. GaAs wafers could also be used for making vertical cavity surface emitting lasers (VCSELs) for facial recognition and micro-LEDs targeting improved screen technology. Ge substrates are used in applications such as solar cells for space and terrestrial photovoltaic applications.

Our supply chain strategy includes several consolidated raw material companies. One of these consolidated companies produces pyrolytic boron nitride (pBN) crucibles used in the high temperature (typically in the range 500 C to 1,500 C) growth process of single crystal ingots, effusion rings when growing OLED (Organic Light Emitting Diode) tools, epitaxial layer growth in MOCVD (Metal-Organic Chemical Vapor Deposition) reactors and MBE (Molecular Beam Epitaxy) reactors. We use these pBN crucibles in our own ingot growth processes and they are also sold in the open market to other companies. A second consolidated company converts raw gallium to purified gallium. We use purified gallium in producing our GaAs substrates and it is also sold in the open market to other companies for use in producing magnetic materials, high temperature thermometers, single crystal ingots, including gallium arsenide, gallium nitride, gallium antimonite and gallium phosphide ingots, and other materials and alloys. In addition to purified gallium, the second consolidated company also produces InP base material which we then use to grow single crystal ingots. Our substrate product group generated 63%, 79%, and 75% of our consolidated revenue and our raw materials product group generated 37%, 21%, and 25% for 2023, 2022, and 2021, respectively.

36

Table of Contents

The following chart shows our substrate products and their materials, diameters and illustrative applications and shows our raw materials group primary products and their illustrative uses and applications.

Products

  

Substrate Group and Wafer Diameter

Sample of Applications

Indium Phosphide

• Data center connectivity using light/lasers

(InP)

• High-speed data transfer in data centers to support AI applications

2”, 3”, 4”

• 5G communications

• Fiber optic lasers and detectors

• Consumer devices

• Passive Optical Networks (PONs)

• Silicon photonics

• Photonic Integrated circuits (PICs)

• Thermo-Photovoltaics (TPVs)

• RF amplifier and switching (military wireless & 5G)

• Infrared light-emitting diode (LEDs) motion control

• Lidar for robotics and autonomous vehicles

• Infrared thermal imaging

Gallium Arsenide

• Wi-Fi devices

(GaAs - semi-insulating)

• IoT devices

1”, 2”, 3”, 4”, 5”, 6”

• High-performance transistors

• Direct broadcast television

• Power amplifiers for wireless devices

• Satellite communications

• High efficiency solar cells for drones and automobiles

• Solar cells

Gallium Arsenide

• High brightness LEDs

(GaAs - semi-conducting)

• Screen displays using micro-LEDs

1”, 2”, 3”, 4”, 5”, 6”, 8”

• Printer head lasers and LEDs

• 3-D sensing using VCSELs

• Data center communication using VCSELs

• Sensors for industrial robotics/Near-infrared sensors

• Laser machining, cutting and drilling

• Optical couplers

• High efficiency solar cells for drones and automobiles

• Other lasers

• Night vision goggles

• Lidar for robotics and autonomous vehicles

• Solar cells

Germanium

• Multi-junction solar cells for satellites

(Ge)

• Optical sensors and detectors

2”, 4”, 6”

• Terrestrial concentrated photo voltaic (CPV) cells

• Infrared detectors

• Carrier wafer for LED

Raw Materials Group

6N+ and 7N+ purified gallium

• Key material in single crystal ingots such as:

- Gallium Arsenide (GaAs)

- Gallium Nitride (GaN)

- Gallium Antimonite (GaSb)

- Gallium Phosphide (GaP)

Boron trioxide (B2O3)

• Encapsulant in the ingot growth of III-V compound semiconductors

Gallium-Magnesium alloy

• Used for the synthesis of organo-gallium compounds in epitaxial growth on semiconductor wafers

pyrolytic boron nitride (pBN) crucibles

• Used when growing single-crystal compound semiconductor ingots

• Used as effusion rings when growing OLED tools

pBN insulating parts

• Used in MOCVD reactors

• Used when growing epitaxial layers in Molecular Beam Epitaxy (MBE) reactors

37

Table of Contents

All of our substrate products and raw material products are manufactured in the People’s Republic of China (PRC or China) by our PRC subsidiaries and PRC joint ventures. The PRC generally has favorable costs for facilities and labor compared with comparable facilities in the United States, Europe or Japan. Our supply chain includes partial ownership of raw material companies in China (subsidiaries/joint ventures). We believe this supply chain arrangement provides us with pricing advantages, reliable supply, market trend visibility and better sourcing lead-times for key raw materials central to manufacturing our substrates. In the event of industry-wide supply shortages we believe our vertically integrated supply chain strategy will be even more advantageous. Our raw material companies produce materials, including raw gallium (4N Ga), high purity gallium (6N and 7N Ga), starting material for InP, arsenic, germanium, germanium dioxide, pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). We have board representation in all of these raw material companies. We consolidate the companies in which we have either a controlling financial interest, or majority financial interest combined with the ability to exercise substantive control over the operations, or financial decisions, of such companies. We use the equity method to account for companies in which we have noncontrolling financial interest and have the ability to exercise significant influence, but not control, over such companies. We purchase portions of the materials produced by these companies for our own use and they sell the remainder of their production to third parties.

In 2015, the Beijing city government announced its decision to move most of its offices to the Tongzhou district where our original manufacturing facility is currently located. The Beijing city government has moved thousands of government employees into this district. The government has constructed showcase tower buildings and overseen the establishment of new apartment complexes, retail stores and restaurants. A large park, named Green Heart City Park, was built across the street from our facility and Universal Studios has developed an amusement park within a few miles of our facility. To create room and upgrade the district, the city instructed virtually all existing manufacturing companies, including Tongmei, to relocate all or some of their manufacturing lines. We were instructed to relocate our gallium arsenide manufacturing lines. For reasons of manufacturing efficiency, we elected to also move part of our germanium manufacturing line. Our indium phosphide manufacturing line, as well as various administrative and sales functions, remain primarily at our original site.

Begun in 2017, the relocation of our gallium arsenide production lines is now completed. Our PRC subsidiary, Baoding Tongmei Xtal Technology Co., Ltd. (“Baoding Tongmei”), entered into volume production in 2020. To mitigate our risks and maintain our production schedule, we moved our gallium arsenide equipment in stages. By December 31, 2019, we had ceased all crystal growth for gallium arsenide in our original manufacturing facility in Beijing and transferred 100% of our ingot production to the new manufacturing facility of our PRC subsidiary, ChaoYang Tongmei Xtal Technology Co., Ltd., (“ChaoYang Tongmei”), in Kazuo, a city approximately 250 miles from Beijing. We transferred our wafer processing equipment for gallium arsenide to Baoding Tongmei’s new manufacturing facility in Dingxing, a city approximately 75 miles from Beijing. These new facilities enabled us to expand capacity and upgrade some of the equipment. In 2021 and 2022, we added additional equipment, including certain more advanced equipment. We have also invested in additional buildings to complement the initial construction and add capacity as needed. Our PRC subsidiaries also acquired sufficient land to enable them to add facilities, if needed in the future. We believe our success in the relocation and our ability to add capacity in the future gives us competitive advantages. In addition, a new level of technological sophistication in our manufacturing capabilities is enabling us to support the major trends that we believe are likely to drive demand for our products in the years ahead.

New customer qualifications and expanding capacity as needed require us to continue to diligently address the many details that arise at each of our sites. A failure to properly accomplish this could result in disruption to our production and have a material adverse impact on our revenue, our results of operations and our financial condition. If we fail to meet the product qualification and volume requirements of a customer, we may lose sales to that customer. Our reputation may also be damaged. Any loss of sales could have a material adverse effect on our revenue, our results of operations and our financial condition.

On November 16, 2020, we announced a strategic initiative to access China’s capital markets by beginning a process to list shares of Tongmei in an initial public offering (the “IPO”) on the STAR Market, an exchange intended to support innovative companies in China. We formed and founded Tongmei in 1998 and believe Tongmei has grown into a company that will be an attractive offering on the STAR Market. To qualify for a STAR Market listing, the first major step in the process was to engage private equity firms in China (“Investors”) to invest funds in Tongmei. By December 31,

38

Table of Contents

2020, Investors, which consist of 10 private equity funds, had entered into two sets of definitive transaction documents, each consisting of a capital increase agreement along with certain supplemental agreements in substantially the same form (collectively, the “Capital Investment Agreements”), with Tongmei for a total investment of approximately $48.1 million. The currency used in the investment transactions was the Chinese renminbi, which has been converted to approximate U.S. dollars for this Quarterly Report on Form 10-Q. The remaining investment of approximately $1.5 million of new capital was funded in January 2021. The government approved the approximately $49 million investment in its entirety on January 25, 2021. In exchange for an investment of approximately $49 million, the Investors received a 7.28% redeemable noncontrolling interest in Tongmei.

Pursuant to the Capital Investment Agreements with the Investors, each Investor has the right to require AXT to redeem any or all Tongmei shares held by such Investor at the original purchase price paid by such Investor, without interest, in the event the IPO fails to pass the audit of the Shanghai Stock Exchange, is not approved by the Chinese Securities Regulatory Commission (“CSRC”) or Tongmei cancels the IPO application. The aggregate redemption amount is approximately $49 million, subject to the foreign exchange rate variable at time of redemption.

Tongmei submitted its IPO application to the Shanghai Stock Exchange in December 2021 and it was formally accepted for review on January 10, 2022. The Shanghai Stock Exchange approved the IPO application on July 12, 2022. On August 1, 2022, the CSRC accepted for review Tongmei’s IPO application. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Subject to review and approval by the CSRC and other authorities, Tongmei hopes to accomplish this goal in the coming months. The listing of Tongmei on the STAR Market will not change the status of AXT as a U.S. public company.

An early step in the STAR Market IPO process involved certain entity reorganizations and alignment of assets under Tongmei. In this regard our two consolidated raw material companies, Nanjing JinMei Gallium Co., Ltd. (“JinMei”) and Beijing BoYu Semiconductor Vessel Craftwork Technology Co., Ltd. (“BoYu”) and their subsidiaries were assigned to Tongmei in December 2020. As of June 30, 2021, AXT-Tongmei, Inc., a wholly owned subsidiary of AXT, was assigned to Tongmei. The assignment to Tongmei of JinMei, BoYu and their subsidiaries, and AXT-Tongmei, Inc. increased the number of customers and employees attributable to Tongmei as well as increased Tongmei’s consolidated revenue.

We are neither a PRC operating company nor do we conduct our operations in China through the use of variable interest entities (“VIEs”). Recent statements and regulatory actions by China’s government on the use of VIEs and data security or anti-monopoly concerns have not impacted our ability to conduct our business or continue to list our common stock on the Nasdaq Global Select Market.

The following organization chart depicts the consolidated structure as of September 30, 2024;

Graphic

39

Table of Contents

The businesses of our PRC subsidiaries and PRC joint ventures are subject to complex and rapidly evolving laws and regulations in the PRC, which can change quickly with little advance notice. The PRC government is a single party form of government with virtually unlimited authority and power to intervene in or influence commercial operations in China. In the past, we have experienced such intervention or influence by the PRC government and a change in the rules and regulations in China when we were instructed by the Beijing municipal government to relocate part of our manufacturing facility in Beijing and expect that such intervention or influence or change in the rules and regulations in China could occur in the future.

In the ordinary course of business, our PRC subsidiaries and PRC joint ventures require permits and licenses to operate in the PRC. Such permits and licenses include permits to use hazardous materials in manufacturing operations. From time to time, the PRC government issues new regulations, which may require additional actions on the part of our PRC subsidiaries and PRC joint ventures to comply. For example, on February 27, 2015, the China State Administration of Work Safety updated its list of hazardous substances. The previous list, which was published in 2002, did not restrict the materials that we use in our wafers. The new list added gallium arsenide. As a result of the newly published list, we were required to seek additional permits. In the ordinary course of business, our PRC subsidiaries and PRC joint ventures apply for permits as required. Any such intervention or influence or change in the rules and regulations in China could result in a material change in our PRC operations and/or the value of our common stock or cause the value of such securities to significantly decline or be worthless.

In September 2018, the Trump Administration announced a list of thousands of categories of goods that became subject to tariffs when imported into the United States. This pronouncement imposed tariffs on the wafer substrates we imported into the United States. The initial tariff rate was 10% and subsequently was increased to 25%. Approximately 6% of our revenue derives from importing our wafers into the United States and we expect the volume to increase. For the nine months ended September 30, 2024 and 2023, we paid approximately $569,000 and $768,000, respectively, in tariffs. The future impact of tariffs and trade wars is uncertain.

Effective as of August 1, 2023, the PRC government instituted a requirement for export licenses for gallium and germanium-related materials and the derivative products using these materials. Tongmei is required to apply for export licenses for gallium arsenide and germanium wafer substrates and each application must state the end use of the product exported. These regulations have required a new level of administration by Tongmei. In some cases, the PRC government has not issued the requisite licenses and our shipments have been delayed.

We have created a vertically integrated supply chain and transfer cash through our corporate structure in three ways. First, we capitalize our investments in our PRC subsidiaries. We licensed to our PRC subsidiaries intellectual property and received from our PRC subsidiaries royalty payments or one-time fees. Second, we use transfer pricing arrangements to buy from our PRC subsidiaries and PRC joint ventures wafers and raw materials. We review the terms of the transfer pricing arrangements annually with our independent registered public accounting firm. In the past, we sold to our PRC subsidiaries capital equipment that we purchased at the request of our PRC subsidiaries and for which we were reimbursed by the applicable PRC subsidiary. In recent years, Tongmei purchases capital equipment from suppliers in Taiwan, Japan, China, Europe or South Korea. Third, our PRC subsidiaries and PRC joint ventures pay dividends to entities within the Company’s corporate structure. For the nine months ended September 30, 2024, the aggregate dividends paid to the Company, directly or to an intermediate entity within our corporate structure, by our PRC subsidiaries and PRC raw material joint ventures were $2.1 million. For the year ended December 31, 2023, the aggregate dividends paid to the Company, directly or to an intermediate entity within our corporate structure, by our PRC subsidiaries and PRC raw material joint ventures were approximately $4.3 million. For the year ended December 31, 2023, the aggregate dividends paid to minority shareholders by our PRC subsidiaries and PRC raw material joint ventures were approximately $0. All of these distributions were paid to our PRC subsidiaries and the minority shareholders. For the nine months ended September 30, 2024 and the year ended December 31, 2023, no transfers, dividends, or distributions were made between the Company and its PRC subsidiaries, or to investors, except for the settlement of amounts owed under our transfer pricing arrangements in the ordinary course of business. We have no current intentions to distribute earnings to our investors under our corporate structure.

40

Table of Contents

The cash generated from one PRC subsidiary is not used to fund another PRC subsidiary’s operations. None of our PRC subsidiaries has faced difficulties or limitations on its ability to transfer cash between our subsidiaries. We have cash management policies that dictate the amount of such funding.

We are subject to a number of unique legal and operational risks associated with our corporate structure, any of which could result in a material change in our operations and/or the value of our common stock or cause the value of such securities to significantly decline or be worthless. Please carefully read the section entitled “Risk Factors” in Part II, Item 1A below. In particular, the following risk factors address issues associated with our corporate structure:

Although we are a Delaware corporation and are neither a PRC operating company nor do we conduct our operations in China through the use of VIEs, in the event we inadvertently concluded that we do not require any permissions or approvals from the CSRC or other PRC central government authorities to complete a public offering of securities in the U.S. or applicable laws, regulations, or interpretations change, we may be required to obtain such permissions or approvals to complete such a public offering of securities.
The PRC central government may intervene in or influence our PRC operations at any time and the rules and regulations in China can change quickly with little advance notice.
The PRC central government may also exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our common stock.
Changes in China’s political, social, regulatory or economic environments may affect our financial performance.
Joint venture raw material companies in China bring certain risks.
Risks exist in utilizing our new gallium arsenide manufacturing sites efficiently.
The Chinese central government is increasingly aware of air pollution and other forms of environmental pollution and their reform efforts can impact our manufacturing, including intermittent mandatory shutdowns.
Shutdowns or underutilizing our manufacturing facilities may result in declines in our gross margins.
Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business.
If China places restrictions on freight and transportation routes and on ports of entry and departure this could result in shipping delays or increased costs for shipping.
Our international operations are exposed to potential adverse tax consequence in China.
We derive a significant portion of our revenue from international sales, and our ability to sustain and increase our international sales involves significant risks.
The terms of the private equity raised in China as a first step toward an IPO on the STAR Market grant each Investor a right of redemption if Tongmei fails to achieve its IPO.
We are subject to foreign exchange gains and losses that may materially impact our statement of operations.
Although the audit report is prepared by an independent registered public accounting firm that is currently inspected fully by the Public Company Accounting Oversight Board (the “PCAOB”), there is no guarantee that future audit reports will be prepared by an independent registered public accounting firm that is completely inspected by the PCAOB.

Our independent registered public accounting firm is BPM LLP (“BPM”), which is registered with the PCAOB. The Holding Foreign Companies Accountable Act (the “HFCA Act”) requires that the PCAOB determine whether it is unable to inspect or investigate completely registered public accounting firms located in a non-U.S. jurisdiction because of a position taken by one or more authorities in that jurisdiction. On December 16, 2021, the PCAOB issued a report on its determinations that the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in the PRC and Hong Kong because of positions taken by PRC authorities in those jurisdictions. BPM is headquartered in the United States and not in the PRC or Hong Kong. As such, BPM is subject to the determinations announced by the PCAOB. Accordingly, the Company does not expect the HFCA Act, the Accelerating Holding Foreign Companies Accountable Act and the related regulations to affect the Company and does not expect to be identified by the Securities and Exchange Commission, or SEC, under the HFCA Act. On December 15, 2022, the PCAOB vacated its

41

Table of Contents

2021 determinations that the positions taken by authorities in the PRC and Hong Kong prevented it from inspecting and investigating completely registered public accounting firms headquartered in those jurisdictions. See “Although the audit report is prepared by an independent registered public accounting firm that is currently inspected fully by the PCAOB, there is no guarantee that future audit reports will be prepared by an independent registered public accounting firm that is completely inspected by the PCAOB” under the section entitled “Risk Factors” in Part II, Item 1A below for further information on risks related to our foreign operations and dependence.

Critical Accounting Policies, Estimates and Change in Accounting Estimates

We prepare our condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Accordingly, we make estimates, assumptions and judgments that affect the amounts reported on our condensed consolidated financial statements. These estimates, assumptions and judgments about future events and their effects on our results cannot be determined with certainty, and are made based upon our historical experience and on other assumptions that are believed to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time.

We have identified the policies below as critical to our business operations and understanding of our financial condition and results of operations. Critical accounting policies are material to the presentation of our condensed consolidated financial statements and require us to make difficult, subjective or complex judgments that could have a material effect on our financial reports and results of operations. They may require us to make assumptions about matters that are highly uncertain at the time of the estimate. Different estimates that we could have used, or changes in the estimate that are reasonably likely to occur, may have a material impact on our financial condition or results of operations.

Revenue Recognition

We manufacture and sell high-performance compound semiconductor substrates including indium phosphide, gallium arsenide and germanium wafers, and our consolidated subsidiaries sell certain raw materials, including high purity gallium (6N and 7N Ga), pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). After we ship our products, there are no remaining obligations or customer acceptance requirements that would preclude revenue recognition. Our products are typically sold pursuant to purchase orders placed by our customers, and our terms and conditions of sale do not require customer acceptance. We account for a contract with a customer when there is a legally enforceable contract, which could be the customer’s purchase order, the rights of the parties are identified, the contract has commercial terms, and collectibility of the contract consideration is probable. The majority of our contracts have a single performance obligation to transfer products and are short term in nature, usually less than six months. Our revenue is measured based on the consideration specified in the contract with each customer in exchange for transferring products that are generally based upon a negotiated, formula, list or fixed price. Revenue is recognized when control of the promised goods is transferred to our customer, which is either upon shipment from our dock, receipt at the customer’s dock, or removal from consignment inventory at the customer’s location, in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods.

Accounts Receivable and Allowance for Credit Losses

Accounts receivable are recorded at the invoiced amount and are not interest bearing. We review at least quarterly, or when there are changes in credit risks, the likelihood of collection on our accounts receivable balances and provide an allowance for credit losses. We measure the expected credit losses on a collective (pool) basis when similar delinquency status exists. We evaluate receivables from U.S. customers with an emphasis on balances in excess of 90 days and for receivables from customers located outside the U.S. with an emphasis on balances in excess of 120 days and establish a reserve allowance on the receivable balances if needed. The reason for the difference in the evaluation of receivables between foreign and U.S. customers is that U.S. customers have historically made payments in a shorter period of time than foreign customers. Foreign business practices generally require us to allow customer payment terms that are longer than those accepted in the United States.

42

Table of Contents

In accordance with ASC 326-20’s current expected credit loss impairment model, we exercise judgment when determining the adequacy of our reserves as we evaluate historical bad debt trends, general economic conditions in the United States and internationally, and reasonable and supportable forecasts of future economic conditions. Uncollectible receivables are recorded as provision for credit losses when a credit loss is expected through the establishment of an allowance, which would then be written off when all efforts to collect have been exhausted and recoveries are recognized when they are received. As of September 30, 2024 and December 31, 2023, our accounts receivable, net balance was $28.0 million and $19.3 million, respectively, which was net of an allowance of $263,000 and $579,000, respectively. If actual uncollectible accounts differ substantially from our estimates, revisions to the estimated allowance for credit losses would be required, which could have a material impact on our financial results for the future periods.

Warranty Reserve

We maintain a product warranty based upon our claims experience during the prior twelve months and any pending claims and returns of which we are aware. Warranty costs are accrued at the time revenue is recognized. As of September 30, 2024 and December 31, 2023, accrued product warranties totaled $392,000 and $703,000, respectively. The decrease in accrued product warranties is primarily attributable to decreased claims for quality issues experienced by customers. If actual warranty costs or pending new claims differ substantially from our estimates, revisions to the estimated warranty liability would be required, which could have a material impact on our financial condition and results of operations for future periods.

Inventory Valuation

Inventories are stated at the lower of cost (approximated by standard cost) or net realizable value. Cost is determined using the weighted-average cost method. Our inventory consists of raw materials as well as finished goods and work in process that include material, labor and manufacturing overhead costs. We routinely evaluate the levels of our inventory in light of current market conditions in order to identify excess and obsolete inventory, and we provide a valuation allowance for certain inventories based upon the age and quality of the product and the projections for sale of the completed products. As of September 30, 2024 and December 31, 2023, we had an inventory reserve of $23.2 million and $21.9 million, respectively, for excess and obsolete inventory and $68,000 and $78,000, respectively, for lower of cost or net realizable value reserves. If actual demand for our products were to be substantially lower than estimated, additional inventory adjustments for excess or obsolete inventory might be required, which could have a material impact on our business, financial condition and results of operations.

Impairment of Investments

We classify marketable investments in debt securities as available-for-sale debt securities in accordance with Accounting Standards Codification (“ASC”) Topic 320, Investments - Debt Securities. All available-for-sale debt securities with a quoted market value below cost (or adjusted cost) are reviewed in order to determine whether the decline is other-than-temporary. Factors considered in determining whether a loss is temporary include the magnitude of the decline in market value, the length of time the market value has been below cost (or adjusted cost), credit quality, and our ability and intent to hold the securities for a period of time sufficient to allow for any anticipated recovery in market value. We also review our debt investment portfolio at least quarterly, or when there are changes in credit risks or other potential valuation concerns to identify and evaluate whether an allowance for expected credit losses or impairment would be necessary.

We also invest in equity instruments of privately-held companies in China for business and strategic purposes. Investments in our unconsolidated PRC joint venture companies are classified as other assets and accounted for under either the equity or fair value method, depending on whether we have the ability to exercise significant influence over the joint venture company’s operations or financial decisions. We monitor our investments for impairment and record reductions in carrying value when events or changes in circumstances indicate that the carrying value may not be recoverable. Determination of impairment is highly subjective and is based on a number of factors, including an assessment of the strength of each company’s management, the length of time and extent to which the fair value has been less than our cost basis, the financial condition and near-term prospects of the company, fundamental changes to the

43

Table of Contents

business prospects of the company, share prices of subsequent offerings, and our intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in our carrying value.

For the year ended December 31, 2023, one of our PRC joint venture raw material companies assessed one of its equity investments was fully impaired. We also divested our equity investment in a PRC joint venture. The impairment and divesture resulted in a total of $1.9 million in impairment charges in our financial results for the year ended December 31, 2023. Except as mentioned above, there were no impairment charges for the remainder of these investments during the three and nine months ended September 30, 2024 and 2023.

Fair Value of Investments

ASC 820, establishes three levels of inputs that may be used to measure fair value.

Level 1 instruments represent quoted prices in active markets. Therefore, determining fair value for Level 1 instruments does not require significant management judgment, and the estimation is not difficult.

Level 2 instruments include observable inputs other than Level 1 prices, such as quoted prices for identical instruments in markets with insufficient volume or infrequent transactions (less active markets), issuer bank statements, credit ratings, non-binding market consensus prices that can be corroborated with observable market data, model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated with observable market data for substantially the full term of the assets or liabilities, or quoted prices for similar assets or liabilities. These Level 2 instruments require more management judgment and subjectivity compared to Level 1 instruments, including:

Determining which instruments are most comparable to the instrument being priced requires management to identify a sample of similar securities based on the coupon rates, maturity, issuer, credit rating, and instrument type, and subjectively select an individual security or multiple securities that are deemed most similar to the security being priced.
Determining which model-derived valuations to use in determining fair value requires management judgment. When observable market prices for similar securities or similar securities are not available, we price our marketable debt instruments using non-binding market consensus prices that are corroborated with observable market data or pricing models, such as discounted cash flow models, with all significant inputs derived from or corroborated with observable market data.

Level 3 instruments include unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. The determination of fair value for Level 3 instruments requires the most management judgment and subjectivity.

We place short-term foreign currency hedges that are intended to offset the potential cash exposure related to fluctuations in the exchange rate between the United States dollar and Japanese yen. We measure the fair value of these foreign currency hedges at each month end and quarter end using current exchange rates and in accordance with U.S. GAAP. At quarter end any foreign currency hedges not settled are netted in “Accrued liabilities” in the condensed consolidated balance sheets and classified as Level 3 assets and liabilities. As of September 30, 2024, the net change in fair value from the placement of the hedge to settlement at each month end during the quarter had a de minimis impact to the condensed consolidated results.

There have been no transfers between fair value measurement levels during the three and nine months ended September 30, 2024 and 2023.

44

Table of Contents

Impairment of Long-Lived Assets

We evaluate the recoverability of property, equipment and intangible assets in accordance with ASC Topic 360, Property, Plant and Equipment. When events and circumstances indicate that long-lived assets may be impaired, we compare the carrying value of the long-lived assets to the projection of future undiscounted cash flows attributable to these assets. In the event that the carrying value exceeds the future undiscounted cash flows, we record an impairment charge against income equal to the excess of the carrying value over the assets’ fair value. Fair values are determined based on quoted market values, discounted cash flows or internal and external appraisals, as applicable. Assets held for sale are carried at the lower of carrying value or estimated net realizable value.  We had no “Assets held for sale” or any impairment of long-lived assets in the condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023.

Stock-based Compensation

We account for stock-based compensation in accordance with ASC Topic 718, Stock-based Compensation. Share-based awards granted include stock options and restricted stock awards. We utilize the Black-Scholes option pricing model to estimate the grant date fair value of stock options, which requires the input of highly subjective assumptions, including estimating stock price volatility and expected term. Historical volatility of our stock price was used while the expected term for our options was estimated based on historical option exercise behavior and post-vesting forfeitures of options, and the contractual term, the vesting period and the expected term of the outstanding options. Further, we apply an expected forfeiture rate in determining the amount of share-based compensation. We use historical forfeitures to estimate the rate of future forfeitures. Changes in these inputs and assumptions can materially affect the measure of estimated fair value of our stock compensation. The cost of restricted stock awards is determined using the fair value of our common stock on the date of grant.

The award of performance Restricted Stock covering Shares (the “Performance Award”) will be subject to vesting requirements relating to both the recipient of the Performance Award (the “Participant”) continuously remaining a Service Provider through specified dates and achievement of specified performance-based criteria (“Performance Criteria”). Any capitalized term not defined herein will have the meaning ascribed to such term in the 2015 Equity Incentive Plan.

The financial Performance Criteria are metrics based upon prior year-end actual results as compared to the Company’s 2023 year-end actual results with respect to the 2023 Performance Awards or based upon the 2024 year-end actual results with respect to the 2024 Performance Awards. All performance shares, if earned, are still subject to annual vesting over a four-year period except that no shares are vested on the first anniversary because the performance measurement is based on year-end results for the entire year.

We recognize the compensation costs net of an estimated forfeiture rate over the requisite service period of the options award, which is generally the vesting term of four years. Compensation expense for restricted stock awards is recognized over the vesting period, which is generally one, three or four years. Stock-based compensation expense is recorded in cost of revenue, research and development, and selling, general and administrative expenses.

Income Taxes

We account for income taxes in accordance with ASC Topic 740, Income Taxes (“ASC 740”), which requires that deferred tax assets and liabilities be recognized using enacted tax rates for the effect of temporary differences between the book and tax bases of recorded assets and liabilities. ASC 740 also requires that deferred tax assets be reduced by a valuation allowance if it is more likely than not that a portion of the deferred tax asset will not be realized. Our deferred tax assets have been reduced to zero by valuation allowance.

We provide for income taxes based upon the geographic composition of worldwide earnings and tax regulations governing each region, particularly China. The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of complex tax laws, particularly in foreign countries such as China.

45

Table of Contents

See Note 14—“Income Taxes” in the notes to condensed consolidated financial statements for additional information.

Impact of the COVID-19 Pandemic

In March 2020, the World Health Organization declared the outbreak of COVID-19 to be a pandemic, which continues to be an ongoing pandemic. In March 2020, the President of the United States declared the COVID-19 outbreak a national emergency. For much of the three months ended March 31, 2020, our manufacturing facilities in China were operating at reduced staffing levels to limit the risk of COVID-19 exposure for our employees. In addition, the Chinese government authorities took a number of actions, which included, among others, lockdowns in China which reduced availability of air transport, port closures, and increased border controls or closures, travel restrictions between China and the U.S. to contain the spread of COVID-19. As of 2023, China has lifted all COVID-19 restrictions, allowing us to return to full staffing levels at all three manufacturing locations in China. On May 5, 2023, the World Health Organization declared that COVID-19 no longer constitutes a public health emergency of international concern. However, the extent of the impact of COVID-19 on our results of operations in the future will be dependent on future developments such as, among others, the potential resurgence of COVID-19, the frequency, duration and extent of outbreaks of COVID-19, future actions we or the authorities may take in response to these developments, all of which remain highly uncertain and unpredictable. There is no assurance that we will be able to adjust our business operations to adapt to such developments in the future.

Results of Operations

Revenue

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

(Decrease)

    

% Change

 

2024

    

2023

    

(Decrease)

    

% Change

 

Product Type:

($ in thousands)

($ in thousands)

Substrates

$

15,007

$

10,385

$

4,622

 

44.5

%

$

51,655

$

34,901

$

16,754

 

48.0

%

Raw materials and other

8,638

6,981

1,657

 

23.7

%

22,601

20,465

2,136

 

10.4

%

Total revenue

$

23,645

$

17,366

$

6,279

36.2

%

$

74,256

$

55,366

$

18,890

34.1

%

Revenue increased $6.3 million, or 36.2%, to $23.6 million for the three months ended September 30, 2024 from $17.4 million for the three months ended September 30, 2023. The substrate revenue increase for the three months ended September 30, 2024 as compared to the same period in 2023 was primarily the result of higher demand for GaAs wafer substrates due to increased demand across a number of applications and higher demand for InP wafer substrates reflecting strong growth from data center applications and continued improvement in passive optical networks and higher demand for Ge wafer substrates in China. Raw materials sales increased $1.7 million, or 23.7%, to $8.6 million for the three months ended September 30, 2024 as compared to the same period in 2023. The increase in raw materials revenue for the three months ended September 30, 2024 as compared to the same period in 2023 was primarily the result of an increase in sales of refined gallium and pBN crucibles resulting from stronger market demand and from the sale of recycled materials.

Revenue increased $18.9 million, or 34.1%, to $74.3 million for the nine months ended September 30, 2024 from $55.4 million for the nine months ended September 30, 2023. The substrate revenue increase for the nine months ended September 30, 2024 as compared to the same period in 2023 was primarily the result of higher demand for GaAs wafer substrates due to increased demand across a number of applications and higher demand for InP wafer substrates reflecting strong growth from data center applications and continued improvement in passive optical networks and higher demand for Ge wafer substrates in China. Raw materials sales increased $2.1 million, or 10.4%, to $22.6 million for the nine months ended September 30, 2024 as compared to the same period in 2023. The increase in raw materials revenue for the nine months ended September 30, 2024 as compared to the same period in 2023 was primarily the result of an increase in sales of refined gallium and pBN crucibles resulting from stronger market demand.

46

Table of Contents

Revenue by Geographic Region

Three Months Ended

2023 to 2024

September 30, 

Increase

    

2024

    

2023

    

(Decrease)

    

% Change

 

($ in thousands)

China

$

13,807

$

10,307

$

3,500

 

34.0

%

% of total revenue

 

58

%  

 

60

%  

Taiwan

 

2,140

 

2,491

(351)

(14.1)

%

% of total revenue

 

9

%  

 

14

%  

Japan

1,623

558

 

1,065

 

190.9

%

% of total revenue

 

7

%  

 

3

%  

Asia Pacific (excluding China, Taiwan and Japan)

 

797

 

894

 

(97)

 

(10.9)

%

% of total revenue

 

3

%  

 

5

%  

Europe (primarily Germany)

 

2,720

 

2,407

 

313

 

13.0

%

% of total revenue

 

12

%  

 

14

%  

North America (primarily the United States)

2,558

709

1,849

260.8

%

% of total revenue

11

%  

4

%  

Total revenue

$

23,645

$

17,366

$

6,279

 

36.2

%

Revenue in China increased $3.5 million for the three months ended September 30, 2024, primarily due to higher demand for our InP, GaAs and Ge wafer substrates and refined gallium and pBN crucibles sold by two of our consolidated subsidiaries. Revenue in Taiwan decreased $0.4 million, primarily due to lower demand for our InP and Ge wafer substrates, partially offset by higher demand for our GaAs wafer substrates. Revenue in Japan increased $1.1 million, primarily due to higher demand for our InP and GaAs wafer substrates and pBN crucibles sold by one of our consolidated subsidiaries. Revenue in Asia Pacific decreased $97,000, primarily due to decreased demand for pBN crucibles sold by one of our consolidated subsidiaries. Revenue in Europe increased $0.3 million, primarily due to increased demand for our GaAs, partially offset by lower demand for our Ge and InP wafer substrates. Revenue in North America increased $1.8 million, primarily due to higher demand for our InP wafer substrates and pBN crucibles sold by one of our consolidated subsidiaries, partially offset by lower demand for our GaAs and Ge wafer substrates.

Nine Months Ended

September 30, 

Increase

    

2024

    

2023

    

(Decrease)

    

% Change

 

($ in thousands)

China

$

42,271

$

28,698

$

13,573

 

47.3

%

% of total revenue

 

57

%  

 

52

%  

Taiwan

 

10,142

 

6,369

 

3,773

 

59.2

%

% of total revenue

 

14

%  

 

12

%  

Japan

 

3,409

 

3,489

 

(80)

 

(2.3)

%

% of total revenue

 

4

%  

 

6

%  

Asia Pacific (excluding China, Taiwan and Japan)

 

2,307

 

2,722

 

(415)

 

(15.2)

%  

% of total revenue

 

3

%  

 

5

%  

Europe (primarily Germany)

11,134

8,992

2,142

23.8

%  

% of total revenue

15

%  

16

%  

North America (primarily the United States)

 

4,993

 

5,096

 

(103)

 

(2.0)

%  

% of total revenue

 

7

%  

 

9

%  

Total revenue

$

74,256

$

55,366

$

18,890

 

34.1

%  

Revenue in China increased $13.6 million for the nine months ended September 30, 2024, primarily due to higher demand for our GaAs, InP and Ge wafer substrates and refined gallium and pBN crucibles sold by two of our consolidated subsidiaries. Revenue in Taiwan increased $3.8 million, primarily due to higher demand for our GaAs and InP wafer substrates, partially offset by lower demand for our Ge wafer substrates. Revenue in Japan decreased $80,000 primarily due to lower demand for our GaAs wafer substrates and refined gallium sold by one of our consolidated

47

Table of Contents

subsidiaries, partially offset by higher demand for pBN crucibles sold by one of our consolidated subsidiaries and for our InP wafer substrates. Revenue in Asia Pacific decreased by $0.4 million, primarily due to decreased demand for our InP, Ge and GaAs wafer substrates and pBN crucibles sold by one of our consolidated subsidiaries, partially offset by higher demand for refined gallium sold by one of our consolidated subsidiaries. Revenue in Europe increased by $2.1 million primarily due to higher demand for our GaAs and InP wafer substrates and pBN crucibles sold by one of our consolidated subsidiaries, partially offset by lower demand for our Ge wafer substrates and for raw gallium sold by one of our consolidated subsidiaries. Revenue in North America decreased by $0.1 million primarily due to lower demand for our GaAs and Ge wafer substrates and pBN crucibles sold by one of our consolidated subsidiaries, partially offset by higher demand for our InP wafer substrates.

Gross Profit

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

    

(Decrease)

    

% Change

2024

    

2023

    

(Decrease)

    

% Change

($ in thousands)

($ in thousands)

Gross profit

$

5,682

$

1,866

$

3,816

 

204.5

%  

$

19,428

$

8,691

$

10,737

 

123.5

%  

Gross Profit %

 

24.0

%  

 

10.7

%  

 

26.2

%  

 

15.7

%  

Gross profit increased $3.8 million, or 204.5%, to $5.7 million for the three months ended September 30, 2024 from $1.9 million for the three months ended September 30, 2023. The increase in gross profit is the result of higher revenue for our wafer substrates. Gross margin as a percentage of revenue increased due to higher unit volume across all wafer substrate and a favorable shift in product mix.

Gross profit increased $10.7 million, or 123.5%, to $19.4 million for the nine months ended September 30, 2024 from $8.7 million for the nine months ended September 30, 2023. The increase in gross profit is the result of higher revenue across all product lines. Gross margin as a percentage of revenue increased due to higher unit volume across all product lines, and a shift in product mix had a positive impact on gross margin.

Selling, General and Administrative Expenses

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

    

(Decrease)

    

% Change

2024

    

2023

    

(Decrease)

    

% Change

($ in thousands)

($ in thousands)

Selling, general and administrative expenses

$

5,650

$

5,667

$

(17)

 

(0.3)

%

$

17,656

$

17,439

$

217

 

1.2

%

% of total revenue

 

23.9

%  

 

32.6

%  

 

23.8

%  

 

31.5

%  

Selling, general and administrative expenses decreased $17,000, or 0.3%, to $5.7 million for the three months ended September 30, 2024 from $5.7 million for the three months ended September 30, 2023. The lower selling, general and administrative expenses were primarily from a decrease in compensation related expenses and bad debt expense, partially offset by higher legal and professional service expenses.

Selling, general and administrative expenses increased $217,000, or 1.2%, to $17.7 million for the nine months ended September 30, 2024 from $17.4 million for the nine months ended September 30, 2023. The higher selling, general and administrative expenses were primarily from an increase in legal and professional service expenses, partially offset by a decrease in compensation related expenses.

48

Table of Contents

Research and Development

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

    

(Decrease)

    

% Change

2024

    

2023

    

(Decrease)

    

% Change

($ in thousands)

($ in thousands)

Research and development

$

3,438

$

2,926

$

512

 

17.5

%

$

10,410

$

9,261

$

1,149

 

12.4

%

% of total revenue

 

14.5

%  

 

16.8

%  

 

14.0

%  

 

16.7

%  

 

Research and development expenses increased $0.5 million, or 17.5%, to $3.4 million for the three months ended September 30, 2024 from $2.9 million for the three months ended September 30, 2023. The increase in research and development expenses for the three months ended September 30, 2024 was primarily due to higher development expenses for crystal ingot processing.

Research and development expenses increased $1.1 million, or 12.4%, to $10.4 million for the nine months ended September 30, 2024 from $9.3 million for the nine months ended September 30, 2023. The increase in research and development expenses for the nine months ended September 30, 2024 was primarily due to higher development expenses for crystal ingot processing.

Interest Expense, Net

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

    

(Decrease)

    

% Change

2024

    

2023

    

(Decrease)

    

% Change

($ in thousands)

($ in thousands)

Interest expense, net

$

391

$

381

$

10

 

2.6

%

$

1,022

$

1,143

$

(121)

 

(10.6)

%

% of total revenue

 

1.7

%  

 

2.2

%  

 

1.4

%  

 

2.1

%  

Interest expense, net increased $10,000, or 2.6%, to $391,000 for the three months ended September 30, 2024 from $381,000 for the three months ended September 30, 2023. Interest expense, net increased primarily due to lower interest income during the three months ended September 30, 2024 as compared to the three months ended September 30, 2023.

Interest expense, net decreased $121,000, or 10.6%, to $1.0 million for the nine months ended September 30, 2024 from $1.1 million for the nine months ended September 30, 2023. Interest expense, net decreased primarily due to increased interest income during the nine months ended September 30, 2024 as compared to the nine months ended September 30, 2023.

Equity in Income of Unconsolidated Joint Ventures

Three Months Ended

Nine Months Ended

September 30, 

Equity in Income

September 30, 

Equity in Income

2024

    

2023

    

Change

    

% Change

2024

    

2023

    

Change

    

% Change

($ in thousands)

($ in thousands)

Equity in income of unconsolidated joint ventures

$

1,007

$

369

$

638

 

172.9

%

$

2,495

$

2,344

$

151

 

6.4

%

% of total revenue

 

4.3

%  

 

2.1

%  

 

3.4

%  

 

4.2

%  

The equity in income of unconsolidated joint venture companies was income of $1.0 million for the three months ended September 30, 2024 as compared to income of $0.4 million for the three months ended September 30, 2023. The increase in income of $0.6 million is primarily due to strong performance in unconsolidated joint ventures.

The equity in income of unconsolidated joint venture companies was income of $2.5 million for the nine months ended September 30, 2024 as compared to income of $2.3 million for the nine months ended

49

Table of Contents

September 30, 2023. The increase in income of $0.2 million is primarily due to strong performance in unconsolidated joint ventures.

Other Income, Net

Three Months Ended

Nine Months Ended

September 30, 

Other Income

September 30, 

Other Income

2024

    

2023

    

Change

    

% Change

2024

    

2023

    

Change

    

% Change

($ in thousands)

($ in thousands)

Other income, net

$

529

$

223

$

306

137.2

%

$

2,052

$

1,282

$

770

 

60.1

%

% of total revenue

 

2.2

%  

 

1.3

%  

 

2.8

%  

 

2.3

%  

Other income, net increased $306,000, or 137.2%, to an income of $529,000 for the three months ended September 30, 2024 from an income of $223,000 for the three months ended September 30, 2023. Other income, net increased primarily due to an increase in government grants.

Other income, net increased $770,000, or 60.1%, to an income of $2.1 million for the nine months ended September 30, 2024 from an income of $1.3 million for the nine months ended September 30, 2023. Other income, net increased primarily due to an increase in government grants.

Provision (benefit) for Income Taxes

Three Months Ended

Nine Months Ended

September 30, 

Increase

September 30, 

Increase

2024

    

2023

    

(Decrease)

    

% Change

    

2024

    

2023

    

(Decrease)

    

% Change

($ in thousands)

($ in thousands)

Provision (benefit) for income taxes

$

626

$

(101)

$

727

 

719.8

%

$

1,021

$

(92)

$

1,113

 

1,209.8

%

% of total revenue

 

2.6

%  

 

(0.6)

%  

 

1.4

%  

 

(0.2)

%  

Provision (benefit) for income taxes increased $727,000, or 719.8%, to a provision of $626,000 for the three months ended September 30, 2024 as compared to a benefit of $101,000 for the three months ended September 30, 2023. The tax expense recorded for the three months ended September 30, 2024 is the result of both foreign taxes and domestic taxes. Provision for income taxes increased $1,113,000, or 1,209.8%, to $1,021,000 for the nine months ended September 30, 2024 as compared to a benefit of $92,000 for the nine months ended September 30, 2023. Additionally, there is uncertainty of generating future profit in the U.S., which has resulted in our deferred tax assets being fully reserved. Our estimated tax rate can vary greatly from year to year because of the change or benefit in the mix of taxable income between our U.S. and China-based operations.

Under the 2017 Tax Cuts and Jobs Act, research and experimental (“R&E”) expenditures incurred or paid for tax years beginning after December 31, 2021 will no longer be immediately deductible for tax purposes. Instead, businesses are now required to capitalize and amortize R&E expenditures over a period of five years for research conducted within the U.S. or 15 years for research conducted in a foreign jurisdiction. We capitalize the R&E expense in our China subsidiaries and amortize it over 15 years.

On August 16, 2022, President Biden signed the Inflation Reduction Act (the “Inflation Reduction Act”) into law finalizing a legislation intended to address inflation by paying down the national debt, lower consumer energy costs, providing incentives for the production of clean energy, and reducing healthcare costs. The Inflation Reduction Act imposes a 1% exercise tax on stock buy backs and a 15% minimum tax on corporations with over $1 billion in profit. The Inflation Reduction Act has no impact on us, since we have no plan to buy back additional shares of our common stock and our profit is not over $1 billion.

50

Table of Contents

Net (Income) loss Attributable to Noncontrolling Interests and Redeemable Noncontrolling Interests

Three Months Ended

Net (income) loss attributable to

Nine Months Ended

Net (income) loss attributable to

noncontrolling interests and

noncontrolling interests and

September 30, 

    

redeemable noncontrolling interests

September 30, 

    

redeemable noncontrolling interests

2024

2023

Change

% Change

2024

2023

Change

% Change

($ in thousands)

($ in thousands)

Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interests

$

(50)

$

592

$

(642)

 

(108.4)

%

$

(402)

$

1,174

$

(1,576)

 

(134.2)

%

% of total revenue

 

(0.2)

%  

 

3.4

%  

 

(0.5)

%  

 

2.1

%  

Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interests increased $642,000 or 108.4% to a gain of $50,000 for the three months ended September 30, 2024, from a loss of $592,000 for the three months ended September 30, 2023, primarily due to higher profitability from our PRC subsidiaries as sales increased.

Net (income) loss attributable to noncontrolling interests and redeemable noncontrolling interests increased $1.6 million, or 134.2%, to an income of $402,000 for the nine months ended September 30, 2024, from a loss of $1.2 million for the nine months ended September 30, 2023, primarily due to higher profitability from our PRC subsidiaries as sales increased.

Liquidity and Capital Resources

We consider cash and short-term investments as liquid and available for use within one year in our current operations. Short-term investments are comprised of U.S. government securities, certificates of deposit and investment-grade corporate notes and bonds.

As of September 30, 2024, our principal source of liquidity was $38.8 million, which consisted of cash of $24.9 million and restricted cash of $13.9 million. In the nine months ended September 30, 2024, cash and restricted cash decreased by $11.3 million and investments decreased by $2.1 million. The decrease in cash and restricted cash of $11.3 million in the nine months ended September 30, 2024 was primarily due to net cash used in operating activities of $13.4 million and net cash used in investing activities of $4.0 million, partially offset by net cash provided by financing activities of $4.5 million and the effect of exchange rate changes of $1.6 million. As of September 30, 2024, we and our PRC subsidiaries held approximately $33.8 million in cash and investments in foreign bank accounts.

As of September 30, 2023, our principal source of liquidity was $43.6 million, which consisted of cash, restricted cash and cash equivalents of $39.3 million and investments of $4.3 million. In the nine months ended September 30, 2023, cash, restricted cash and cash equivalents decreased by $2.0 million and investments decreased by $7.2 million. The decrease in cash, restricted cash and cash equivalents of $2.0 million in the nine months ended September 30, 2023 was primarily due to net cash used in investing activities of $4.8 million and the effect of exchange rate changes of $1.4 million, partially offset by cash provided by financing activities of $2.2 million and net cash provided by operating activities of $2.0 million. As of September 30, 2023, we and our consolidated joint ventures in China held approximately $30.2 million in cash and investments in foreign bank accounts.

Net cash used in operating activities of $13.4 million for the nine months ended September 30, 2024 was primarily comprised of a net change of $15.9 million in operating assets and liabilities, a net loss before income

51

Table of Contents

attributable to noncontrolling interest and redeemable noncontrolling interests of $6.1 million, and income from equity method investments of $2.5 million, partially offset by the adjustment for non-cash items of depreciation and amortization of $6.7 million, stock-based compensation of $2.3 million and return of equity method investments as dividends of $2.1 million.

Net cash provided by operating activities of $2.0 million for the nine months ended September 30, 2023 was primarily comprised of a net change of $6.8 million in operating assets and liabilities, the adjustment for non-cash items of depreciation and amortization of $6.4 million, return of equity method investments (dividends) of $3.7 million, stock-based compensation of $2.7 million and deferred tax assets of $0.1 million, partially offset by net loss before income attributable to noncontrolling interest and redeemable noncontrolling interests of $15.4 million and income from equity method investments of $2.3 million.

Net cash used in investing activities of $4.0 million for the nine months ended September 30, 2024 was primarily from the purchase of property, plant and equipment of $5.6 million, and investment in non-marketable equity investments of $0.6 million, partially offset by proceeds from sales and maturities of available-for-sale debt securities of $2.2 million.

Net cash used in investing activities of $4.8 million for the nine months ended September 30, 2023 was primarily from the purchase of property, plant and equipment of $11.2 million and investments in non-marketable equity investments of $1.9 million, partially offset by proceeds from sales and maturities of available-for-sale debt securities of $7.4 million and proceeds from sale of equity securities of $0.8 million.

Net cash provided by financing activities was $4.5 million for the nine months ended September 30, 2024, which consisted of proceeds from short-term loans of $41.6 million, long-term loan of $5.8 million and common stock options exercised of $28,000, partially offset by repayment of short-term loans of $42.3 million and repayment of long-term loan of $0.6 million.

Net cash provided by financing activities was $2.2 million for the nine months ended September 30, 2023, which consisted of proceeds from short-term loans of $42.2 million, a capital increase in subsidiary shares from noncontrolling interests of $0.7 million and common stock options exercised of $10,000, partially offset by repayment of short-term loans of $40.7 million.

On October 27, 2014, our Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $5.0 million of our outstanding common stock. These repurchases could be made from time to time in the open market and could be funded from our existing cash balances and cash generated from operations. During 2015, we repurchased approximately 908,000 shares at an average price of $2.52 per share for a total purchase price of approximately $2.3 million under the stock repurchase program. Since 2015, no shares were repurchased under this program. During the nine months ended September 30, 2024, we did not repurchase any shares under the approved stock repurchase program. As of September 30, 2024, approximately $2.7 million remained available for future repurchases under this program. Currently, we do not plan to repurchase additional shares.

Dividends accrue on our outstanding Series A preferred stock, and are payable as and when declared by our Board of Directors. We have never declared or paid any dividends on the Series A preferred stock.  By the terms of the Series A preferred stock, so long as any shares of Series A preferred stock are outstanding, neither the Company nor any subsidiary of the Company shall redeem, repurchase or otherwise acquire any shares of common stock, unless all accrued dividends on the Series A preferred stock have been paid. During 2013 and 2015, we repurchased shares of our outstanding common stock. As of December 31, 2015, the Series A preferred stock had cumulative dividends of $2.9 million and we include such cumulative dividends in “Accrued liabilities” in our condensed consolidated balance sheets. At the time we pay this accrued liability, our cash will be reduced. We account for the cumulative year to date dividends on the Series A preferred stock when calculating our earnings per share. 

Occasionally, one of our PRC subsidiaries or PRC raw material joint ventures declares and pays a dividend. These dividends generally occur when the PRC joint venture declares a dividend for all of its shareholders. Dividends paid to the Company are subject to a 10% PRC withholding tax. The Company is required to obtain approval from the

52

Table of Contents

State Administration of Foreign Exchange (“SAFE”) to transfer funds in or out of the PRC. SAFE requires a valid agreement to approve the transfers, which are processed through a bank. Other than PRC foreign exchange restrictions, the Company is not subject to any PRC restrictions and limitations on its ability to distribute earnings from its businesses, including its PRC subsidiaries and PRC joint ventures, to the Company and its investors as well as the ability to settle amounts owed by the Company to its PRC subsidiaries and PRC joint ventures. If SAFE approval is denied the dividend payable to the Company would be owed but would not be paid.

For the nine months ended September 30, 2024 and 2023, the aggregate dividends paid to us, directly or to an intermediate entity within our corporate structure, by our PRC subsidiaries and PRC raw material joint ventures were $2.1 million and $3.7 million, respectively. For the nine months ended September 30, 2024 and 2023, there were no dividends paid to minority shareholders by our PRC subsidiaries or PRC raw material joint ventures. For the nine months ended September 30, 2024, no transfers, dividends, or distributions have been made to date between the Company and its PRC subsidiaries, or to investors, except for the settlement of amounts owed under our transfer pricing arrangements in the ordinary course of business.

We have no current intentions to distribute to our investors earnings under our corporate structure. We settle amounts owed under our transfer pricing arrangements in the ordinary course of business.

The cash generated from one PRC subsidiary is not used to fund another PRC subsidiary’s operations. None of our PRC subsidiaries has faced difficulties or limitations on its ability to transfer cash between our subsidiaries. AXT has cash management policies that dictate the amount of such funding.

As one of the first steps in the process of listing Tongmei on the STAR Market and going public, we sold approximately 7.28% of Tongmei to private equity investors for approximately $49 million in the aggregate. Pursuant to the Capital Investment Agreements with the Investors, each Investor has the right to require AXT to redeem any or all Tongmei shares held by such Investor at the original purchase price paid by such Investor, without interest, in the event the IPO fails to pass the audit of the Shanghai Stock Exchange, is not approved by the CSRC or Tongmei cancels the IPO application. The aggregate redemption amount is approximately $49 million.

Tongmei submitted its IPO application to the Shanghai Stock Exchange, and it was formally accepted for review on January 10, 2022. The Shanghai Stock Exchange approved the IPO application on July 12, 2022. On August 1, 2022, the CSRC accepted for review Tongmei’s IPO application. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Subject to review and approval by the CSRC and other authorities, Tongmei expects to accomplish this goal in the coming months. The listing of Tongmei on the STAR Market will not change the status of AXT as a U.S. public company.  

Our bank loans and credit facilities typically have a term of 12 months or less and are included in “Short-term loans” in our condensed consolidated balance sheets. The following table represents short-term bank loans as of September 30, 2024 and December 31, 2023 (in thousands, except interest rate data):

53

Table of Contents

Loan

Interest

December 31, 

September 30, 

Subsidiary

Bank

Detail

Rate

Start Date

Due Date

2023

2024

Tongmei

Bank of China (1)

$

1,848

3.5

%  

January-23

January-24

$

1,795

$

-

2,184

2.8

%  

March-23

March-24

2,118

-

376

2.7

%  

September-23

September-24

386

-

876

3.5

%  

November-23

November-24

876

884

1,003

3.5

%  

November-23

November-24

1,003

1,012

Bank of China (2)

2,911

3.5

%  

January-23

January-24

2,825

-

2,770

3.0

%  

January-24

January-25

-

2,851

Bank of China (5)

1,426

2.4

%  

September-24

September-25

-

1,426

Bank of Communications (1)

1,455

3.3

%  

January-23

January-24

1,414

-

1,380

3.8

%  

May-23

May-24

1,414

-

1,373

3.8

%  

July-23

May-24

1,414

-

1,376

3.0

%  

May-24

May-25

-

1,426

2,480

3.0

%  

June-24

May-25

-

2,566

China Merchants Bank (1)

4,367

3.7

%  

January-23

January-24

4,235

-

1,386

3.5

%  

January-24

January-25

-

1,426

692

3.5

%  

February-24

February-25

-

713

692

3.5

%  

April-24

April-25

-

713

Bank of Beijing (3)

2,290

4.2

%  

January-23

January-24

2,220

-

3,541

3.2

%  

June-23

May-24

3,626

-

1,380

3.2

%  

June-23

February-24

1,414

-

1,414

3.0

%  

December-23

December-24

1,414

1,426

3,600

3.0

%  

March-24

February-25

-

3,706

1,386

3.0

%  

March-24

December-24

-

1,426

3,580

3.0

%  

June-24

June-25

-

3,706

Industrial Bank (1)

2,757

4.3

%  

June-23

June-24

2,825

-

2,744

4.3

%  

July-23

July-24

2,825

-

2,744

4.3

%  

September-23

September-24

2,825

-

2,851

3.9

%  

September-24

September-25

-

2,851

NingBo Bank (1)

2,744

4.2

%  

August-23

September-24

2,820

-

1,271

4.3

%  

November-23

November-24

1,271

1,284

2,825

4.3

%  

December-23

December-24

2,825

2,851

1,647

4.3

%  

January-24

January-25

-

1,700

1,258

4.3

%  

May-24

March-25

-

1,303

Industrial and Commercial Bank of China (1)

2,744

3.3

%  

September-23

September-24

2,825

-

2,851

3.3

%  

September-24

September-25

-

2,851

NanJing Bank (1)

2,752

3.8

%  

October-23

October-24

2,752

2,779

China Citic Bank (1)

2,752

3.0

%  

June-24

June-25

-

2,851

2,851

2.9

%  

July-24

July-25

-

2,851

1,426

2.9

%  

September-24

September-25

-

1,426

BoYu

Industrial and Commercial Bank of China (4)

1,414

2.7

%  

December-23

December-24

1,414

-

Industrial and Commercial Bank of China (1)

1,426

2.8

%  

September-24

September-25

-

1,426

Bank of China (1)

1,204

2.4

%  

January-23

January-24

849

-

1,145

2.3

%  

September-24

September-25

-

1,145

NingBo Bank (1)

1,414

3.3

%  

November-23

May-24

1,414

-

1,376

3.0

%  

May-24

November-24

-

1,426

1,145

3.2

%  

July-24

October-24

-

1,140

Industrial Bank (1)

688

3.6

%  

September-23

September-24

708

-

Bank of Communications (1)

1,414

3.0

%  

November-23

May-24

1,414

-

275

3.0

%  

May-24

May-25

-

285

NanJing Bank (1)

1,386

3.5

%  

January-24

January-25

-

1,426

Loan Balance

$

52,921

$

52,876

Collateral for the above bank loans and line of credit

(1)Not collateralized.
(2)ChaoYang LiMei time deposit.
(3)AXT time deposit.
(4)BoYu’s land use rights and its building located at its facility in Tianjin, China. In addition, the December 2023 loan attracts a guarantee fee amounting to 0.7% of the loan amount.
(5)Baoding Tongmei’s land use rights and its building located at its facility in Dingxing, China. In addition, the loan attracts a guarantee fee amounting to 1.0% of the loan amount.

On January 30, 2024, the Company secured a new line of credit amounting to $9.7 million, structured as a five-year bank loan. The credit facility bears interest at a rate of 6.5% per annum on the amount drawn from the line of credit. The credit facility is collateralized by the real estate properties owned by ChaoYang Tongmei. In January 2024, the Company borrowed $5.8 million against the credit facility. The intended use of the credit facility is for construction of

54

Table of Contents

fixed assets. As of September 30, 2024, $5.4 million is included in “Other long-term liabilities” and $428,000 is included in “Short-term loans” in our consolidated balance sheets.

In December 2023, one of our consolidated subsidiaries, ChaoYang XinMei secured a loan of approximately $2.1 million from an unrelated financing company. According to the agreement, ChaoYang XinMei temporarily transferred ownership of its production line and related equipment to the financing company, while retaining the right to use the property for production. At the end of the 30-month contractual period, ChaoYang XinMei holds the option to repurchase the production line and related equipment for $14.00. As of September 30, 2024, $965,000 is included in “Other long-term liabilities” and $748,000 is included in “Short-term loans” in our consolidated balance sheets.

On July 27, 2021, we filed with the SEC a registration statement on Form S-3 (as amended, the “Shelf Registration Statement”), pursuant to which we may offer up to $60 million of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights, purchase contracts and/or units in one or more offerings and in any combination. A prospectus supplement, which we will provide each time we offer securities, will describe the specific amounts, prices and terms of the securities we determine to offer. We currently expect to use the net proceeds from the sale of securities under the Shelf Registration Statement for working capital, capital expenditures and other general corporate purposes. We may also use a portion of the net proceeds to acquire, license or invest in complementary products, technologies or businesses. On May 17, 2022, the SEC declared the Shelf Registration Statement effective.

We believe that we have adequate cash and investments to meet our operating needs and capital expenditures over the next 12 months. If our sales decrease, however, our ability to generate cash from operations will be adversely affected which could adversely affect our future liquidity, require us to use cash at a more rapid rate than expected, and require us to seek additional capital.

Cash from operations could be affected by various risks and uncertainties, including, but not limited to those set forth below under the section entitled “Risk Factors” in Part II, Item 1A below.

Contract to Purchase Goods and Services

Purchase orders or contracts for the purchase of certain goods and services are not considered to be part of our contractual obligations. We cannot determine the aggregate amount of such purchase orders that represent contractual obligations because purchase orders may represent authorizations to purchase rather than binding agreements. For the purposes of this disclosure, contractual obligations for purchase of goods or services are defined as agreements that are enforceable and legally binding and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Our purchase orders are based on our current needs and are fulfilled by our vendors within short time horizons. We also enter into contracts for outsourced services; however, the obligations under these contracts were not significant and the contracts generally contain clauses allowing for cancellation without significant penalty. Contractual obligations that are contingent upon the achievement of certain milestones would also not be included.

Land Purchase and Investment Agreement

 

In 2017, Baoding Tongmei established a wafer processing production line in Dingxing, China. In addition to a land rights and building purchase agreement that Baoding Tongmei entered into with a private real estate development company to acquire our new manufacturing facility, Baoding Tongmei also entered into a cooperation agreement with the Dingxing local government. In addition to pledging its full support and cooperation, the Dingxing local government will issue certain tax credits to Baoding Tongmei as Baoding Tongmei achieves certain milestones. Baoding Tongmei, in turn, agreed to hire local workers over time, pay taxes when due and eventually demonstrate a total investment of approximately $90 million in value, assets and capital. The investment will include cash paid for the land and buildings, cash on deposit in our name at local banks, the gross value of new and used equipment (including future equipment that might be used for indium phosphide and germanium substrates production), the deemed value for our customer list or the end user of our substrates (for example, the end users of the 3-D sensing VCSELs), a deemed value for employment of local citizens, a deemed value for our proprietary process technology, other intellectual property, other intangibles and additional items of value. There is no timeline or deadline by which this must be accomplished, rather it is a good faith

55

Table of Contents

covenant entered into between Baoding Tongmei and the Dingxing local government. Further, there is no specific penalty contemplated if either party breaches the agreement, however the agreement does state that each party has a right to seek from the other party compensation for losses. Under certain conditions, the Dingxing local government may purchase the land and building at the appraised value. We believe that such cooperation agreements are normal, customary and usual in China and that the future valuation is flexible. Chaoyang Tongmei has a similar agreement with the city of Kazuo, China, although on a smaller scale. The total investment targeted by Chaoyang Tongmei in Kazuo is approximately $15 million in value, assets and capital. In addition, BoYu has a similar agreement with the city of Kazuo. The total investment targeted by BoYu in Kazuo is approximately $8 million in value, assets and capital.

Off-Balance Sheet Arrangements

As of September 30, 2024, we did not have any off-balance sheet financing arrangements and have never established any special purpose entities as defined under SEC Regulation S-K Item 303(a)(4)(ii).

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Risk

A significant portion of our business is conducted in currencies other than the U.S. dollar. Foreign exchange losses have had a material adverse effect on our operating results and cash flows in the past and could have a material adverse effect on our operating results and cash flows in the future. If we do not effectively manage the risks associated with this currency risk, our revenue, cash flows and financial condition could be adversely affected. During 2023 and 2022, we recorded a foreign exchange gain of $0.2 million and $1.6 million, respectively, and during 2021 we recorded a net foreign exchange loss of $0.4 million, included as part of “Other income, net” in our condensed consolidated statements of operations. We incur foreign currency transaction exchange gains and losses due to operations in general. In the future we may experience foreign exchange losses on our non-functional currency denominated receivables and payables to the extent that we have not mitigated our exposure. Foreign exchange losses could have a materially adverse effect on our operating results and cash flows.

Our product sales to Japanese customers are typically invoiced in Japanese yen. As such, we have foreign exchange exposure on our accounts receivable and on any Japanese yen denominated cash deposits. To partially protect us against fluctuations in foreign currency resulting from accounts receivable in Japanese yen, starting in 2015, we instituted a foreign currency hedging program. We place short term hedges that are intended to offset the potential cash exposure related to fluctuations in the exchange rate between the United States dollar and Japanese yen. We measure the fair value of these hedges at each month end and quarter end using current exchange rates and in accordance with U.S. GAAP. At quarter end and year end any foreign currency hedges not settled are netted on the condensed consolidated balance sheet and consolidated balance sheet, respectively, and classified as Level 3 assets and liabilities. As September 30, 2024 and December 31, 2023, the net change in fair value from the placement of the hedge to settlement at each month end during the quarter had a de minimis impact to the condensed consolidated results.

The functional currency for our foreign operations is the renminbi, the local currency of China, and in the future we may establish short term hedges covering renminbi. Most of our operations are conducted in China and most of our costs are incurred in Chinese renminbi, which subjects us to fluctuations in the exchange rates between the U.S. dollar and the Chinese renminbi. We incur transaction gains or losses resulting from consolidation of expenses incurred in local currencies for our Chinese subsidiaries, as well as in translation of the assets and liabilities at each balance sheet date. Our financial results could be adversely affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets, including the revaluation by China of the renminbi, and any future adjustments that China may make to its currency such as any move it might make to a managed float system with opportunistic interventions. We may also experience foreign exchange losses on our non-functional currency denominated receivables and payables.

We currently are using a hedging program to minimize the effects of currency fluctuations relating to the Japanese yen. While we may apply this program to other currencies, such as the Chinese renminbi, our hedging position is partial and may not exist at all in the future. It may not succeed in minimizing our foreign currency fluctuation risks.

56

Table of Contents

Our primary objective in holding these instruments is to reduce the volatility of earnings and cash flows associated with changes in foreign currency. The program is not designated for trading or speculative purposes. The company may choose not to hedge certain foreign exchange exposures for a variety of reasons, including but not limited to accounting considerations and the prohibitive economic cost of hedging particular exposures. However, even with our hedging program, we still experience losses on foreign exchange from time to time.

Interest Rate Risk

Cash and restricted cash earning interest and certain variable rate debt instruments are subject to interest rate fluctuations. The following table sets forth the probable impact of a 10% change in interest rates (in thousands):

    

    

    

    

Proforma 10%

    

Proforma 10%

 

Balance as of

Current

Projected Annual

Interest Rate

Interest Rate

 

September 30, 

Interest

Interest

Decline

Increase

 

Instrument

2024

Rate

Income

Income

Income

 

Cash and restricted cash

$

38,791

 

0.90

%  

$

349

$

314

$

384

Investments in marketable debt securities

 

 

%  

 

 

 

$

349

$

314

$

384

The primary objective of our investment activities is to preserve principal while maximizing income without significantly increasing risk. Financial instruments that potentially subject us to concentration of credit risk consist primarily of cash, short-term investments, and accounts receivable. We invest primarily in money market accounts, certificates of deposits, corporate bonds and notes, and government securities. We are exposed to credit risks in the event of default by the issuers to the extent of the amount recorded on the condensed consolidated balance sheets. These securities are generally classified as available-for-sale and consequently are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income (loss), net of estimated tax, further reduced by a valuation allowance for expected credit losses, if any. Our cash and short-term investments and long-term investments are in high-quality instruments placed with major banks and financial institutions and commercial paper. We have no investments in auction rate securities.

Credit Risk

We perform ongoing credit evaluations of our customers’ financial condition, and limit the amount of credit extended when deemed necessary, but generally do not require collateral. The credit risk in our accounts receivable is mitigated by our credit evaluation process and the broad dispersion of sales transactions. One customer accounted for more than 10% of our accounts receivable balance as of September 30, 2024, and no customer accounted for more than 10% of our accounts receivable balance as of December 31, 2023. 

Impairment of Equity Investment Risk

As part of our supply chain strategy, we maintain minority investments in privately-held raw material companies located in China either invested directly by us or by one of our supply chain companies in China. These minority investments are reviewed for other than-temporary declines in value on a quarterly basis. These investments are classified as other assets in the condensed consolidated balance sheets and accounted for under either the equity or fair value method, depending on whether we have the ability to exercise significant influence over the raw material company’s operations or financial decisions. We monitor our investments for impairment and record reductions in carrying value when events or changes in circumstances indicate that the carrying value may not be recoverable. Reasons for other-than-temporary declines in value include whether the related company would have insufficient cash flow to operate for the next twelve months, significant changes in the operating performance and changes in market conditions. Our minority investments under the equity method as of September 30, 2024 and December 31, 2023 totaled $13.5 million and $12.5 million, respectively. Our minority investment under the fair value method as of September 30, 2024 and December 31, 2023 totaled $0.6 million and $0.6 million, respectively. See Note 7 for a discussion on the new fair value method investment.

57

Table of Contents

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined under Exchange Act Rules 13a-15(e) and 15d-15(e) were effective at the reasonable assurance level to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Securities and Exchange Commission and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Our disclosure controls and procedures include components of our internal control over financial reporting. Management’s assessment of the effectiveness of our internal control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well designed and operated, can provide only reasonable assurance that the control system’s objectives will be met.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a or 15(d) of the Exchange Act that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

58

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we may be involved in judicial or administrative proceedings concerning matters arising in the ordinary course of business. We do not expect that any of these matters, individually or in the aggregate, will have a material adverse effect on our business, financial condition, cash flows or results of operation.

Shareholder Class Action

On May 6, 2024, a shareholder class action complaint was filed in the U.S. District Court for the Eastern District of New York on behalf of persons or entities who purchased or acquired our publicly traded securities, against us, Morris S. Young, our Chief Executive Officer, and Gary L. Fischer, our Chief Financial Officer. The court transferred the case to the Northern District of California, where our headquarters is located. A lead plaintiff has been appointed and an amended complaint was filed. The amended complaint asserts a putative class period from March 24, 2021 and April 3, 2024, inclusive (the “Class Period”). The amended complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Rule 10b-5 promulgated thereunder by the defendants, and seeks unspecified monetary relief, interest, and attorneys’ fees. The motion to dismiss is due on November 8, 2024.

Derivative Action

On August 22, 2024, a derivative lawsuit was filed in the Northern District of California by a shareholder against Morris S. Young, our Chief Executive Officer, Gary L. Fischer, our Chief Financial Officer, current directors David C. Chang, Jesse Chen, and Christine Russell, and former director Leonard J. LeBlanc, with the Company named as a nominal defendant. The complaint asserts that the defendants breached their fiduciary duties to the Company based on the allegations asserted in the original complaint in the putative shareholder class action. The motion to dismiss is due on November 15, 2024.

It is not possible at this time to reasonably assess the final outcomes of these litigations or reasonably to estimate the possible loss or range of loss with respect to these litigations. Management believes these claims to be meritless and intends to vigorously defend against them.

Item 1A. Risk Factors

For ease of reference, we have divided these risks and uncertainties into the following general categories:

I.Summary Risk Factors;
II.Risks Related to Our Business and Operations;
III.Risks Related to International Aspects of Our Business;
IV.Risks Related to Our Financial Results and Capital Structure;
V.Risks Related to Our Intellectual Property; and
VI.Risks Related to Compliance, Environmental Regulations and Other Legal Matters.
I.Summary Risk Factors
We are subject to a number of unique legal and operational risks associated with our corporate structure.
The PRC central government may intervene in or influence our PRC operations at any time and the rules and regulations in China can change quickly with little advance notice.

59

Table of Contents

Although the audit report included in our 2023 Annual Report was prepared by an independent registered public accounting firm who is currently inspected fully by the Public Company Accounting Oversight Board (the “PCAOB”), there is no guarantee that future audit reports will be prepared by an independent registered public accounting firm that is completely inspected by the PCAOB.
Our NASDAQ stock price is volatile and our stock price could decline. Unpredictable fluctuations in our operating results, changes and events in our end markets and global trends cause volatility in our stock price.
COVID-19 or other contagious diseases may affect our business operations and financial performance. Lack of supply of current vaccines and resistance by some to be vaccinated could prolong COVID-19.
We face litigation and legal proceedings which could adversely affect our business, financial condition, results of operations or cash flows.
Global economic and political conditions, including trade tariffs, import-export restrictions, and other restrictions, may have a negative impact on our business and financial results.
Changes in China’s political, social, regulatory or economic environments may affect our financial performance.
The Chinese central government is increasingly aware of air pollution and other forms of environmental pollution and their reform efforts can impact our manufacturing, including intermittent mandatory shutdowns. Shutdowns or underutilizing our manufacturing facilities may result in declines in our gross margins.
Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business.
If China places restrictions on freight and transportation routes and on ports of entry and departure this could result in shipping delays or increased costs for shipping.
Our international operations are exposed to potential adverse tax consequence in China.
Our gross margin has fluctuated historically and may decline or increase due to several factors. Factors such as product mix, unit volume, yields and other manufacturing efficiencies can cause our gross margin to decrease or increase from quarter to quarter.
The proposed Tongmei IPO on the STAR Market in China could fail to be completed. This could result in investor disappointment and in failure to secure sufficient capital needed to take advantage of market opportunities for our products. Our stock price could decline.
The terms of the private equity raised by Tongmei in China grant each investor a right of redemption if the IPO fails to pass the audit of the Shanghai Stock Exchange, is not approved by the CSRC or Tongmei cancels the IPO application. This could result in disgorging the cash that we raised from the Investors.
Defects in our products could diminish demand for our products. Our ability to receive orders from tier one customers is contingent on producing wafer substrates of very high quality and deploying best practices in manufacturing. We may not always be able to meet these requirements and we could then lose revenue.
Difficulties in accurately estimating market demand could result in over-investing in inventory, equipment and capacity expansion or losing market share if we do not invest sufficiently.
Attracting and retaining tier one customers requires that we succeed in our research and development programs. Customers establish difficult to meet product specifications regarding defect densities, surface flatness, diameter size and other specifications pushing the boundaries of material science. We may not achieve these specifications.
We are subject to foreign exchange gains and losses that materially impact our condensed consolidated statements of operations. Because we are a global company we are exposed to changes and swings in foreign exchange, particularly when currencies experience periods of volatility.
Joint venture raw material companies in China bring certain risks.
We derive a significant portion of our revenue from international sales, and our ability to sustain and increase our international sales involves significant risks.

60

Table of Contents

II.Risks Related to Our Business and Operations

Silicon substrates (wafers) are significantly lower in cost compared to substrates made from specialty materials, such as those that we produce, and new silicon-based technologies could enable silicon-based substrates to replace specialty material-based substrates for certain applications.

Historically silicon wafers or substrates are less expensive than specialty material substrates, such as those that we produce. Electronic circuit designers will generally consider silicon first and only turn to alternative materials if silicon cannot provide the required functionality in terms of power consumption, speed, wave lengths or other specifications. Beginning in 2011, certain applications that had previously used GaAs substrates, specifically the RF chip in mobile phones, adopted a new silicon-based technology called silicon on insulator, or SOI. SOI technology uses a silicon-insulator-silicon layered substrate in place of conventional silicon substrates in semiconductor manufacturing. SOI substrates cost less than GaAs substrates and, although their performance is not as robust as GaAs substrates in terms of power consumption, heat generation and speed, they became acceptable in mobile phones and other applications that were previously dominated by GaAs substrates. The adoption of SOI resulted in decreased GaAs wafer demand, and decreased revenue. If SOI or new silicon-based technologies gain more widespread market acceptance, or are used in more applications, our sales of specialty material-based substrates could be reduced and our business and operating results could be significantly and adversely affected.

Our gross margin has fluctuated historically and may decline due to several factors.

Our gross margin has fluctuated from period to period as a result of increases or decreases in total revenue, unit volume, shifts in product mix, shifts in the cost of raw materials, costs related to the relocation of our gallium arsenide and germanium production lines, including costs related to hiring additional manufacturing employees at our new locations, tariffs imposed by the U.S. government, the introduction of new products, decreases in average selling prices for products, utilization of our manufacturing capacity, fluctuations in manufacturing yields and our ability to reduce product costs. These factors and other variables change from period to period and these fluctuations are expected to continue in the future. For example, in the third quarter of 2022 our gross margin was 42.0% but it dropped to 10.7% in the third quarter of 2023 as a result of several of these factors.

Our raw material companies experience selling price volatility and purchase price volatility in acquiring base materials. We consolidate the results of two of these raw material companies, and any reduction in their gross margins could have a significant, adverse impact on our overall gross margins. One or more of our companies has in the past sold, and may in the future sell, raw materials at significantly reduced prices in order to gain volume sales or sales to new customers. In addition, the market price of gallium dropped below our per unit inventory cost and we incurred an inventory write down under the lower of cost or net realizable value accounting rules.

Shutdowns or underutilizing our manufacturing facilities may result in declines in our gross margins.

An important factor in our success is the extent to which we are able to utilize the available capacity in our manufacturing facilities. A number of factors and circumstances may reduce utilization rates, including periods of industry overcapacity, low levels of customer orders, operating inefficiencies, mechanical failures and disruption of operations due to expansion, power interruptions, fire, flood, other natural disasters or calamities or government-ordered mandatory factory shutdowns, including as a result of the COVID-19 pandemic. Severe air pollution in Beijing can trigger mandatory factory shutdowns. For example, in the first quarter of 2018, over 300 manufacturing companies, including Tongmei, were intermittently shut down by the local government for a total of ten days from February 27 to March 31, due to severe air pollution. Further, we have increased capacity by adding two new sites and this could reduce our utilization rate and increase our depreciation charges. Because many portions of our manufacturing costs are relatively fixed, high utilization rates are critical to our gross margins and operating results. If we fail to achieve acceptable manufacturing volumes or experience product shipment delays, our results of operations will be negatively affected. During periods of decreased demand, we have underutilized our manufacturing lines. If we are unable to improve utilization levels at our facilities during periods of decreased demand and correctly manage capacity, the fixed

61

Table of Contents

expense levels will have an adverse effect on our business, financial condition and results of operations. For example, in the three months ended September 30, 2023, our revenue dropped to $17.4 million and our gross margin was only 10.7%.

If we are unable to utilize the available capacity in our manufacturing facilities, we may need to implement a restructuring plan, which could have a material adverse effect on our revenue, our results of operations and our financial condition. For example, in 2013, we concluded that incoming orders were insufficient and that we were significantly underutilizing our factory capacity. As a result, in February 2014, we announced a restructuring plan with respect to our China company, Tongmei, in order to better align manufacturing capacity with demand. Under the restructuring plan, we recorded a charge of approximately $907,000 in the first quarter of 2014.

If we receive fewer customer orders than forecasted or if our customers delay or cancel orders, we may not be able to reduce our manufacturing costs in the short-term and our gross margins would be negatively affected. In addition, lead times required by our customers are shrinking, which reduces our ability to forecast orders and properly balance our capacity utilization.

Global economic and political conditions, including trade tariffs, import-export restrictions, and other restrictions, may have a negative impact on our business and financial results.

In September 2018, the Trump Administration announced a list of thousands of categories of goods that became subject to tariffs when imported into the United States from China. This pronouncement imposed tariffs on wafer substrates we imported into the United States. The initial tariff rate was 10% and subsequently was increased to 25%. Approximately 6% of our revenue derives from importing our wafers into the United States. In the first three quarters of 2024 we paid approximately $569,000 in tariffs. In the years ended December 31, 2023, 2022 and 2021 we paid approximately $1.0 million, $3.3 million and $1.3 million, respectively, in tariffs. The future impact of tariffs and trade wars is uncertain.

The economic and political conditions between China and the United States, in our view, create an unstable business environment. The United States has restricted access by certain Chinese technology companies to items produced domestically and abroad from U.S. technology and software, which may impact our ability to grow our revenue. Trade restrictions against China have resulted in a greater determination within China to be self-sufficient and produce more goods domestically. Government agencies in China may be encouraging and supporting the founding of new companies, the addition of new products in existing companies and more vertical integration within companies. These factors could negatively impact our sales in China.

Our operations and financial results depend on worldwide economic and political conditions and their impact on levels of business spending, which has deteriorated significantly in many countries and regions. Uncertainties in the political, financial and credit markets and U.S. financial system may cause our customers to postpone deliveries. The COVID-19 virus remains an additional cause of uncertainty. Additionally, U.S. bank failures may affect our customers. Delays in the placement of new orders and extended uncertainties may reduce future sales of our products and services. The revenue growth and profitability of our business depends on the overall demand for our substrates. Because the end users of our products are primarily large companies whose businesses fluctuate with general economic and business conditions, a softening of demand for products that use our substrates, caused by a weakening economy, may result in decreased revenue. Customers may find themselves facing excess inventory from earlier purchases and may defer or reconsider purchasing products due to the downturn in their business and in the general economy. For example, global business conditions deteriorated in the second half of 2022. In the second quarter of 2022, our revenue totaled $39.5 million. In the fourth quarter of 2022, our revenue declined to $26.8 million and in the third quarter of 2023, our revenue further declined to $17.4 million. If market conditions deteriorate, we may experience increased collection times and greater write-offs, either of which could have a material adverse effect on our profitability and our cash flow.

Future tightening of credit markets and concerns regarding the availability of credit may make it more difficult for our customers to raise capital, whether debt or equity, to finance their purchases of capital equipment or of the products we sell. Delays in our customers’ ability to obtain such financing, or the unavailability of such financing, would adversely affect our product sales and revenue and, therefore, harm our business and operating results. We cannot predict

62

Table of Contents

the timing, duration of or effect on our business of any future economic downturn or the timing or strength of any subsequent recovery.

COVID-19 or other contagious diseases may affect our business operations and financial performance.

The spread of COVID-19 impacted our operations and financial performance. The outbreak of COVID has triggered references to the SARS outbreak, which occurred in 2003 and affected our business operations. Any severe occurrence of an outbreak of a contagious disease such as COVID-19, SARS, Avian Flu or Ebola may cause us or the government to temporarily close our manufacturing operations in China. In January 2020, virtually all companies in China were ordered to remain closed after the traditional Lunar New Year holiday ended, including our subsidiaries in China. In December 2022, the PRC government ended its zero-COVID policy. If there is a renewed surge of the COVID-19 pandemic in cities in which our PRC subsidiaries and PRC joint ventures are located, the Chinese government may require these companies to close again. If one or more of our key suppliers is required to close for an extended period, we might not have enough raw material inventories to continue manufacturing operations. In addition, travel restrictions between China and the U.S. were disrupted and this impacted our efficiency. In the future, if our manufacturing operations were closed for a significant period or we experience difficulty in shipping our products, we could lose revenue and market share, which would depress our financial performance and could be difficult to recapture. If one of our key customers is required to close for an extended period, this may delay the placement of new orders. As a result, our revenue would decline.

If we have low product yields, the shipment of our products may be delayed and our product cost and operating results may be adversely impacted.

A critical factor in our product cost is yield. Our products are manufactured using complex crystal growth and wafer processing technologies, and the number of usable wafer substrates we produce can fluctuate as a result of many factors, including:

poor control of furnace temperature and pressure;
impurities in the materials used;
contamination of the manufacturing environment;
quality control and inconsistency in quality levels;
lack of automation and inconsistent processing requiring manual manufacturing steps;
substrate breakage during the manufacturing process; and
equipment failure, power outages or variations in the manufacturing process.

An example where yield is of special concern is for our six-inch semi-conducting gallium arsenide substrates, which can be used for manufacturing industrial lasers and LED lighting. These applications require very low defect densities, also called EPD, and our yields will be lower than the yields achieved for the same substrate when it will be used in other applications. If we are unable to achieve the targeted quantity of low defect density substrates, then our manufacturing costs would increase and our gross margins would be negatively impacted.

In addition, we may modify our process to meet a customer specification, but this can impact our yields. If our yields decrease, our revenue could decline if we are unable to produce products to our customers’ requirements. At the same time, our manufacturing costs could remain fixed, or could increase. Lower yields negatively impact our gross margin. We have experienced product shipment delays and difficulties in achieving acceptable yields on both new and older products, and such delays and poor yields have adversely affected our operating results. We may experience similar problems in the future and we cannot predict when they may occur, their duration or severity.

63

Table of Contents

If our manufacturing processes result in defects in our products making them unfit for use by our customers, our products would be rejected, resulting in compensation costs paid to our customers, and possible disqualification. This could lead to revenue loss and market share loss.

Problems incurred in our raw material companies or our investment partners could result in a material adverse impact on our financial condition or results of operations.

We have invested in raw material companies in China that produce materials, including 99.99% pure gallium (4N Ga), high purity gallium (6N and 7N Ga), arsenic, germanium, germanium dioxide, pyrolytic boron nitride (pBN) crucibles and boron oxide (B2O3). We purchase a portion of the materials produced by these companies for our use and they sell the remainder of their production to third parties. We consolidate the companies in which we have a majority or controlling financial interest and employ equity accounting for the companies in which we have a smaller ownership interest. Several of these companies occupy space within larger facilities owned and/or operated by one of the other investment partners. Several of these partners are engaged in other manufacturing activities at or near the same facility. In some facilities, we share access to certain functions, including water, hazardous waste treatment or air quality treatment. If a partner in any of these ventures experiences problems with its operations, or deliberately withholds or disrupts services, disruptions in the operations of our companies could occur, having a material adverse effect on the financial condition and results of operation in these companies, and correspondingly on our financial condition or results of operations. For example, since gallium is a by-product of aluminum, our raw gallium company in China, which is housed in and receives services from an affiliated aluminum plant, could generate lower production and shipments of gallium as a result of reduced services provided by the aluminum plant. Accordingly, in order to meet customer supply obligations, our supply chain may have to source materials from another independent third-party supplier, resulting in higher costs and reduced gross margin.

The China central government has tightened control over hazardous chemicals and other hazardous materials. Further, the central government encourages employees to report to the appropriate regulatory agencies possible safety or environmental violations, but there may not be actual violations. Regular use in the normal course of business of hazardous chemicals or hazardous materials or a company’s failure to meet the ever-tightening standards for control of hazardous chemicals or hazardous materials could result in orders to shut down permanently, fines or other severe measures. Any such orders directed at one of our raw material companies could result in impairment charges if the company is forced to close its business, cease operations or incurs fines or operating losses, which would have a material adverse effect on our financial results.

Further, some of our raw material companies share facilities with our raw material investment partners. If either company is deemed to have violated applicable laws, rules or regulations governing the use, storage, discharge or disposal of hazardous chemicals, their operations could be adversely affected and we could be subject to substantial liability for clean-up efforts, personal injury, fines or suspension or termination of operations. Employees working for these companies could bring litigation against us even though we are not directly controlling those operations. While we would expect to defend ourselves vigorously in any litigation that is brought against us, litigation is inherently uncertain and it is possible that our business, financial condition, results of operations or cash flows could be affected. Even if we are not deemed responsible for the actions of the raw material companies or investment partners, litigation could be costly, time consuming to defend and divert management attention; in addition, if we are deemed to be the most financially viable of the partners, plaintiffs may decide to pursue us for damages.

Unforeseen manufacturing issues and restrictions at the new manufacturing sites could occur.

In 2015, the Beijing city government announced its decision to move most of its offices to the Tongzhou district where our original manufacturing facility is currently located. The Beijing city government has moved thousands of government employees into this district. To create room and upgrade the district, the government instructed virtually all existing manufacturing companies, including Tongmei, to relocate all or some of their manufacturing lines. We were instructed to move our gallium arsenide manufacturing lines out of the area.

Although the relocation is completed and we are in volume production at the new sites, unforeseen manufacturing issues and restrictions at the new sites could occur. Problems could occur as we add capacity or comply

64

Table of Contents

with strict guidelines as customers perform their qualifications. All of this will require us to continue to diligently address the many details that arise at each of our new sites. A failure to properly accomplish this could result in disruption to our production and have a material adverse impact on our revenue, our results of operations and our financial condition. If we fail to meet the product qualification and volume requirements of a customer, we may lose sales to that customer. Our reputation may also be damaged. Any loss of sales could have a material adverse effect on our revenue, our results of operations and our financial condition.

The Chinese government has in the past imposed temporary restrictions on manufacturing facilities, such as the restrictions imposed on polluting factories for the 2008 Olympics and the 2014 Asian Pacific Economic Cooperation event. These restrictions included a shutdown of the transportation of materials and power plants to reduce air pollution. To reduce air pollution in Beijing, the Chinese government has sometimes limited the construction of new, or expansion of existing, facilities by manufacturing companies in the Beijing area or required mandatory factory shutdowns. For example, in the first quarter of 2018, over 300 manufacturing companies, including Tongmei, were intermittently shut down by the local government for a total of ten days from February 27 to March 31 due to severe air pollution. If the government applies restrictions to us or requires mandatory factory shutdowns in the future, then such restrictions or shutdowns could have an adverse impact on our results of operations and our financial condition. Our ability to supply current or new orders could be significantly impacted. Customers could then be required to purchase products from our competitors, causing our competitors to take market share from us.

In addition, from time to time, the Chinese government issues new regulations, which may require additional actions on our part to comply. On February 27, 2015, the China State Administration of Work Safety updated its list of hazardous substances. The previous list, which was published in 2002, did not restrict the materials that we use in our wafers. The new list added gallium arsenide. As a result of the newly published list, we were required to seek additional permits.

Demand for our products may decrease if demand for the end-user applications decrease or if manufacturers downstream in our supply chain experience difficulty manufacturing, marketing or selling their products.

Our products are used to produce components for electronic and opto-electronic products. Accordingly, demand for our products is subject to the demand for end-user applications, including certain consumer applications, which utilize our products. For example, we have developed an 8-inch gallium arsenide wafer targeting an application in a consumer product. Our customer recently informed us that its end-user customer has cancelled its project. Production of the intended product was scheduled to begin in 2025. While there may be other end users, this particular cancellation is the loss of a potentially high-volume sales opportunity. Other factors affecting the ability of the manufacturers downstream in our supply chain to introduce and market their products successfully, include:

worldwide economic and political conditions and their impact on levels of business spending;
the competition such manufacturers face in their particular industries;
end of life obsolescence of products containing devices built on our wafers;
the technical, manufacturing, sales, marketing and management capabilities of such manufacturers;
the financial and other resources of such manufacturers; and
the inability of such manufacturers to sell their products if they infringe third-party intellectual property rights.

If demand for the end-user applications for which our products are used decreases, or if manufacturers downstream in our supply chain are unable to develop, market and sell their products, demand for our products will decrease. For example, during 2019 widespread political and economic instability and trade war concerns resulted in a general slowdown and our revenue decreased significantly. Additionally, in the second half of 2016, manufacturers producing and selling passive optical network devices known as EPONs and GPONs experienced a slowdown in demand

65

Table of Contents

resulting in surplus inventory on hand. The slowdown persisted until late in 2017. This resulted in a slowdown of sales of our InP substrates used in the PON market. More recently, global business conditions deteriorated, beginning in the second half of 2022. In general, many companies purchased more inventory than needed, in part due to fears of shortages resulting from COVID. In the second quarter of 2022, our revenue totaled $39.5 million. In the fourth quarter of 2022 our revenue declined to $26.8 million, in the second quarter of 2023, our revenue declined to $18.6 million and in the third quarter of 2023, our revenue further declined to $17.4 million. We expect similar cycles of strong demand followed by lower demand will occur for various InP, GaAs or Ge substrates in the future.

Our financial performance can be adversely affected if there are unfavorable financial results in any of our raw material companies.

The raw material companies in our vertically integrated supply chain have historically made a positive contribution to our financial performance. However, if there are unfavorable changes in revenue, average selling prices, gross margins or operating expenses in one or more of the consolidated companies, then this can result in a negative impact on our consolidated revenue, gross margin and profitability. If the companies are accounted for under the equity method, then these changes can result in a reduction in Equity in Income of Unconsolidated Joint Venture Companies. In 2023 and 2022, the companies accounted for under the equity method of accounting contributed a gain of $1.9 million and $6.0 million, respectively, to our condensed consolidated financial statements. In 2023, the total includes impairment charges of $1.9 million. The last time the companies accounted for under the equity method of accounting contributed a loss was 2019 with a loss of $1.9 million.

Intense competition in the markets for our products could prevent us from increasing revenue and achieving profitability.

The markets for our products are intensely competitive. We face competition for our wafer substrate products from other manufacturers of substrates, such as Sumitomo, JX, Freiberger, Umicore, Vital and CCTC, and from companies, such as Qorvo and Skyworks, that are actively considering alternative materials to GaAs and marketing semiconductor devices using these alternative materials. Sumitomo and JX also compete with us in the InP market. If we are unable to compete effectively, our revenue may decrease and we may not maintain profitability. We face many competitors that have a number of significant advantages over us, including:

greater name recognition and market share in the business;
more manufacturing experience;
extensive intellectual property; and
significantly greater financial, technical and marketing resources.

Our competitors could develop new or enhanced products that are more effective than our products.

The level and intensity of competition has increased over the past years and we expect competition to continue to increase in the future. Competitive pressures have resulted in reductions in the prices of our products, and continued or increased competition could reduce our market share, require us to further reduce the prices of our products, affect our ability to recover costs and result in reduced gross margins and profitability.

In addition, new competitors have and may continue to emerge, such as a company established by a former employee in China that is supplying semi-conducting GaAs wafers to the LED market. Competition from sources such as this could increase, particularly if these competitors are able to obtain large capital investments. Further, recent trade tensions between China and the United States have resulted in a greater determination within China to be self-sufficient and produce more goods domestically. This could result in the formation of new competitors that would compete against us and adversely affect our financial results.

66

Table of Contents

Cyber-attacks, system security risks and data protection issues could disrupt our internal operations and cause a reduction in revenue, increase in expenses, negatively impact our results of operation or result in other adverse consequences.

Like most technology companies, we could be targeted in cyber-attacks. We face a risk that experienced computer programmers and hackers may be able to penetrate our network security and misappropriate or compromise our confidential and proprietary information, potentially without being detected. Computer programmers and hackers also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our information technology infrastructure and demand a ransom payment. The costs to us to eliminate or alleviate cyber or other security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and our efforts to address these problems may not be successful and could result in interruptions and delays that may impede our sales, manufacturing, distribution, accounting or other critical functions.

Breaches of our security measures could create system disruptions or cause shutdowns or result in the accidental loss, inadvertent disclosure or unapproved dissemination of proprietary information or sensitive or confidential data about us. Cyber-attacks could use fraud, trickery or other forms of deception. A cyber-attack could expose us to a risk of loss or misuse of information, result in litigation and potential liability, damage our reputation or otherwise harm our business. In addition, the cost and operational consequences of implementing further data protection measures could be significant.

Portions of our information technology infrastructure might also experience interruptions, delays or cessations of service or produce errors in connection with systems integration or migration work that takes place from time to time, which may have a material impact on our business. We may not be successful in implementing new systems and transitioning data, which could cause business disruptions and be more expensive, time consuming, disruptive and resource-intensive than originally anticipated. Such disruptions could adversely impact our ability to fulfill orders and interrupt other processes. Delayed sales, lower margins or lost customers could adversely affect our financial results and reputation.

The average selling prices of our substrates may decline over relatively short periods, which may reduce our revenue and gross margins.

Since the market for our products is characterized by declining average selling prices resulting from various factors, such as increased competition, overcapacity, the introduction of new products and decreased sales of products incorporating our products, the average selling prices for our products may decline over relatively short time periods. We have in the past experienced, and in the future may experience, substantial period-to-period fluctuations in operating results due to declining average selling prices. In certain years, we have experienced an average selling price decline of our substrate selling prices of approximately 5% to 10%, depending on the substrate product. It is possible that the pace of the decline of average selling prices could accelerate beyond these levels for certain products in a commoditizing market. We anticipate that average selling prices may decrease in the future in response to the unstable demand environment, price reductions by competitors, or by other factors, including pricing pressures from significant customers. When our average selling prices decline, our revenue and gross profit decline, unless we are able to sell more products or reduce the cost to manufacture our products. We generally attempt to combat an average selling price decline by improving yields and manufacturing efficiencies and working to reduce the costs of our raw materials and of manufacturing our products. We also need to sell our current products in increasing volumes to offset any decline in their average selling prices, and introduce new products, which we may not be able to do, or do on a timely basis.

In order to remain competitive, we must continually improve our processes, work to reduce the cost of manufacturing our products and improve our yields and manufacturing efficiencies. Our efforts may not allow us to keep pace with competitive pricing pressures which could adversely affect our margins. There is no assurance that any changes effected by us will result in sufficient cost reductions to allow us to reduce the price of our products to remain competitive or improve our gross margins.

67

Table of Contents

The loss of one or more of our tier one substrate customers would significantly hurt our operating results.

From time to time, sales to one or more of our tier one customers individually represent more than 10% of our revenue and if we were to lose a major customer the loss would negatively impact our revenue. Our customers are not obligated to purchase a specified quantity of our products or to provide us with binding forecasts of product purchases. In addition, our customers may reduce, delay or cancel orders. In the past, we have experienced a slowdown in bookings, significant push-outs and cancellation of orders from customers. If we lose a major customer or if a customer cancels, reduces or delays orders, our revenue would decline. In addition, customers that have accounted for significant revenue in the past may not continue to generate revenue for us in any future period. Any loss of customers or any delay in scheduled shipments of our products could cause revenue to fall below our expectations and the expectations of market analysts or investors, causing our stock price to decline.

We have made and may continue to make strategic investments in raw materials suppliers, which may not be successful and may result in the loss of all or part of our investment.

We have made direct investments or investments through our subsidiaries in raw material suppliers in China, which provide us with opportunities to gain supplies of key raw materials that are important to our substrate business. These affiliates each have a market beyond that provided by us. We may not have significant influence over every one of these companies and in some we have made only a strategic, minority investment. We may not be successful in achieving the financial, technological or commercial advantage upon which any given investment is premised, and we could end up losing all or part of our investment which would have a negative impact on our results of operations. In the first quarter of 2019, we incurred an impairment charge of $1.1 million for a germanium materials company in China in which we had a 25% ownership interest, writing down our investment to zero value. During the second quarter of 2023, one of our equity investments assessed one of its equity investments was fully impaired, leading to a $754,000 impairment charge in our financial results for the second quarter of 2023. In the fourth quarter of 2023, we divested another equity investment, incurring a net impairment charge of $1.1 million. A significant decline in the selling prices of raw materials began in 2015 and weakened some of these companies and their losses negatively impacted our financial results for several years. Further, the increasing concern and restrictions in China of hazardous chemicals and other hazardous materials could result in orders to shut down permanently, fines or other severe measures. Any such orders directed at one of our joint venture companies could result in impairment charges if the company is forced to close its business, cease operations or incurs fines, or operating losses, which would have a material adverse effect on our financial results.

If any of our facilities are damaged by occurrences such as fire, explosion, power outage or natural disaster, we might not be able to manufacture our products.

The ongoing operation of our manufacturing and production facilities is critical to our ability to meet demand for our products. If we are not able to use all or a significant portion of our facilities for prolonged periods for any reason, we would not be able to manufacture products for our customers. For example, a fire or explosion caused by our use of combustible chemicals, high furnace temperatures or, in the case of InP, high pressure during our manufacturing processes could render some of our facilities inoperable for an indefinite period of time. Actions outside of our control, such as earthquakes or other natural disasters, could also damage our facilities, rendering them inoperable. If we are unable to operate our facilities and manufacture our products, we would lose customers and revenue and our business would be harmed.

On the evening of March 15, 2017, an electrical short-circuit fire occurred at our Beijing manufacturing facility. The electrical power supply supporting 2-inch, 3-inch and 4-inch gallium arsenide and germanium crystal growth was damaged and production in that area was stopped. In addition, a wastewater pipe was damaged resulting in a halt to wafer processing for four days until the pipe could be repaired. We were able to rotate key furnace hardware and use some of the 6-inch capacity for smaller diameter crystal growth production to mitigate the impact of the fire and resume production. If we are unable to recover from a fire or natural disaster, our business and operating results could be materially and adversely affected.

68

Table of Contents

Defects in our products could diminish demand for our products.

Our wafer products are complex and may contain defects, including defects resulting from impurities inherent in our raw materials or inconsistencies in our manufacturing processes. We have experienced quality control problems with some of our products, which caused customers to return products to us, reduce orders for our products, or both. If we experience quality control problems, or experience other manufacturing problems, customers may return product for credit, cancel or reduce orders or purchase products from our competitors. We may be unable to maintain or increase sales to our customers and sales of our products could decline. Defects in our products could cause us to incur higher manufacturing costs and suffer product returns and additional service expenses, all of which could adversely impact our operating results. If new products developed by us contain defects when released, our customers may be dissatisfied and we may suffer negative publicity or customer claims against us, lose sales or experience delays in market acceptance of our new products.

Our substrate products have a long qualification cycle that makes it difficult to forecast revenue from new customers or for new products sold to existing customers.

New customers typically place orders with us for our substrate products three months to a year or more after our initial contact with them. The sale of our products is subject to our customers’ lengthy internal evaluation and qualification processes. During this time, we may incur substantial expenses and expend selling, marketing and management efforts while the customers evaluate our products. These expenditures may not result in sales of our products. If we do not achieve anticipated sales in a period as expected, we may experience an unplanned shortfall in our revenue. As a result, our operating results would be adversely affected. In addition, if we fail to meet the product qualification requirements of the customer, we may not have another opportunity to sell that product to that customer for many months or even years. In the current competitive climate, the average qualification and sales cycle for our products has lengthened even further and is expected to continue to make it difficult for us to forecast our future sales accurately. We anticipate that sales of any future substrate products will also have lengthy qualification periods and will, therefore, be subject to risks substantially similar to those inherent in the lengthy sales cycles of our current substrate products.

The cyclical nature of the semiconductor industry may limit our ability to maintain or increase net sales and operating results during industry downturns.

The semiconductor industry is highly cyclical and periodically experiences significant economic downturns characterized by diminished product demand, resulting in production overcapacity and excess inventory in the markets we serve. A downturn can result in lower unit volumes and rapid erosion of average selling prices. The semiconductor industry has experienced significant downturns, often in connection with, or in anticipation of, maturing product cycles of both semiconductor companies’ and their customers’ products or a decline in general economic conditions. This may adversely affect our results of operations and the value of our business.

A recent example of a cyclical downcycle took shape in the second half of 2022 and has continued into 2024. Early in its history, COVID began to impact supply chains resulting in shortages. As a result, in 2021 and into 2022 almost all companies purchased more inventory than they needed as a safety precaution. In the second half of 2022 companies began to realize they were holding too much inventory and entered into the “inventory correction” period. Our consolidated revenue had reached $39.7 million in the first quarter of 2022. In the third quarter of 2023, our revenue had declined to $17.4 million.

Our continuing business depends in significant part upon manufacturers of electronic and opto-electronic compound semiconductor devices, as well as the current and anticipated market demand for these devices and products using these devices. As a supplier to the semiconductor industry, we are subject to the business cycles that characterize the industry. The timing, length and volatility of these cycles are difficult to predict. The compound semiconductor industry has historically been cyclical due to sudden changes in demand, the amount of manufacturing capacity and changes in the technology employed in compound semiconductors. The rate of changes in demand, including end demand, is high, and the effect of these changes upon us occurs quickly, exacerbating the volatility of these cycles. These changes have affected the timing and amounts of customers’ purchases and investments in new technology. These industry cycles create pressure on our revenue, gross margin and net income.

69

Table of Contents

Our industry has in the past experienced periods of oversupply and that has resulted in significantly reduced prices for compound semiconductor devices and components, including our products, both as a result of general economic changes and overcapacity. Oversupply causes greater price competition and can cause our revenue, gross margins and net income to decline. During periods of weak demand, customers typically reduce purchases, delay delivery of products and/or cancel orders for our products. Order cancellations, reductions in order size or delays in orders could occur and would materially adversely affect our business and results of operations. Actions to reduce our costs may be insufficient to align our structure with prevailing business conditions. We may be required to undertake additional cost-cutting measures, and may be unable to invest in marketing, research and development and engineering at the levels we believe are necessary to maintain our competitive position. Our failure to make these investments could seriously harm our business.

A significant portion of our operating expense and manufacturing costs are relatively fixed. If revenue for a particular quarter is lower than we expect, we likely will be unable to proportionately reduce our operating expenses or fixed manufacturing costs for that quarter, which would harm our operating results.

If we do not successfully develop new product features and improvements and new products that respond to customer requirements, our ability to generate revenue, obtain new customers, and retain existing customers may suffer.

Our success depends on our ability to offer new product features, improved performance characteristics and new products, such as larger diameter substrates, low defect density substrates, thicker or thinner substrates, substrates with extreme surface flatness specifications, substrates that are manufactured with a doped crystal growth process or substrates that incorporate leading technology and other technological advances. This is an ongoing iterative research and development process performed by our China team in collaboration with our manufacturing managers. New products must meet customer needs and compete effectively on quality, price and performance. The markets for our products are characterized by rapid technological change, changing customer needs and evolving industry standards. If our competitors introduce products employing new technologies or performance characteristics, our existing products could become obsolete and unmarketable. Over time, we have seen our competitors selling more substrates manufactured using a crystal growth technology similar to ours, which has eroded our technological differentiation.

The development of new product features, improved performance characteristics and new products can be a highly complex process, and we may experience delays in developing and introducing them. Any significant delay could cause us to fail to timely introduce and gain market acceptance of new products. Further, the costs involved in researching, developing and engineering new products could be greater than anticipated. If we fail to offer new products or product enhancements or fail to achieve higher quality products, we may not generate sufficient revenue to offset our development costs and other expenses or meet our customers’ requirements.

We purchase critical raw materials and parts for our equipment from single or limited sources, and could lose sales if these sources fail to fill our needs.

We depend on a limited number of suppliers for certain raw materials, components and equipment used in manufacturing our products, including key materials such as quartz tubing, and polishing solutions. We generally purchase these materials through standard purchase orders and not pursuant to long-term supply contracts, and no supplier guarantees supply of raw materials or equipment to us. If we lose any of our key suppliers, our manufacturing efforts could be significantly hampered and we could be prevented from timely producing and delivering products to our customers. We have experienced delays obtaining critical raw materials and spare parts, including gallium, and we could experience such delays again in the future due to shortages of materials or for other reasons. Delays in receiving equipment or materials could result in higher costs and cause us to delay or reduce production of our products. If we have to delay or reduce production, we could fail to meet customer delivery schedules and our revenue and operating results could suffer.

We may not be able to identify or form additional complementary raw material joint ventures.

We might invest in additional joint venture companies in order to remain competitive in our marketplace and ensure a supply of critical raw materials. However, we may not be able to identify additional complementary joint

70

Table of Contents

venture opportunities or, even once opportunities are identified, we may not be able to reach agreement on the terms of the business venture with the other investment partners. Further, geopolitical tensions and trade wars could result in government agencies blocking such new joint ventures. New joint ventures could require cash investments or cause us to incur additional liabilities or other expenses, any of which could adversely affect our financial condition and operating results.

The financial condition of our customers may affect their ability to pay amounts owed to us.

Some of our customers may be undercapitalized and cope with cash flow issues. Because of competitive market conditions, we may grant our customers extended payment terms when selling products to them. Subsequent to our fulfilling an order, some customers have been unable to make payments when due, reducing our cash balances and causing us to incur charges to allow for a possibility that some accounts might not be paid. We observed an increase in our accounts receivable in the first quarter of 2020 and believe this has resulted from work stoppages, shelter-in-place orders and general cautiousness due to the COVID-19 pandemic. In the past, we have had some customers file for bankruptcy. If our customers do not pay amounts owed to us then we will incur charges that would reduce our earnings.

We depend on the continuing efforts of our senior management team and other key personnel. If we lose members of our senior management team or other key personnel, or are unable to successfully recruit and train qualified personnel, our ability to manufacture and sell our products could be harmed.

Our future success depends on the continuing services of members of our senior management team and other key personnel. Our industry is characterized by high demand and intense competition for talent, and the turnover rate can be high. We compete for qualified management and other personnel with other specialty material companies and semiconductor companies. Our employees could leave with little or no prior notice and would be free to work for a competitor. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. The loss of any of these individuals or our ability to attract or retain qualified personnel could adversely affect our business.

Our results of operations may suffer if we do not effectively manage our inventory.

We must manage our inventory of raw materials, work in process and finished goods effectively to meet changing customer requirements, while keeping inventory costs down and improving gross margins. Although we seek to maintain sufficient inventory levels of certain materials to guard against interruptions in supply and to meet our near term needs, we may experience shortages of certain key materials. Alternatively, a sudden decline in demand could result in holding too much inventory which occurred in the second half of 2022. Some of our products and supplies have in the past, and may in the future, become obsolete while in inventory due to changing customer specifications, or become excess inventory due to decreased demand for our products and an inability to sell the inventory within a foreseeable period. This would result in charges that reduce our gross profit and gross margin. Furthermore, if market prices drop below the prices at which we value inventory, we would need to take a charge for a reduction in inventory values in accordance with the lower of cost or net realizable value valuation rule. We have in the past had to take inventory valuation and impairment charges. Any future unexpected changes in demand or increases in costs of production that cause us to take additional charges for un-saleable, obsolete or excess inventory, or to reduce inventory values, would adversely affect our results of operations.

The effect of terrorist threats and actions on the general economy could decrease our revenue.

Countries such as the United States and China continue to be on alert for terrorist activity. The potential near and long-term impact terrorist activities may have in regards to our suppliers, customers and markets for our products and the economy is uncertain. There may be embargos of ports or products, or destruction of shipments or our facilities, or attacks that affect our personnel. There may be other potentially adverse effects on our operating results due to significant events that we cannot foresee. Since we perform all of our manufacturing operations in China, terrorist activity or threats against U.S. owned enterprises are a particular concern to us.

71

Table of Contents

III.Risks Related to International Aspects of Our Business

The Chinese central government is increasingly aware of air pollution and other forms of environmental pollution and their reform efforts can impact our manufacturing, including intermittent mandatory shutdowns.

The Chinese central government is demonstrating strong leadership to improve air quality and reduce environmental pollution. These efforts have impacted manufacturing companies through mandatory shutdowns, increased inspections and regulatory reforms. In the fourth quarter of 2017, many manufacturing companies in the greater Beijing area, including Tongmei, were instructed by the local government to cease most manufacturing for several days until the air quality improved. In the first quarter of 2018, from February 27 to March 31 over 300 manufacturing companies, including Tongmei, were again intermittently shut down by the local government for a total of ten days, or 30 percent of the remaining calendar days, due to severe air pollution. Our shipments were delayed and our revenue for the quarter was negatively impacted. We expect that mandatory factory shutdowns may occur in the future. If the frequency of such shutdowns increases, especially at the end of a quarter, or if the total number of days of shutdowns prevents us from producing enough wafers to ship, then these shutdowns will have a material adverse effect on our manufacturing output, revenue and factory utilization. Each of our raw material supply chain companies could also be impacted by environmental related orders from the central government.

Although we are a Delaware corporation and are neither a PRC operating company nor do we conduct our operations in China through the use of VIEs, in the event we inadvertently concluded that we do not require any permissions or approvals from the CSRC or other PRC central government authorities to complete a public offering of securities in the U.S. or applicable laws, regulations, or interpretations change, we may be required to obtain such permissions or approvals to complete such a public offering of securities.

We are a Delaware corporation and are neither a PRC operating company nor do we conduct our operations in China through the use of VIEs. All of our products are manufactured in the PRC by our PRC subsidiaries and PRC joint ventures. We believe that we do not require any permissions or approvals from the CSRC or other PRC central government authorities to complete a public offering of securities in the U.S. because we are a Delaware corporation with our principal corporate office in Fremont, California and the PRC laws and regulations that govern the listing of securities on a U.S. securities exchange apply to PRC companies. However, in the event that we inadvertently concluded that such permission or approvals are not required or applicable laws, regulations, or interpretations change and we are required to obtain such permissions or approvals in the future and we fail to obtain such permissions or approvals, then we may not be able to complete a public offering of securities in the U.S. We may also be pressured to delist our securities, which would force the holders to sell these securities and could result in a material adverse effect on the value of these securities. We may face sanctions by the CSRC or other PRC central government authorities or pressure from the PRC government in various business matters for failure to obtain such permissions or approvals. These sanctions or pressure may include fines and penalties on our operations in China, limitations on our operating privileges in China, delays in or restrictions on the repatriation of the proceeds from a public offering of securities in the U.S. into the PRC, restrictions on or prohibition of the payments or remittance of dividends by our subsidiaries in China, or other actions that could have a material and adverse effect on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our common stock.

The PRC central government may intervene in or influence our PRC operations at any time and the rules and regulations in China can change quickly with little advance notice.

The businesses of our PRC subsidiaries and PRC joint ventures are subject to complex and rapidly evolving laws and regulations in the PRC, which can change quickly with little advance notice. The PRC central government is a single party form of government with virtually unlimited authority and power to intervene in or influence commercial operations in China. In the past, we have experienced such intervention or influence by the PRC central government and a change in the rules and regulations in China when we were instructed by the Beijing municipal government to relocate our gallium arsenide manufacturing facility in Beijing and expect that such intervention or influence or change in the rules and regulations in China could occur in the future.

72

Table of Contents

In the ordinary course of business, our PRC subsidiaries and PRC joint ventures require permits and licenses to operate in the PRC. Such permits and licenses include permits to use hazardous materials in manufacturing operations. From time to time, the PRC government issues new regulations, which may require additional actions on the part of our PRC subsidiaries and PRC joint ventures to comply. For example, on February 27, 2015, the China State Administration of Work Safety updated its list of hazardous substances. The previous list, which was published in 2002, did not restrict the materials that we use in our wafers. The new list added gallium arsenide. As a result of the newly published list, we were required to seek additional permits. Any such intervention or influence or change in the rules and regulations in China could result in a material change in our PRC operations and/or the value of our common stock.

Enhanced trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers may materially harm our business.

On July 3, 2023, China adopted new export control regulations on gallium- and germanium-related materials and the derivative products using these materials, effective as of August 1, 2023, which require Tongmei to proceed to immediately seek permits from the applicable Chinese authorities to export gallium arsenide and germanium substrates. Indium phosphide substrates are not included in the new export control regulations, and, therefore, exports of indium phosphide will not require export approvals as part of these regulations. While Tongmei has received its initial China export permits to resume shipping gallium arsenide and germanium substrates to certain customers, there can be no assurances that Tongmei will continue to receive China export permits to resume shipping gallium arsenide and germanium substrates to other customers or that China will not adopt additional export control regulations that affect our business, financial condition and results of operations.

All of our wafer substrates are manufactured in China and in the years 2023, 2022 and 2021, sales to customers in North America, primarily in the U.S., were approximately 10%, 14% and 10% of our revenue, respectively. In September 2018, the Trump Administration announced a list of thousands of categories of goods that became subject to tariffs when imported into the United States from China. This pronouncement imposed tariffs on wafer substrates we imported into the United States. The initial tariff rate was 10% and subsequently was increased to 25%. In the first three quarters of 2024 we paid approximately $569,000 in tariffs. In the years 2023, 2022 and 2021, we paid approximately $1.0 million, $3.3 million and $1.3 million, respectively, in tariffs. The future impact of tariffs and trade wars is uncertain. We may be required to raise prices, which may result in the loss of customers and our business, financial condition and results of operations may be materially harmed. Additionally, it is possible that our business could be adversely impacted by retaliatory trade measures taken by China or other countries in response to existing or future tariffs, which could cause us to raise prices or make changes to our operations, which could materially harm our business, financial condition and results of operations.

The economic and political conditions between China and the United States, in our view, create an unstable business environment. The United States government has restricted access by certain Chinese technology companies to items produced domestically and abroad from U.S. technology and software, which may impact our ability to maintain or grow our revenue. Trade restrictions against China have resulted in a greater determination within China to be self-sufficient and produce more goods domestically. Government agencies in China may be encouraging and supporting the founding of new companies, the addition of new products in existing companies and more vertical integration within companies. These factors have resulted in lower revenue from sales of our wafer substrates in China. Further, the continued threats of tariffs and other trade restrictions could have a generally disruptive impact on the global economy and, therefore, negatively impact our sales.

In addition, we may incur increases in costs and other adverse business consequences, including losses of customers and revenue or decreased gross margins, due to changes in tariffs, import or export restrictions, further trade barriers, or unexpected changes in regulatory requirements. In addition, in July 2012, we received notice of retroactive value-added taxes (VATs) levied by the tax authorities in China, which applied for the period from July 1, 2011 to June 30, 2012. We expensed the retroactive VATs of approximately $1.3 million in the quarter ended June 30, 2012, which resulted in a decrease in our gross margins. These VATs will continue to negatively impact our gross margins for the future quarters. Given the relatively fluid regulatory environment in China and the United States, there could be

73

Table of Contents

additional tax or other regulatory changes in the future. Any such changes could directly and materially adversely impact our financial results and general business condition.

COVID-19 or other contagious diseases may affect our business operations and financial performance.

The spread of COVID-19 impacted our operations and financial performance. The outbreak of COVID has triggered references to the SARS outbreak, which occurred in 2003 and affected our business operations. Any severe occurrence of an outbreak of a contagious disease such as COVID-19, SARS, Avian Flu or Ebola may cause us or the government to temporarily close our manufacturing operations in China. In January 2020, virtually all companies in China were ordered to remain closed after the traditional Lunar New Year holiday ended, including our subsidiaries in China. In December 2022, the PRC government ended its zero-COVID policy. If there is a renewed surge of the COVID-19 pandemic in cities in which our PRC subsidiaries and PRC joint ventures are located, the Chinese government may require these companies to close again. If one or more of our key suppliers is required to close for an extended period, we might not have enough raw material inventories to continue manufacturing operations. In addition, travel restrictions between China and the U.S. were disrupted and this impacted our efficiency. In the future, if our manufacturing operations were closed for a significant period or we experience difficulty in shipping our products, we could lose revenue and market share, which would depress our financial performance and could be difficult to recapture. If one of our key customers is required to close for an extended period, this may delay the placement of new orders. As a result, our revenue would decline.

Changes in China’s political, social, regulatory or economic environments may affect our financial performance.

Our financial performance may be affected by changes in China’s political, social, regulatory or economic environments. The role of the Chinese central and local governments in the Chinese economy is significant. The Beijing municipal government’s decision to move to the Tongzhou district, the original location of our China company, resulted in the city instructing virtually all existing manufacturing companies, including AXT, to relocate all or some of their manufacturing lines. We were instructed to move our gallium arsenide manufacturing line out of the area. Chinese policies toward hazardous materials, including arsenic, environmental controls, air pollution, economic liberalization, laws and policies affecting technology companies, foreign investment, currency exchange rates, taxation structure and other matters could change, resulting in greater restrictions on our ability to do business and operate our manufacturing facilities in China. We have observed a growing fluidity and tightening of regulations concerning hazardous materials, other environmental controls and air pollution. The Chinese government could revoke, terminate or suspend our operating licenses for reasons related to environmental control over the use of hazardous materials, air pollution, labor complaints, national security and similar reasons without compensation to us. Further, the central government encourages employees to report to the appropriate regulatory agencies possible safety or environmental violations, but there may not be actual violations. In days of severe air pollution the government has ordered manufacturing companies to stop all production. For example, in the first quarter of 2018, from February 27 to March 31, over 300 manufacturing companies, including us, were again intermittently shut down by the local government for a total of ten days due to severe air pollution. Our shipments were delayed and our revenue for the quarter was negatively impacted. We expect that mandatory factory shutdowns may occur in the future. Any failure on our part to comply with governmental regulations could result in the loss of our ability to manufacture our products. Further, any imposition of surcharges or any increase in Chinese tax rates or reduction or elimination of Chinese tax benefits could hurt our financial results.

Financial market volatility and adverse changes in the domestic, global, political and economic environment could have a significant adverse impact on our business, financial condition and operating results.

We are subject to the risks arising from adverse changes and uncertainty in domestic and global economies. Uncertain global economic and political conditions or low or negative growth in China, Europe or the United States, along with volatility in the financial markets and U.S. financial system, increasing national debt and fiscal concerns in various regions and the adoption and availability of fiscal and monetary stimulus measures to counteract the impact of the COVID-19 pandemic, pose challenges to our industry. Currently China’s economy is slowing and this could impact our financial performance. In addition, tariffs, trade restrictions, trade wars, high levels of inflation, high interest rates, the Russian invasion of Ukraine, the Middle East conflict, the Red Sea shipping disruptions, Brexit, heightened tensions between the U.S. and China, and U.S. bank failures in 2023, among other factors, are creating an unstable environment

74

Table of Contents

and can disrupt or restrict commerce. Although we remain well-capitalized, the cost and availability of funds may be adversely affected by illiquid credit markets. Volatility in U.S. and international markets and economies may adversely affect our liquidity, financial condition and profitability. Another severe or prolonged economic downturn could result in a variety of risks to our business, including:

inventory corrections;
increased volatility in our stock price;
increased volatility in foreign currency exchange rates;
delays in, or curtailment of, purchasing decisions by our customers or potential customers;
increased credit risk associated with our customers or potential customers, particularly those that may operate in industries most affected by the economic downturn; and
impairment of our tangible or intangible assets.

A recent example of economic volatility took shape in the second half of 2022 and has continued into 2024. Early in its history, COVID began to impact supply chains resulting in shortages. As a result, in 2021 and into 2022 almost all companies purchased more inventory than needed as a safety net. In the second half of 2022 companies began to realize they had too much inventory and entered into the “inventory correction” period. Our consolidated revenue had reached $39.7 million in the first quarter of 2022. In the third quarter of 2023 our revenue had declined to $17.4 million. In the fourth quarter of 2018 and continuing in 2019, we experienced delays in customer purchasing decisions and disruptions in a normal volume of customer orders that we believe were in part due to the uncertainties in the global economy, resulting in an adverse impact on consumer spending. During challenging and uncertain economic times and in tight credit markets, many customers delay or reduce technology purchases. Should similar events occur again, our business and operating results could be significantly and adversely affected.

The PRC central government may also exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our common stock.

The PRC central government may also exert more control over offerings conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and/or the value of our common stock. The PRC central government may also seek to significantly limit or completely hinder our ability to offer or continue to offer our securities to investors and cause the value of such securities to significantly decline or be worthless.

Our international operations are exposed to potential adverse tax consequence in China.

Our international operations create a risk of potential adverse tax consequences. Taxes on income in our China-based companies are dependent upon acceptance of our operational practices and intercompany transfer pricing by local tax authorities as being on an arm's length basis. Due to inconsistencies among taxing authorities in application of the arm’s length standard, transfer pricing challenges by tax authorities could, if successful, materially increase our consolidated income tax expense. We are subject to tax audits in China and an audit could result in the assessment of additional income tax against us. This could have a material adverse effect on our operating results or cash flows in the period or periods for which that determination is made and could result in increases to our overall tax expense in subsequent periods. Various taxing agencies in China are increasingly focused on tax reform and other legislative action to increase tax revenue. In addition to risks regarding income tax we have in the past been retroactively assessed value added taxes (“VAT” or “sales tax”) and such VAT assessments could occur again in the future.

75

Table of Contents

Uncertainty regarding the United States’ foreign policy, particularly with regards to China, could disrupt our business.

We manufacture our substrates in China and, in the year ended December 31, 2023, approximately 90% of our sales were to customers located outside the United States. Further, we have partial ownership of raw material companies in China as part of our supply chain. The United States’ current foreign policy has created uncertainty and caution in the international business community, resulting in disruptions in manufacturing, import/export, trade tariffs, sales, investments and other business activity. Such disruptions have had an adverse impact on our financial performance and could continue in the future.

Dividends from within our corporate structure are subject to PRC withholding tax and SAFE approval.

Occasionally, one of our PRC subsidiaries or PRC raw material joint ventures declares and pays a dividend. These dividends generally occur when the PRC joint venture declares a dividend for all of its shareholders. We have no current intentions to distribute to our investors earnings under our corporate structure. Dividends paid to the Company are subject to a 10% PRC withholding tax. The Company is required to obtain approval from SAFE to transfer funds in or out of the PRC. SAFE requires a valid agreement to approve the transfers, which are processed through a bank. Other than PRC foreign exchange restrictions, the Company is not subject to any PRC restrictions and limitations on its ability to distribute earnings from its businesses. If SAFE approval is denied the dividend payable to the Company would be owed but would not be paid.

Our PRC subsidiaries and PRC joint ventures are subject to data security oversight.

Our PRC subsidiaries and PRC joint ventures are subject to oversight by the Cyberspace Administration of China (the “CAC”) regarding data security. Except for routine personal information necessary to process payroll and other benefits and emergency contact information, our PRC subsidiaries and PRC joint ventures do not collect or maintain personal information. All of our products are manufactured in the PRC by our PRC subsidiaries and PRC joint ventures. Although we are neither a PRC operating company nor do we conduct our operations in China through the use of VIEs, cybersecurity is increasingly a focus of the central government and the CAC could require AXT to comply with PRC cybersecurity regulations, which could cause us to make changes to our operations that could materially harm our business, financial condition and results of operations.

We derive a significant portion of our revenue from international sales, and our ability to sustain and increase our international sales involves significant risks.

Approximately 90% of our revenue is from international sales. We expect that sales to customers outside the United States, particularly sales to customers in Japan, Taiwan, Europe and China, will continue to represent a significant portion of our revenue. Therefore, our revenue growth depends significantly on the expansion of our international sales and operations.

All of our manufacturing facilities and most of our suppliers are also located outside the United States. Managing our overseas operations presents challenges, including periodic regional economic downturns, trade balance issues, threats of trade wars, varying business conditions and demands, political instability, variations in enforcement of intellectual property and contract rights in different jurisdictions, differences in the ability to develop relationships with suppliers and other local businesses, changes in U.S. and international laws and regulations, including import and export restrictions, fluctuations in interest and currency exchange rates, the ability to provide sufficient levels of technical support in different locations, cultural differences and perceptions of U.S. companies, shipping delays and terrorist acts or acts of war, natural disasters and epidemics or pandemics, such as COVID-19, among other risks. Many of these challenges are present in China, which represents a large potential market for semiconductor devices. Global uncertainties with respect to: (i) economic growth rates in various countries; (ii) sustainability of demand for electronic products; (iii) capital spending by semiconductor manufacturers; (iv) price weakness for certain semiconductor devices; (v) changing and tightening environmental regulations; (vi) political instability in regions where we have operations and (vii) trade wars may also affect our business, financial condition and results of operations.

76

Table of Contents

Our dependence on international sales involves a number of risks, including:

changes in tariffs, import restrictions, export restrictions, or other trade barriers;
unexpected changes in regulatory requirements;
longer periods to collect accounts receivable;
foreign exchange rate fluctuations;
changes in export license requirements;
political and economic instability; and
unexpected changes in diplomatic and trade relationships.

Most of our sales are denominated in U.S. dollars, except for sales to our Chinese customers which are denominated in renminbi and our Japanese customers which are denominated in Japanese yen. We also have some small sales denominated in Euro. Increases in the value of the U.S. dollar could increase the price of our products in non-U.S. markets and make our products more expensive than competitors’ products in these markets.

We are subject to foreign exchange gains and losses that may materially impact our condensed consolidated statements of operations.

We are subject to foreign exchange gains and losses that may materially impact our condensed consolidated statements of operations. For example, in 2023 and 2022, we incurred foreign exchange gains of $169,000 and $1.6 million, respectively, and in 2021, we incurred a foreign exchange loss of $434,000.

The functional currency of our companies in China is the Chinese renminbi, the local currency. We can incur foreign exchange gains or losses when we pay dollars to one of our China-based companies or a third-party supplier in China. Similarly, if a company in China pays renminbi into one of our bank accounts transacting in dollars the renminbi will be converted to dollars and we can incur a foreign exchange gain or loss. Hedging renminbi will be considered in the future but it is complicated by the number of companies involved, the diversity of transactions and restrictions imposed by the banking system in China.

Sales to Japanese customers are denominated in Japanese yen. This subjects us to fluctuations in the exchange rates between the U.S. dollar and the Japanese yen and can result in foreign exchange gains and losses. This has been problematic in the past and, therefore, we instituted a foreign currency hedging program dealing with yen which has historically mitigated the gains and losses caused by fluctuations in the exchange rates.

Joint venture raw material companies in China bring certain risks.

Since our consolidated subsidiaries and all of our joint venture raw material companies operate in China, their activities could subject us to a number of risks associated with conducting operations internationally, including:

import and export restrictions;
unexpected changes in regulatory requirements that may limit our ability to manufacture, export the products of these companies, sell into particular jurisdictions or impose multiple conflicting tax laws and regulations;
the imposition of tariffs, trade barriers and duties;

77

Table of Contents

difficulties in managing geographically disparate operations;
difficulties in enforcing agreements through non-U.S. legal systems;
political and economic instability, civil unrest or war;
terrorist activities that impact international commerce;
difficulties in protecting our intellectual property rights, particularly in countries where the laws and practices do not protect proprietary rights to as great an extent as do the laws and practices of the United States;
new or changing laws and policies affecting economic liberalization, foreign investment, currency convertibility or exchange rates, taxation or employment;
new or changing PRC regulations and policies regarding data security and oversight by the CAC of our consolidated subsidiaries and all of our joint venture raw material companies; and
nationalization of foreign-owned assets, including intellectual property.

If China places restrictions on freight and transportation routes and on ports of entry and departure this could result in shipping delays or increased costs for shipping.

In August 2015, there was an explosion at the Port of Tianjin, China. As a result of this incident the government placed restrictions on importing certain materials and on freight routes used to transport these materials. We experienced some modest disruption from these restrictions. If the government were to place additional restrictions on the transportation of materials, then our ability to transport our raw materials or products could be limited and result in manufacturing delays or bottlenecks at shipping ports, affecting our ability to deliver products to our customers. During periods of such restrictions, we may increase our stock of critical materials (such as arsenic, gallium and other items) for use during the period that these restrictions are likely to last, which will increase our use of cash and increase our inventory level. Any of these restrictions could materially and adversely impact our results of operations and our financial condition.

Our operating results depend in large part on continued customer acceptance of our substrate products manufactured in China and continued improvements in product quality.

We manufacture all of our products in China, and source most of our raw materials in China. We have in the past experienced quality problems with our China manufactured products. Our previous quality problems caused us to lose market share to our competitors as some of our customers reduced their orders until our wafer surface quality was as good and as consistent as that offered by our competitors. If we are unable to continue to achieve customer qualifications for our products, or if we are unable to control product quality, customers may not increase purchases of our products, our China facilities will become underutilized, and we will be unable to achieve revenue growth.

If there are power shortages in China, we may have to temporarily close our China operations, which would adversely impact our ability to manufacture our products and meet customer orders, and would result in reduced revenue.

In the past, China has faced power shortages resulting in power demand outstripping supply in peak periods. Instability in electrical supply has caused sporadic outages among residential and commercial consumers causing the Chinese government to implement tough measures to ease the energy shortage. If further problems with power shortages occur in the future, we may be required to make temporary closures of our operations or of our subsidiary and joint venture raw material companies. We may be unable to manufacture our products and would then be unable to meet customer orders except from finished goods inventory on hand. As a result, our revenue could be adversely impacted, and our relationships with our customers could suffer, impacting our ability to generate future revenue. In addition, if

78

Table of Contents

power is shut off at any of our facilities at any time, either voluntarily or as a result of unplanned brownouts, during certain phases of our manufacturing process including our crystal growth phase, the work in process may be ruined and rendered unusable, causing us to incur costs that will not be covered by revenue, and negatively impacting our cost of revenue and gross margins.

Although the audit report is prepared by an independent registered public accounting firm who is currently inspected fully by the PCAOB, there is no guarantee that future audit reports will be prepared by an independent registered public accounting firm that is completely inspected by the PCAOB.

Our independent registered public accounting firm, BPM, is registered with the PCAOB and is subject to regular inspections by the PCAOB to assess its compliance with the applicable professional standards. Although we have operations in China, a jurisdiction where the PCAOB was, until recently, unable to conduct inspections without the approval of the Chinese government authorities, our independent registered public accounting firm is currently inspected fully by the PCAOB.

Inspections of other independent registered public accounting firms conducted by the PCAOB outside China have at times identified deficiencies in those independent registered public accounting firms’ audit procedures and quality control procedures, which may be addressed as part of the inspection process to improve future audit quality. The lack of PCAOB inspections of audit work undertaken in China prevented the PCAOB from regularly evaluating independent registered public accounting firms’ audits and their quality control procedures. As a result, to the extent that any component of our independent registered public accounting firm’s work papers is or becomes located in China, such work papers may not be subject to inspection by the PCAOB. As a result, investors would be deprived of such PCAOB inspections, which could result in limitations or restrictions to our access of the U.S. capital markets.

As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in particular PRC laws, in June 2019, a bipartisan group of lawmakers introduced bills in both houses of the U.S. Congress which, if passed, would require the SEC to maintain a list of issuers for which PCAOB is not able to inspect or investigate the audit work performed by a non-U.S. independent registered public accounting firm completely. The proposed Ensuring Quality Information and Transparency for Abroad-Based Listings on our Exchanges Act prescribes increased disclosure requirements for these issuers and, beginning in 2025, the delisting from U.S. national securities exchanges such as the Nasdaq Global Select Market of issuers included on the SEC’s list for three consecutive years. It is unclear if this proposed legislation will be enacted. Furthermore, there have been recent deliberations within the U.S. government regarding potentially limiting or restricting companies based in China from accessing U.S. capital markets. On May 20, 2020, the U.S. Senate passed the HFCA Act, which includes requirements for the SEC to identify issuers whose audit work is performed by independent registered public accounting firms that the PCAOB is unable to inspect or investigate completely because of a restriction imposed by a non-U.S. authority in the independent registered public accounting firms’ local jurisdiction. The U.S. House of Representatives passed the HFCA Act on December 2, 2020, and the HFCA Act was signed into law on December 18, 2020. Additionally, in July 2020, the U.S. President’s Working Group on Financial Markets issued recommendations for actions that can be taken by the executive branch, the SEC, the PCAOB or other federal agencies and department with respect to Chinese companies listed on U.S. stock exchanges and their independent registered public accounting firms, in an effort to protect investors in the United States. In response, on November 23, 2020, the SEC issued guidance highlighting certain risks (and their implications to U.S. investors) associated with investments in issuers based in China and summarizing enhanced disclosures the SEC recommends issuers based in China make regarding such risks. On March 18, 2021, the SEC adopted interim final rules to implement the HFCA Act, which requires the SEC to identify certain issuers that filed annual reports with audit reports issued by registered public accounting firms located in foreign jurisdictions and that the PCAOB is unable to inspect or investigate completely because of a position taken by an authority in those jurisdictions (the “Commission-Identified Issuers”). Specifically, the SEC implemented the submission and disclosure requirements of the HFCA Act. On December 2, 2021, the SEC issued amendments to finalize the interim final rules. Further, the SEC established procedures to identify Commission-Identified Issuers and prohibit the trading of the securities of Commission-Identified Issuers as required by the HFCA Act. We will be required to comply with these rules if the SEC identifies us as a Commission-Identified Issuer. Under the HFCA Act, our securities may be prohibited from trading on the Nasdaq Global Select Market or other U.S. stock exchanges if we are determined to be a Commission-Identified Issuer for three consecutive years, and this ultimately could result in our common stock being delisted. Furthermore, on

79

Table of Contents

June 22, 2021, the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, which, if enacted, would amend the HFCA Act and require the SEC to prohibit an issuer’s securities from trading on any U.S. stock exchanges if the issuer is determined to be a Commission-Identified Issuer for two consecutive years instead of three. On December 15, 2021, the Accelerating Holding Foreign Companies Accountable Act was introduced to the U.S. House of Representatives. On September 22, 2021, the PCAOB adopted a final rule implementing the HFCA Act, which provides a framework for the PCAOB to use when determining, as contemplated under the HFCA Act, whether the PCAOB is unable to inspect or investigate completely independent registered public accounting firms located in a non-U.S. jurisdiction because of a position taken by one or more authorities in that jurisdiction and was approved by the SEC on November 5, 2021. On December 16, 2021, the PCAOB issued a report on its determinations that the PCAOB is unable to inspect or investigate completely registered public accounting firms headquartered in the PRC and Hong Kong because of positions taken by PRC authorities in those jurisdictions.

Beginning in March 2022, the SEC listed companies on either its conclusive list of issuers identified under the HFCA Act or its provisional list of issuers identified under the HFCA Act. Companies listed on the SEC’s conclusive list of issuers identified under the HFCA Act are determined to be Commission-Identified Issuers. The SEC did not list AXT, Inc. on either its conclusive list of issuers identified under the HFCA Act or its provisional list of issuers identified under the HFCA Act.

On December 15, 2022, the PCAOB vacated its 2021 determinations that the positions taken by authorities in the PRC and Hong Kong prevented it from inspecting and investigating completely registered public accounting firms headquartered in those jurisdictions. As a result, the SEC will not provisionally or conclusively identify an issuer as a Commission-Identified Issuer if it files an annual report with an audit report issued by a registered public accounting firm headquartered in either jurisdiction on or after December 15, 2022, until such time as the PCAOB issues a new determination. The SEC will continue to include any Commission-Identified Issuer on the provisional or conclusive list if they filed an annual report with an audit report issued by a registered public accounting firm headquartered in mainland China and Hong Kong prior to the PCAOB’s decision to vacate its 2021 determinations.

While an agreement has been reached among the CSRC, the SEC and the PCAOB regarding the inspection of PCAOB-independent registered public accounting firms in China, there can be no assurance that we will be able to comply with requirements imposed by U.S. regulators. If the PRC authorities do not fully perform their obligations under the agreement with the PCAOB in the future, or if authorities in the PRC otherwise take positions that render the PCAOB unable to inspect or investigate completely registered public accounting firms headquartered in the PRC and Hong Kong, the PCAOB will make determinations under the HFCA Act. Delisting of our common stock would force holders of our common stock to sell their shares. The market price of our common stock could be adversely affected as a result of anticipated negative impacts of these executive or legislative actions upon, as well as negative investor sentiment towards, companies with operations in China that are listed in the United States, regardless of whether these executive or legislative actions are implemented and regardless of our actual operating performance.

IV.         Risks Related to Our Financial Results and Capital Structure

We may utilize our cash balances for relocating manufacturing lines, adding capacity, acquiring state-of-the-art equipment or offsetting a business downturn resulting in the decline of our existing cash and if we need additional capital, funds may not be available on acceptable terms, or at all.

Our liquidity is affected by many factors, including among others, the relocation of our gallium arsenide manufacturing lines, the expansion of our capacity to meet market demand, the acquisition of state-of-the-art equipment, other capital expenditures, operating activities, the effect of exchange rate changes and other factors related to the uncertainties of the industry and global economies. Such matters could draw down our cash reserves, which could adversely affect our financial condition, require us to incur debt, reduce our value and possibly impinge our ability to raise debt and equity funding in the future, at a time when we might need to raise additional cash or elect to raise additional cash. Accordingly, there can be no assurance that events will not require us to seek additional capital or, if required, that such capital would be available on terms acceptable to us, if at all.

80

Table of Contents

The terms of the private equity raised in China as a first step toward an IPO on the STAR Market grant each Investor a right of redemption if Tongmei fails to achieve its IPO.

Pursuant to the Capital Investment Agreements with the Investors, each Investor has the right to require AXT to redeem any or all Tongmei shares held by such Investor at the original purchase price paid by such Investor, without interest, in the event the IPO fails to pass the audit of the Shanghai Stock Exchange, is not approved by the CSRC or Tongmei cancels the IPO application. The aggregate redemption amount is approximately $49 million.

Tongmei submitted its IPO application to the Shanghai Stock Exchange and it was formally accepted for review on January 10, 2022. The Shanghai Stock Exchange approved the IPO application on July 12, 2022. On August 1, 2022, the CSRC accepted for review Tongmei’s IPO application. The STAR Market IPO remains subject to review and approval by the CSRC and other authorities. The process of going public on the STAR Market includes several periods of review and, therefore, is a lengthy process. Subject to review and approval by the CSRC and other authorities, Tongmei expects to accomplish this goal in the coming months. The listing of Tongmei on the STAR Market will not change the status of AXT as a U.S. public company. There can be no assurances that Tongmei will complete its IPO in 2024 or at all. In the event that investors exercise their redemption rights, we may be required to seek additional capital in order to redeem their Tongmei shares and there would be no assurances that such capital would be available on terms acceptable to us, if at all. Any redemptions could have a material adverse effect on our business, financial condition and results of operations.

Unpredictable fluctuations in our operating results could disappoint analysts or our investors, which could cause our stock price to decline.

We have experienced, and may continue to experience, significant fluctuations in our revenue, gross margins and earnings. Our quarterly and annual revenue and operating results have varied significantly in the past and may vary significantly in the future due to a number of factors, including:

inventory corrections within the technology sector;
our ability to develop, manufacture and deliver high quality products in a timely and cost-effective manner;
unforeseen disruptions at our new sites;
disruptions in manufacturing if air pollution, or other environmental hazards, or outbreaks of contagious diseases causes the Chinese government to order work stoppages;
fluctuation of our manufacturing yields;
decreases in the prices of our or our competitors’ products;
fluctuations in demand for our products;
the volume and timing of orders from our customers, and cancellations, push-outs and delays of customer orders once booked;
decline in general economic conditions or downturns in the industry in which we compete;
expansion of our manufacturing capacity;
expansion of our operations in China;
limited availability and increased cost of raw materials;

81

Table of Contents

costs incurred in connection with any future acquisitions of businesses or technologies; and
increases in our expenses, including expenses for research and development.

Due to these factors, we believe that period-to-period comparisons of our operating results may not be meaningful indicators of our future performance.

A substantial percentage of our operating expenses are fixed, and we may be unable to adjust spending to compensate for an unexpected shortfall in revenue. As a result, any delay in generating revenue could cause our operating results to fall below the expectations of market analysts or investors, which could also cause our stock price to decline.

If our operating results and financial performance do not meet the guidance that we have provided to the public, our stock price may decline.

We provide public guidance on our expected operating and financial results. Although we believe that this guidance provides our stockholders, investors and analysts with a better understanding of our expectations for the future, such guidance is comprised of forward-looking statements subject to the risks and uncertainties described in this Report and in our other public filings and public statements. Our actual results may not meet the guidance we have provided. If our operating or financial results do not meet our guidance or the expectations of investment analysts, our stock price may decline.

We have adopted certain anti-takeover measures that may make it more difficult for a third party to acquire us.

Our Board of Directors has the authority to issue up to 800,000 shares of preferred stock in addition to the outstanding shares of Series A preferred stock and to determine the price, rights, preferences and privileges of those shares without any further vote or action by the stockholders. The rights of the holders of common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of shares of preferred stock could have the effect of making it more difficult for a third party to acquire a majority of our outstanding voting stock. We have no present intention to issue additional shares of preferred stock.

Provisions in our restated certificate of incorporation and amended and restated bylaws may have the effect of delaying or preventing a merger, acquisition or change of control, or changes in our management, which could adversely affect the market price of our common stock. The following are some examples of these provisions:

the division of our Board of Directors into three separate classes, each with three-year terms;
the right of our Board of Directors to elect a director to fill a space created by a board vacancy or the expansion of the board;
the ability of our Board of Directors to alter our amended and restated bylaws; and
the requirement that only our Board of Directors or the holders of at least 10% of our outstanding shares may call a special meeting of our stockholders.

Furthermore, because we are incorporated in Delaware, we are subject to the provisions of Section 203 of the Delaware General Corporation Law. These provisions prohibit us from engaging in any business combination with any interested stockholder (a stockholder who owns 15% or more of our outstanding voting stock) for a period of three years following the time that such stockholder became an interested stockholder, unless:

662/3% of the shares of voting stock not owned by the interested stockholder approve the merger or combination, or

82

Table of Contents

the Board of Directors approves the merger or combination or the transaction which resulted in the stockholder becoming an interested stockholder.

Our common stock may be delisted from The Nasdaq Global Select Market, which could negatively impact the price of our common stock and our ability to access the capital markets.

Our common stock is listed on The Nasdaq Global Select Market. The bid price of our common stock has in the past closed below the $1.00 minimum per share bid price required for continued inclusion on The Nasdaq Global Select Market under Marketplace Rule 5450(a). If the bid price of our common stock remains below $1.00 per share for thirty consecutive business days, we could be subject to delisting from the Nasdaq Global Select Market.

Any delisting from The Nasdaq Global Select Market could have an adverse effect on our business and on the trading of our common stock. If a delisting of our common stock were to occur, our common stock would trade in the over-the-counter market and be quoted on a service such as those provided by OTC Markets Group, Inc. Such alternatives are generally considered to be less efficient markets, and our stock price, as well as the liquidity of our common stock, may be adversely impacted as a result. Delisting from The Nasdaq Global Select Market could also have other negative results, including the potential loss of confidence by customers, suppliers and employees, the loss of institutional investor interest and fewer business development opportunities, as well as the loss of liquidity for our stockholders.

Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.

As of December 31, 2023, we had U.S. federal net operating loss carryforwards of approximately $40.2 million. We have net operating loss carryforwards of approximately $115,000, primarily in the state of California, as of December 31, 2023. We do not expect to utilize the loss carryforwards in the next several years unless Tongmei pays a dividend. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income and taxes may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We might have undergone prior ownership changes, and we may undergo ownership changes in the future, which may result in limitations on our net operating loss carryforwards and other tax attributes. Any such limitations on our ability to use our net operating loss carryforwards and other tax attributes could adversely impact our business, financial condition and results of operations.

V.         Risks Related to Our Intellectual Property

Intellectual property infringement claims may be costly to resolve and could divert management attention.

Other companies may hold or obtain patents on inventions or may otherwise claim proprietary rights to technology necessary to our business. The markets in which we compete are comprised of competitors that in some cases hold substantial patent portfolios covering aspects of products that could be similar to ours. We could become subject to claims that we are infringing patent, trademark, copyright or other proprietary rights of others. We may incur expenses to defend ourselves against such claims or enter into cross license agreements that require us to pay royalty payments to resolve such claims. For example, in 2020, we and a competitor entered into a cross license and covenant agreement (the “Cross License Agreement”), which has a term that began on January 1, 2020 and expires on December 31, 2029. We have in the past been involved in lawsuits alleging patent infringement, and could in the future be involved in similar litigation.

If we are unable to protect our intellectual property, including our non-patented proprietary process technology, we may lose valuable assets or incur costly litigation.

We rely on a combination of patents, copyrights, trademarks, trade secrets and trade secret laws, non-disclosure agreements and other intellectual property protection methods to protect our proprietary technology. We believe that our

83

Table of Contents

internal, non-patented proprietary process technology methods, systems and processes are a valuable and critical element of our intellectual property. We must establish and maintain safeguards to avoid the theft of these processes. Our ability to establish and maintain a position of technology leadership also depends on the skills of our development personnel. Despite our efforts to protect our intellectual property, third parties can develop products or processes similar to ours. Our means of protecting our proprietary rights may not be adequate, and our competitors may independently develop similar technology, duplicate our products or design around our patents. We believe that at least two of our competitors ship GaAs substrates produced using a process similar to our VGF process. Our competitors may also develop and patent improvements to the VGF technology upon which we rely, and thus may limit any exclusivity we enjoy by virtue of our patents or trade secrets.

It is possible that pending or future United States or foreign patent applications made by us will not be approved, that our issued patents will not protect our intellectual property, or that third parties will challenge our ownership rights or the validity of our patents. In addition, the laws of some foreign countries may not protect our proprietary rights to as great an extent as do the laws of the United States and it may be more difficult to monitor the use of our intellectual property. Our competitors may be able to legitimately ascertain non-patented proprietary technology embedded in our systems. If this occurs, we may not be able to prevent the development of technology substantially similar to ours.

We may have to resort to costly litigation to enforce our intellectual property rights, to protect our trade secrets or know-how or to determine their scope, validity or enforceability. Enforcing or defending our proprietary technology is expensive, could cause us to divert resources and may not prove successful. Our protective measures may prove inadequate to protect our proprietary rights, and if we fail to enforce or protect our rights, we could lose valuable assets.

VI.           Risks Related to Compliance, Environmental Regulations and Other Legal Matters

If we, or any of our partially owned supply chain companies, fail to comply with environmental and safety regulations, we may be subject to significant fines or forced to cease our operations.

We are subject to federal, state and local environmental and safety laws and regulations in all of our operating locations, including laws and regulations of China, such as laws and regulations related to the development, manufacture and use of our products, the use of hazardous materials, the operation of our facilities, and the use of our real property. These laws and regulations govern the use, storage, discharge and disposal of hazardous materials during manufacturing, research and development, and sales demonstrations. If we, or any of our partially owned supply chain companies, fail to comply with applicable regulations, we could be subject to substantial liability for clean-up efforts, personal injury, fines or suspension or be forced to close or temporarily cease our operations, and/or suspend or terminate the development, manufacture or use of certain of our products, the use of our facilities, or the use of our real property, each of which could have a material adverse effect on our business, financial condition and results of operations.

The Chinese central government is demonstrating strong leadership to improve air quality and reduce environmental pollution. The central government encourages employees to report to the appropriate regulatory agencies possible safety or environmental violations but there may not be actual violations. These efforts have impacted manufacturing companies through mandatory shutdowns, increased inspections and regulatory reforms. In the first quarter of 2018, from February 27 to March 31 over 300 manufacturing companies were again intermittently shut down by the local government for a total of ten days, or 30 percent of the remaining calendar days, due to severe air pollution. Our shipments were delayed and our revenue for the quarter was negatively impacted. We expect that mandatory factory shutdowns may occur in the future. If the frequency of such shutdowns increases, especially at the end of a quarter, or if the total number of days of shutdowns prevents us from producing enough wafers to ship, then the shutdowns will have a material adverse effect on our manufacturing output, revenue and factory utilization. We believe the relocation of our gallium arsenide and germanium manufacturing lines mitigates our exposure to factory shutdowns. Each of our raw material supply chain companies could also be impacted by environmental related orders from the central government.

In addition, from time to time, the Chinese government issues new regulations, which may require additional actions on our part to comply. For example, on February 27, 2015, the China State Administration of Work Safety updated its list of hazardous substances. The previous list, which was published in 2002, did not restrict the materials

84

Table of Contents

that we use in our wafers. The new list added gallium arsenide. As a result of the newly published list, we were required to seek additional permits.

We face litigation and legal proceedings which could adversely affect our business, financial condition, results of operations or cash flows.

We are subject to lawsuits, investigations and claims covering a wide range of matters. We are currently the subject of complaints alleging violations of various laws, including but not limited to federal securities laws, including a shareholder class action, described under the “Legal Proceedings” elsewhere in this report, and in the future could be subject to other proceedings. This litigation and any other regulatory proceedings or actions may be time consuming, could cause us to incur significant defense costs, and could damage our reputation or adversely affect our stock price. In the event that there is an adverse ruling in any legal or regulatory proceeding or action, we may be required to make payments to third parties that could have a material adverse effect on our business, financial condition, results of operations or cash flows.

We could be subject to suits for personal injuries caused by hazardous materials.

In 2005, a complaint was filed against us alleging personal injury, general negligence, intentional tort, wage loss and other damages, including punitive damages, as a result of exposure of plaintiffs to high levels of gallium arsenide in gallium arsenide wafers, and methanol. Other current and/or former employees could bring litigation against us in the future. Although we have in place engineering, administrative and personnel protective equipment programs to address these issues, our ability to expand or continue to operate our present locations could be restricted or we could be required to acquire costly remediation equipment or incur other significant expenses if we were found liable for failure to comply with environmental and safety regulations. Existing or future changes in laws or regulations in the United States and China may require us to incur significant expenditures or liabilities, or may restrict our operations. In addition, our employees could be exposed to chemicals or other hazardous materials at our facilities and we may be subject to lawsuits seeking damages for wrongful death or personal injuries allegedly caused by exposure to chemicals or hazardous materials at our facilities.

Litigation is inherently uncertain and while we would expect to defend ourselves vigorously, it is possible that our business, financial condition, results of operations or cash flows could be affected in any particular period by litigation pending and any additional litigation brought against us. In addition, future litigation could divert management’s attention from our business and operations, causing our business and financial results to suffer. We could incur defense or settlement costs in excess of the insurance covering these litigation matters, or that could result in significant judgments against us or cause us to incur costly settlements, in excess of our insurance limits.

We are subject to internal control evaluations and attestation requirements of Section 404 of the Sarbanes-Oxley Act.

Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, we must include in our Annual Report on Form 10-K a report of management on the effectiveness of our internal control over financial reporting. Ongoing compliance with this requirement is complex, costly and time-consuming and it extends to our companies in China. If: (1) we fail to maintain effective internal control over financial reporting; or (2) our management does not timely assess the adequacy of such internal control, we could be subject to regulatory sanctions and the public’s perception of us may be adversely impacted.

85

Table of Contents

We need to continue to improve or implement our systems, procedures and controls.

We rely on certain manual processes for data collection and information processing, as do our joint venture companies. If we fail to manage these procedures properly or fail to effectively manage a transition from manual processes to automated processes, our systems and controls may be disrupted. To manage our business effectively, we may need to implement additional management information systems, further develop our operating, administrative, financial and accounting systems and controls, add experienced senior level managers, and maintain close coordination among our executive, engineering, accounting, marketing, sales and operations organizations.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

During our last fiscal quarter, no director or officer, as defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” each as defined in Regulation S-K Item 408.

86

Table of Contents

Item 6. Exhibits

a. Exhibits

Exhibit
Number

Description

31.1

Certification by Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Certification by Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

Inline XBRL Instance.

101.SCH

Inline XBRL Taxonomy Extension Schema.

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase.

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase.

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase.

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase.

104

Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

† The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of AXT, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.

87

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

AXT, INC.

Dated: November 12, 2024

By:

/s/ MORRIS S. YOUNG

Morris S. Young

Chief Executive Officer and Chairman of the Board of Directors

(Principal Executive Officer)

/s/ GARY L. FISCHER

Gary L. Fischer

Chief Financial Officer and Corporate Secretary

(Principal Financial Officer and Principal Accounting Officer)

88